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Introduction and outline of the thesis 
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Introduction  
Chapter 1 8 
Introduction 9 
CANCER INCIDENCE IN EUROPE AND THE 
NETHERLANDS 
In 2006, only in Europe more than 3 million cancer cases were estimated to be 
diagnosed with an overall mortality of about 53%. The total number of new 
cases of cancer in Europe has increased by 300 000 since 2004, and ageing of 
the population will cause these numbers to continue to increase 1. It is thus clear 
that cancer will remain one of the major health problems in Europe for years to 
come. One of the most common malignancies is lung cancer (12.1%) and with 
an estimated 334 800 deaths (19.7% of total cancer deaths), it is currently the 
most common cause of death from cancer. The overwhelming majority of these 
lung cancers are caused by smoking tobacco. 
 
In the Netherlands an average increase of 1.5% - 2% new cancer cases is ob-
served each year. In 2005 about 6000 men and 2800 women died of lung can-
cer. The incidence of lung cancer for men has decreased by one third between 
1989 and 2003, but for women the incidence has increased with 80% in the 
same period. This can be explained by a change in smoking habits between men 
and women. The increasingly similar smoking habits of men and women have 
resulted in a convergence of lung cancer incidence between men and women. 
 
Lung cancer can be subdivided in two main pathological subtypes: Small Cell 
Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). The majority 
(80%) of patients have NSCLC, a disease only rarely diagnosed at an early 
stage. Five years after the first diagnosis only 10% - 15% of all NSCLC patients 
are alive (www.ikc.nl), both due to a high incidence of local tumor failure and 
distant metastases. Research on lung cancer is therefore an important research 
field aimed at achieving better survival. 
Radiotherapy for patients with lung cancer 
Surgery remains the treatment of choice for patients with early stage NSCLC. If 
patients with stage I-II are medically inoperable because of age or co-morbidity 
(e.g. poor lung function tests), radiotherapy can be curative. For patients with 
stage III, often referred as locally advanced NSCLC, combined chemotherapy 
and radiotherapy has evolved as the standard treatment 2-4, resulting in an over-
all 5 year survival of 5% - 40% 5, 6. 
The two main causes of death in locally advanced NSCLC cancer are distant 
metastases and lack of local tumor control. Local tumor control with radiother-
apy is a function of the total delivered tumor dose in a certain overall treatment 
time. In addition, improved local control has been shown to yield an improved 
overall survival 7, 8. Therefore increasing radiation dose or dose escalation could 
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lead to better local control and hence improve overall survival 9. However, dose 
escalation is hampered by the risk of radiation-induced side effects, like radia-
tion pneumonitis, esophageal damage, spinal cord and heart injury 10, 11. The 
goal of radiotherapy is to find an optimum between local tumor control and 
these side effects. 
 
To improve local tumor control, NSCLC patients are increasingly treated with 
innovative techniques such as highly conformal three-dimensional external 
beam radiotherapy 12, Stereotactic Body Radiation Therapy 13 (SBRT), Intensity 
modulated radiotherapy 14 (IMRT), Image Guided Radiotherapy 15 (IGRT) and 
in-vivo dosimetry using Electronic Portal Imaging Devices (EPID) 16, some-
times called as Dose Guided Radiotherapy (DGRT) 17. To perform these tech-
niques state-of-the-art equipment is used, this means modern linear accelerators 
equipped with Multi Leaf Collimators (MLC), to shape the radiation beam to 
the tumor and spare as much as possible the normal tissue, extensive imaging 
modalities for monitoring the patient’s setup in two dimensions (EPID, stereo-
scopic imaging 18, ... ) as well as three dimensions (Kilo Voltage or Mega Volt-
age Cone Beam CT) and possibilities for four-dimensional (4D) radiotherapy 
(gated radiotherapy 19). Also a Record and Verify system in combination with 
unfailing digital (DICOM) connections between all used systems is essential to 
assure a safe patient treatment and to archive and analyze the huge amount of 
(imaging) data in a systematic central database. 
Tumor delineation is one of the weak points of the radiotherapy chain. Large 
interobserver variations in delineation lung tumors on CT images were reported 
and especially identification of atelectasis and pathological lymph nodes seems 
to be difficult 20-22. 
 
In this thesis two approaches to improve radiotherapy for patients with lung 
cancer are investigated. The first approach is to better define the target using 
novel imaging techniques such as 4D-CT and 4D-CT-PET. In the second ap-
proach the target is followed during treatment using repeated CT and CT-PET 
imaging, with the final goal being adaptation of radiotherapy during treatment. 
Improving radiotherapy for lung cancer patients by better target definition 
One of the most important critical steps in the radiation treatment process is the 
definition of the tumor and surrounding tissues. Currently a CT scan is widely 
used to delineate the gross tumor volume (GTV), which consists of all clinically 
macroscopic disease, including what is visible on imaging modalities 23, 24. 
Safety margins are added to this volume to prevent geographical misses. The 
clinical target volume (CTV) is created by adding a certain margin to account 
for microscopic disease. After accurate definition of this GTV and CTV, geo-
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metric uncertainties like set-up errors and tumor motion are covered by an addi-
tional safety margin to create the planning target volume (PTV). These geomet-
rical errors can be divided into systematic (every fraction the same) and random 
(varying from fraction to fraction) deviations from the planned situation. Sev-
eral margin ‘recipes’ are described in literature to calculate the CTV-PTV mar-
gin 25-27. Once the target volume is accurately delineated, treatment fields can be 
defined and the dose distribution can be calculated and optimized. 
Optimizing target definition for radiotherapy is therefore extremely important; 
below are two ways to improve target delineation in lung cancer patients de-
scribed. 
(1) Adding PET to improve GTV delineation 
Computed Tomography (CT) with the current multislice scanners is a fast imag-
ing technique which provides anatomical information. This imaging technique 
is based on the physical principle of attenuation on an X-Ray fan beam through 
the patient. A three-dimensional representation of the patient is acquired and 
different densities are visualized as a grey value with a certain Hounsfield unit. 
These Hounsfield units can be converted to electron densities which are used to 
calculate the planned dose distribution. Based on the CT scan, Digitally Recon-
structed Radiographs (DRR) which is a computer generated fluoroscopic image, 
can be created and used as a template for the verification of the patient’s posi-
tion during treatment. 
 
However, CT images are limited to visualize anatomic information only, and 
they yield no data on intra-tumor heterogeneity. With the advent of Positron 
Emission Tomography (PET) scanning however, it became possible to visualize 
and quantify heterogeneities within the tumor. PET is based on the emission of 
two gamma rays, created by the annihilation of an emitted positron and an elec-
tron, which are simultaneous detected. A tracer combined with a radioactive 
isotope (positron emitter) is injected in the patient. After a rest period, which is 
needed for the tracer to be diffused within the patient, the patient is imaged. 
PET images are acquired in several table positions (about 16 cm) of several (2-
5) minutes. A whole PET procedure will last between 30-45 minutes. Compared 
to CT, PET imaging is therefore a slow imaging technique. 
 
The most currently used tracer in PET scanning for radiotherapy is 18F-fluoro-
deoxyglucose (FDG). This radiotracer is a measure for the rate of glycolysis in 
the tumor. FDG-PET has a higher sensitivity, specificity and accuracy for detec-
tion of tumor involvement than CT and results in a more accurate staging of 
malignancies, both for the primary tumor as well as for lymph nodes and distant 
metastases 28. FDG-PET, and more specifically the Standardized Uptake Value 
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(SUV), can also be very useful for evaluation of treatment response and predic-
tion of recurrence and/or survival after surgery, radiotherapy and chemotherapy 
29, 30. It has also been proven to be safe to only irradiate PET positive lymph 
nodes and thus reducing target volume resulting in a higher tumor dose 31-33. 
 
Interobserver variation in lung cancer delineation is very large using only CT as 
imaging information, which could be reduced by standardized institutional pro-
tocols 20-22, 34. Delineation accuracy could be further improved by using PET 
images which also decrease the observer variation 35-38. An autocontouring 
method, based on the Source-to-Background ratio in PET images 39, which was 
validated in laryngeal carcinomas 40 was applied in NSCLC patients. With this 
method we also found a good correlation with pathology, currently the gold 
standard in defining the tumor, both for the maximal diameter of the primary 
tumor as well as for the involved lymph nodes 41. In addition, the delineation 
variability amongst observers could be reduced even further with the autocon-
touring method in NSCLC patients. 
Incorporating PET imaging in the treatment planning process seems very prom-
ising 42-44 and could for example improve treatment outcome since using this 
information can lead to sparing of normal tissue and by escalating radiation 
dose to achieve a higher tumor control probability. Another big advantage of 
PET imaging is that it can give information on biological characteristics of the 
tumor and the different areas within the tumor. This might be used in the future 
to delineate a biological target volume and to adapt radiotherapy treatment. PET 
imaging is therefore often described as functional or molecular imaging. 
 
Given these benefits, there has been an exponentially growing interest in using 
(CT-) PET for radiotherapy, as reflected by the number of publications on this 
subject (Fig. 1). 
(2) Adding respiration correlated CT and PET to improve PTV delineation 
One of the major challenges when imaging and treating lung lesions is respira-
tion. The current radiotherapy practice is to account for respiration via a safety 
margin, usually a population based margin applied to all lung cancer patients. 
However some lung tumors move more than this margin, resulting in part of the 
tumor receiving a too low dose (geographic miss) while other tumors barely 
move, resulting in normal tissue being unnecessarily irradiated. Therefore 
knowledge of the motion for the individual tumor could optimize radiation ther-
apy. 
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Respiration Correlated CT 
With a fast helical multislice CT scanner the tumor is actually freezed at one 
location. As this is not necessarily the average tumor position, fast CT scanning 
can cause a large systematic error. Moreover, it can also lead to distortions of 
the tumor’s shape 45. Efforts should focus on minimizing these systematic er-
rors, rather than controlling the breathing motion during irradiation (gating) 46. 
Several strategies have been investigated to solve these problems when imaging 
and treating moving lung tumors, such as immobilization of the tumor by Deep 
Inspiration Breath Hold techniques (DIBH), respiratory gating 47 or Four-
Dimensional (4D) CT/Respiration Correlated CT (RC-CT) imaging. Other 
methods are in detail described in a recent report of the AAPM 19. 
 
RC-CT is an oversampled or low-pitch CT scan during which the respiration 
signal is recorded. This respiration signal can be measured with different meth-
ods, e.g. a thorax band with a pressure sensor 48, 49, infrared markers placed on 
the patient’s chest which is visualized with a camera 50, measuring the flow of 
warm (expiration) and cold (inspiration) air with a thermocouple in a mouth 
mask 51, magnetic sensors placed on the patients skin 52,… . Afterwards the CT 
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Figure 1: Evolution of the number of publications on PET for radiotherapy. A Medline 
(www.pubmed.com) search was performed on June 1st 2007 using the terms: [PET AND radio-
therapy]. (extrapolated numbers for 2007) 
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images can be sorted (‘binned’) according to the respiration phase or respiration 
amplitude 53, 54. Instead of one CT dataset, several datasets, according to the 
number of bins, are available for treatment planning. Based on these datasets, 
movies can be generated in which the motion of the tumor can be measured in 
all directions. 
 
Incorporating this four-dimensional information into the treatment planning is 
possible in different ways. Some investigators use Maximum Intensity Projec-
tions (MIPs), which reflects the highest data value encountered along the view-
ing ray for each pixel of volumetric data, giving rise to a full intensity display of 
the brightest object along each ray on the projection image 55. Others propose to 
use only one phase of the respiration, the half-ventilation phase, i.e. the phase 
where the tumor is at its average position, together with a margin ‘recipe’ to 
account for the motion 49, 56. 
Respiration correlated CT-PET (RC-CT-PET) 
As mentioned above, a lung tumor can be much better imaged with the combi-
nation of PET and CT, than with CT alone. As RC-CT has also shown to be 
beneficial to image lung cancer, the effect of respiration on PET and the possi-
bility of respiration correlated CT-PET, needs careful consideration in lung can-
cer. 
PET imaging is a slow imaging technique, several minutes are necessary to 
achieve an acceptable signal/noise ratio. Therefore multiple respiration periods 
are covered by the images and this obviously blurs the images. This causes arti-
facts when matching with fast CT images 57. Some investigators pose that PET 
is the ideal imaging technique of lung cancer patients because the respiration is 
already taken into account in the imaging process and the visible lesion repre-
sents an Internal Target Volume (ITV) 58. Many arguments can be raised against 
this point of view. First, PET images are extremely sensitive to Window/Level 
settings, therefore automatic delineation software should be developed. Valida-
tion of these methods should occur by correlating these PET images with pa-
thology 59, which is extremely difficult with blurred PET images. Second, accu-
rate information of several parameters, such as the maximal Standardized Up-
take Value (SUVmax), is not present in classic CT-PET imaging 
60. Moreover, 
SUV measurements are only reliable when no or little movements of the target 
are present. Third, attenuation correction could be wrongly performed when 
combining the fast imaging technique (CT) with the slow one (PET) 61. Finally, 
normal CT-PET scanning will represent different intra-tumor heterogeneity due 
to the respiration, with regard to the tracer uptake. Therefore accurate treatment 
of these regions, by for example dose painting, is not possible. 
Since standard PET procedures, with its respiration blurring, have these limita-
tions in lung cancer, four-dimensional or respiration correlated PET imaging 
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have been developed. Similar to RC-CT, these techniques rely on the simulta-
neous acquisition of list-mode PET data and the respiration signal 51, 62-64. 
Improving radiotherapy for lung cancer patients by target adaptation 
(Adaptive Radiotherapy) 
Nowadays the planned dose distribution is mostly based on a single CT(-PET) 
scan, taken before the treatment. So the time trends of the tumor are not taken 
into account in the treatment. Repeated imaging of the tumor during the therapy 
could give more insight in its dynamics, posing the question if the anatomical 
and/or biological changes are worthwhile to adapt. A radiation treatment proc-
ess where the treatment plan can be modified using a systematic feedback of 
measurements is called ‘adaptive radiation therapy’ (ART) 65. With repeated 
4D-CT-PET images knowledge is gained about tumor volume (CT), tumor mo-
tion (4D) and tumor biological/molecular properties (PET). Several groups are 
now investigating the time trends of several parameters using different imaging 
modalities like CT 66, Mega Voltage CT 67, 68, 4D-CT 69, 70, CT-PET 70. Haas-
beek et al. showed that for their patient population the dosimetric consequences 
were minimal and therefore adaptive treatment planning was of limited value 
for fractionated stereotactic radiotherapy 71. This information about changes 
during therapy is not only of interest for the primary tumor but also for the in-
volved lymph nodes, since these are also part of the treatment volumes. Until 
now, this information was never reported. 
Since FDG-PET uptake pre-treatment, and more specifically the maximal stan-
dardized uptake value (SUVmax), is correlated with outcome 
29, 30, it is of interest 
to know the variations of this parameter during treatment. Also an FDG-PET 
scan post-treatment can predict residual disease and hence outcome in NSCLC 
patients 72, 73. Therefore, the evolution of the FDG uptake may reflect intrinsic 
tumor characteristics and might finally be useful to adapt and individualize the 
treatment early during the course of radiotherapy. This could theoretically be 
done by adjusting the fractionation scheme or by adding other treatment modali-
ties, such as surgery or drugs. 
OBJECTIVES AND OUTLINE OF THE THESIS 
In this thesis two approaches to improve radiotherapy for patients with lung 
cancer are investigated. The first approach is to better define the target using 
novel imaging techniques such as respiration correlated (RC-) CT and respira-
tion correlated CT-PET. These techniques take into account the intra-fraction 
variations and artifacts due to respiration. In the second approach the target is 
followed during treatment using repeated (RC-) CT and CT-PET imaging, with 
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the final goal being adaptation of radiotherapy during treatment and tackle inter-
fraction changes. 
 
In Chapter 2 we investigated how to use the four-dimensional CT information 
into the treatment planning. More specifically different methods of defining the 
internal target volume (ITV) were compared with respect to the optimal Clinical 
Target Volume (CTV) coverage. This was an “in silico” (plannings) study based 
on real RC-CT patient data. 
In Chapter 3 our first results are described with RC-CT-PET imaging with 
phantom measurements (a lollipop phantom). It mainly concerned the technical 
feasibility of acquiring RC-CT-PET images and it also investigated differences 
in uptake using different CTs for the attenuation correction. The purpose of the 
study was to investigate the difference in uptake between phased attenuation 
correction and normal attenuation correction. 
A similar study was performed in Chapter 4, but now based on real patient 
data. More different strategies to perform the attenuation correction were stud-
ied. Besides the phased attenuation and a fast CT scan we also looked at the 
average CT data. The influence of tumor motion and tumor location on the SUV 
recovery was also reported. 
Chapter 5 is dedicated to the time trends in tumor volume, tumor motion and 
breathing frequency of locally advanced lung cancer patients during fraction-
ated radiotherapy. In Chapter 6, we also looked at the changes in biological 
parameters and more specifically the maximum Standardized Uptake Value 
(SUVmax) between metabolic responders and non-responders during and after 
radiotherapy, for the same patients as in the previous chapter. In the last Chap-
ter 7, the time trends in volume and motion are described for the involved 
lymph nodes. 
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ABSTRACT 
Background and Purpose: To determine which method of internal target volume 
(ITV) definition based on a respiration correlated CT (RC-CT) allows optimal 
tumor coverage. 
Material and Methods: A free breathing CT (CTfb) and an RC-CT scan were 
acquired in forty-one lung cancer patients. For twelve patients with a motion > 
7 mm in any direction, a detailed analysis was made. The RC-CT scan was used 
to measure tumor motion and to reconstruct a CT at 10 phases (CT10ph), amongst 
which the half ventilation CT (CThv). By averaging the CT10ph, a slow CT 
(CTslow) was reconstructed. Based on those scans ITVs were delineated and 
treatments were planned, where for the ITVhv an internal margin of (motion am-
plitude)/4 was used. The treatment plans for the ITVs were projected on the 10 
respiration phases. Doses were calculated and averaged over the ten phases to 
estimate the actual CTV coverage. 
Results: The 3D motion was on average 8.1 mm ± 1.0 mm (1 SD) for all pa-
tients; no statistical difference was found between lower and upper lobe tumors. 
The ITVslow was the smallest volume on average (142 cm³ ± 38 cm³), followed 
by the ITVhv (160 cm³ ± 40 cm³), the ITV10ph (161 cm³ ± 41 cm³) and the ITVfb 
(250 cm³ ± 63 cm³). Mean CTV doses were between 95% and 107% of the pre-
scribed dose for nearly all patients and treatment plans. Analysis of the CTV 
coverage suggested that underdosage may occur when the CTslow is used and a 
geographical miss occurred using the CTfb, due to uncorrect localization of the 
average tumor position. 
Conclusions: The CThv seems to be the optimal dataset for delineation, using an 
adequate anisotropic internal margin of (motion amplitude)/4. 
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INTRODUCTION 
Non-small cell lung cancer (NSCLC) has a poor prognosis. If surgery is not 
possible, radiation therapy, alone or in combination with chemotherapy, is the 
principal mode of treatment, resulting in 5 year survival rates of 5% - 40% 11, 17-
19. This poor outcome is due to distant metastases and local recurrences. Since 
an improved local control (LC) results in a better survival 20, 22, improvement of 
local treatment is important. One of the strategies to improve LC, is radiation 
dose escalation. 
Dose escalation, however, is associated with an increased risk of complications, 
especially from damage to the lung and the esophagus. Therefore it is important 
to define ways to decrease the volume of irradiated normal tissues allowing 
dose escalation without undue side effects. In our department, we investigated 
two complementary strategies in lung cancer: 1) better definition of invaded 
nodes with CT-PET 5, 24 and 2) respiratory correlated CT to individualize the 
margin needed to account for tumor motion and avoiding geographic misses due 
to respiration (this paper). 
Commonly, the PTV margin is split into a set-up margin, to account for daily 
set-up and machine variations, and an internal margin to account for tumor mo-
tion, i.e. with respiration 1. Individualizing the internal margin around the tumor 
may thus tackle two major causes of local failure: first decreasing for some pa-
tients irradiated normal tissue volumes thereby allowing dose escalation and 
second, by decreasing geographical miss. 
Respiratory correlated CT (RC-CT) is a new development 8, 13 with which the 
systematic error (geographical miss) can be minimized and the random error 
(tumor motion during a radiotherapy fraction) can be estimated for an individual 
patient. With an RC-CT, separate CTs can be reconstructed from multiple 
phases of the respiration, allowing estimation of tumor motion as well as the 
selection of a CT with the tumor in its central position (the half ventilation CT). 
In our institution, we assume that the tumor moves 7 mm, peak to peak, in all 
patients. With our known set-up error, standard deviation of 2 mm both for sys-
tematic and random error, and the margin recipe 25, this assumption results in a 
10 mm total PTV margin in all lung cancer patients (see Appendix). However, it 
is well known that there is a large variation in tumor motion, ranging from 7 
mm in most patients but much larger amplitudes in some other 21, 26, which illus-
trates the need for patient-specific measurement of tumor motion and patient-
specific PTV margins. 
Based on the literature, we hypothesized that the application of RC-CT would 
offer significant benefits over using free breathing CT by reducing the internal 
margin but still avoiding geographic misses, thus making radiation dose escala-
tion possible4. Furthermore, we expected a benefit of RC-CT over a slow CT 15, 
27 in the delineation of the tumor. With a slow CT the tumor is smeared out due 
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to the breathing motion. Therefore the contrast for tumors located close to the 
mediastinum or surrounded by atelactic tissue will decrease compared with the 
non-blurred RC-CT. In this case the delineation will be more difficult and sub-
ject to intra- and interobserver variability. 
 
We therefore set up an “in silico” clinical trial in lung cancer patients to com-
pare four treatment plans based on four different datasets: a free breathing CT 
(CTfb, with standard margins for motion), a slow CT (CTslow, no margins for 
motion), the half ventilation CT (CThv, with margins based on measured tumor 
motion), and the complete 10-phase RC-CT (CT10ph, no margins for motion). 
The goal of this study was to evaluate which of these four methods results in the 
best tumor coverage. 
MATERIALS AND METHODS 
Patients and CT scans 
Forty-one patients, with stage I to IIIB inoperable non-small cell lung cancer, 
underwent a free breathing CT immediately followed by an RC-CT scan. The 
RC-CT scan was performed using offline correlation of a 10-slice spiral CT 
scan (Siemens Sensation 10, Erlangen, Germany) that was modified to enable a 
low pitch (minimum 0.1), in combination with a respiratory signal obtained by a 
pressure sensor in a chest belt (AZ-733V, Anzai Medical Corporation, Tokyo, 
Japan). The raw CT data was reconstructed in 10 phases, from 0% to 100% in 
steps of 10% of the respiration period starting at end inspiration. In-house de-
veloped software with Matlab (Mathworks Inc, Natick, MA) was used to meas-
ure the motion of the lesion in all three orthogonal directions by choosing a 
clearly visible tumor edge and measuring the distance between the extreme po-
sitions in an axial, coronal and sagittal movie using the 10 respiratory phases 
reconstructed from the RC-CT scan. A slow CT was reconstructed by averaging 
these 10 phases of the RC-CT. 
A detailed analysis was performed on patients with a motion in any direction of 
more than 7 mm, since we currently use an internal margin based on a motion of 
7 mm (see Appendix). Since the influence of breathing was assumed to be larg-
est for the primary tumor, only the primary tumor was delineated without taking 
into account the nodal status. 
All patients gave written informed consent before entering this study, which 
was approved by the Medical Ethical Committee according to the Dutch law. 
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Target Volume Delineation 
The internal target volume (ITV) was defined as the clinical target volume 
(CTV) with margins for tumor motion based on the ICRU 62 1. 
We used four different methods to determine the margin for internal motion, 
resulting in four ITVs: 
 
1. Free breathing CT: On the CTfb, the gross tumor volume (GTV) was de-
lineated with a window/level setting of 1700/-300 Hounsfield Units 
(HU), and a 5 mm margin for microscopic disease was added to obtain 
the clinical target volume (CTV). For the internal target volume (ITV), 
an 8 mm internal margin in all directions was added to the CTV to ac-
count for internal motion of the tumor (see Appendix). This was per-
formed using commercial delineation software (Focal 4.2.0, CMS, St. 
Louis, USA). This ITV will later be referred to as ITVfb. 
2. Slow CT: On the CTslow, the tumor was smeared out, and the resulting 
visible structure was delineated with a window/level setting of 1700/-
300 HU. After adding the 5 mm margin to the GTV for microscopic 
disease, this was assumed to reflect the ITVslow. 
3. Half ventilation CT: With in-house built software, the motion of the 
tumor in 3 orthogonal directions was measured. Thereafter the CT from 
the phase with the tumor in its central position (half ventilation CT = 
CThv) was selected and exported to the delineation software. On this 
CThv, the GTV and CTV (= GTV+5 mm) were delineated. To obtain the 
ITVhv, the CTV was expanded with an asymmetric margin of A/4, with 
A being the peak-to-peak amplitude of tumor motion in each of the 
three orthogonal directions (see Appendix for an explanation of this in-
ternal margin). 
4. Ten-phase CT: In the same in-house built software, a volume was 
drawn around the moving visible tumor. This volume was termed the 
internal gross tumor volume (IGTV). To get the ITV10ph, a 5 mm margin 
was added to the IGTV for microscopic disease. Finally, this ITV10ph 
was projected on the slow CT and exported to the delineation software. 
Influence of tumor motion on CTV coverage 
To compare the influence of tumor motion on the actually delivered dose in the 
CTV for the four delineation methods, we chose to ignore set-up uncertainties. 
Therefore, treatment plans were made for the four different ITVs (XiO version 
4.2.0, CMS, St. Louis, USA) using a multigrid superposition algorithm. To be 
able to compare the four methods, the same number of beams and similar gantry 
angles were used and only field blocking, weight and/or wedge angle were dif-
ferent between the four plans. Criteria for the planning were a dose of 70.2 Gy 
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(39 × 1.8 Gy, BID) to the ITV (acceptable inhomogeneity 95% − 107%) and a 
spinal cord dose below 55 Gy. 
 
 
To estimate the actually delivered dose, the plans were projected on all the ten 
phases of the RC-CT. The CTV was contoured on all phases by delineating the 
visible tumor and 3D-expanding this volume with 5 mm for microscopic dis-
ease. For each phase the dose volume histogram (DVH) of the CTV was calcu-
lated, and the average dose distribution was calculated over all ten phases, for 
each of the four ITV treatment plans. From these DVHs, the minimal dose and 
the mean dose in the CTV was recorded. 
Statistical analysis 
All results are expressed as mean ± standard error of the mean (SEM). Statisti-
cal differences between paired parameters from treatment plans based on CTfb 
versus CTslow, CThv and CT10ph were evaluated using the Wilcoxon signed rank 
test. The statistical difference in tumor motion between the different tumor loca-
tions were evaluated using a student t-test. Differences were considered to be 
significant if the 2-tailed p-value was less than 0.05. 
RESULTS 
Patient characteristics 
The 3D vector motion of all 41 patients is displayed in Fig. 1. Two different 
groups were identified according to their location, upper lobe tumors (n = 27) 
versus lower lobe tumors (n = 14). The average 3D motion for the entire group 
was 8.1 mm ± 1.0 mm (1 SD) . There was no statistically significant difference 
of tumor motion between the tumor locations (p = 0.136), although the average 
motion was somewhat bigger for lower lobe tumors, on average 10.1 mm ± 2.1 
mm, compared with the upper lobe tumors, on average 7.0 mm ± 1.0 mm. Fif-
teen patients (36.5%) showed a tumor motion > 7 mm in any direction. Due to 
technical reasons we could not complete a full analysis for three of these 15 pa-
tients. In the remaining 12 patients we performed a more detailed analysis (Ta-
ble 1). As stated in the methods section, patients with N+ disease (8/12) were 
planned as if they had no metastatic lymph nodes (N0). 
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Table 1: Patient characteristics of the 12 patients with a tumor motion in any direction > 7 mm. 
The GTV size of the primary tumor was measured on the free breathing CT. 
Patient no. Age Gender Stage GTV Size (cm3) Location 
1 74 F T2N0M0 64.9 Right upper lobe 
2 56 M T1N3M0 0.4 Left upper lobe 
3 79 M T2N0M0 65.0 Right lower lobe 
4 79 M T2N2M0 50.9 Right upper lobe 
5 79 M T4N0M0 12.2 Right lower lobe 
6 58 F T2N2M0 272.2 Right upper lobe 
7 79 M T4N2M0 33.5 Right lower lobe 
8 60 M T1N0M0 5.0 Left lower lobe 
9 52 F T2N3M0 79.0 Left lower lobe 
10 71 M T4N2M0 7.3 Right upper lobe 
11 61 F T2N2M0 101.9 Right upper lobe 
12 60 M T1N3M0 7.5 Right upper lobe 
Figure 1: Overview of the 3D vector motion of all 41 patients for different tumor locations. The 
big markers indicate the patients which were studied more in detail and had an individual motion 
> 7 mm in any direction. 
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Tumor motion 
For the 12 patients with a tumor motion > 7 mm in any direction, the mean am-
plitude for tumor motion was 5.0 mm ± 1.5 mm (1 SD) in anterior-posterior 
(AP), 12.5 mm ± 1.7 mm in craniocaudal (CC) and 3.1 mm ± 1.1 mm in lateral 
(LR) direction (Table 2). The maximum craniocaudal motion was 28.5 mm. The 
quadratic sum of the motion, i.e. the 3D vector motion, was 14.5 mm ± 2.1 mm. 
 
 
Table 2: Tumor motion (mm) in all three orthogonal directions, Anterior-Posterior (AP), Cranio-
caudal (CC), Left-Right (LR) and the quadratic sum (Vector) for the 12 patients with a tumor 
motion > 7 mm 
Patient no. AP CC LR Vector 
1 9.8 28.5 14.7 33.5 
2 16.6 18 0 24.5 
3 1 15 3 15.3 
4 3 15 2.9 15.6 
5 0 12 2.9 12.3 
6 10.8 12 2.4 16.3 
7 0 9 0 9.0 
8 2 9 0 9.2 
9 2.5 9 2 9.6 
10 8,8 9 5.9 13.9 
11 6.4 9 3 11.4 
12 2.5 7.4 2 8.1 
MEAN 5.0 12.5 3.1 14.5 
SEM 1.5 1.7 1.1 2.1 
 
ITVs for the four different methods 
As shown in Fig. 2, the ITVs based on the CTslow, the CThv and the CT10ph were 
all considerably smaller than the ITV based on the CTfb (p = 0.002, p = 0.002 
and p = 0.002 respectively). On average, the ITV obtained from the CTslow was 
the smallest (49% ± 6% of the ITVfb), the ITV from the CT10ph and the ITV 
from the CThv were comparable, 57% ± 6% and 59% ± 6% of the ITVfb respec-
tively. 
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CTV coverage 
The CTV coverage for treatment plans based on the ITVs for the four different 
delineation methods for all 12 patients is shown in Fig. 3. The CTVs drawn for 
each technique were projected on all the 10 respiratory phases and the mean 
dose to the CTV was calculated (100% = 70.2 Gy). The mean CTV doses re-
sulting from the 3 alternative plans were not significantly different from the 
conventional free breathing plan. Almost all mean CTV doses were between 
95% and 107% of 70.2 Gy, suggesting that the margins used were adequate. 
When looking at the minimum doses per respiration phase, we found that in one 
patient in one phase the treatment plan based on the CTslow and in one patient 
the treatment plan based on the CTfb did not reach the 95% minimum dose re-
quirement. 
 
Figure 2: Internal target volumes for four different delineation methods in 12 patients. Volumes 
are shown relative to the free breathing Internal Target Volume (ITVfb). On average (M) the vol-
umes, ITVslow, ITVhv, and ITV10ph, can be reduced to about 50%. Error bars on the average values 
show the Standard Error of the Mean. 
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Although the mean CTV doses were thus adequate, localized underdosage in the 
CTV may occur, since the volumes were drastically reduced with the respiration 
correlated techniques compared to the conventional CTfb. Detailed analysis of 
the minimum doses in all datasets showed that there were several patients who 
showed a significant underdosage using the CTslow for treatment planning. To 
study this issue in more detail, a 3-point moving average was calculated for all 
minimal doses (for example for phase 2 the mean of the minimum doses of 
Figure 3: CTV coverage for four different treatment plans in 12 patients. The CTVs delineated on 
the free breathing scan (CTVfb), on the slow CT (CTVslow), the half ventilation CT scan (CTVhv) 
and the 10 phases of the RC-CT (CTV10ph) were projected on all 10 phases. For each phase of the 
respiration and for each technique the mean CTV dose was calculated, where 100% equals 70.2 
Gy. In almost all patients good CTV coverage is achieved in all phases for all the four different 
treatment plans. Only in one patient in one phase the treatment plan based on the slow CT plan, 
the CTV did not reach the 95% dose requirement, and in one patient in two phases in de CTfb). 
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phases 1, 2 and 3 was calculated). Assuming that cold spots in consecutive 
phases were located in the same area of the tumor, using the 3-point moving 
average, a dose less than 83% in three consecutive phases meant that it was 
likely there was a real coldspot, since a dose less than 83% in three phases can-
not be compensated by normal doses in other phases ((3×83%+7×100%) 
/10≈95%. In Fig. 4, the 3-point moving average is shown for the minima in the 
CTV. For several patients it was shown that the CTslow plan results in underdos-
age.  
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Figure 4: Representation of possible underdosage of four different treatment plans for 12 patients. 
The average minimum CTV dose of three adjacent respiration phases are shown for the treatment 
plans based on the CTfb, the CTslow, the CThv and the CT10ph. For several patients the CTslow treat-
ment plan shows for almost every respiration phase a dose less then 83%, which strongly suggests 
a real underdosage. The underdosage in the treatment plan based on the CTfb was due to geo-
graphical miss. 
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A possible explanation of this underdosage is shown in Fig. 5, where one 
Beams Eye View (BEV) of the treatment plan based on the CTslow scan for a 
patient is projected on all 10 respiratory phases. It is clearly visible that for 
some phases the CTV is not adequately covered by the beam settings caudally.  
 
The underdosage for one patient using the treatment plan based on the CT10ph 
can be explained by the difficult delineation of the IGTV for this patient without 
using positron emission tomography information. For some patients also the 
treatment plan based on the CTfb showed underdosage, caused by the fact that 
the position of the isocentre, defined as the centre of mass of the ITVfb, was lo-
cated close to end inspiration instead of half ventilation, thereby causing a 
“geographical miss”. In Fig. 6, the craniocaudal trajectory is shown for the pa-
tient with the largest motion, with the position of the isocentre of the different 
treatment plans indicated. 
DISCUSSION 
The internal margin due to respiration has two main contributors in CT based 
radiotherapy planning. First, CT is a fast imaging technique that captures the 
Figure 5: Projection of one (gantry=0°) beam of the treatment plan based on the CTslow scan for 
the patient with a cranial caudal motion of 15 mm, on all ten phases of the respiration. In blue the 
CTV is shown on all ten phases. It is clearly shown that in some phases the tumor is not ade-
quately covered by the beam settings. 
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tumor at only one phase of the respiration 2. If the tumor is not at its central po-
sition when it is imaged, a systematic error is introduced possibly resulting in a 
geographic miss 6. Second, the motion of the tumor with respiration causes an 
intra-fractional random error, which cannot be estimated on a single CT. The 
systematic error has a much larger contribution to the internal margin than the 
random error 25. 
 
Respiration correlated CT (RC-CT) scans give information about tumor motion 
during respiration. Including this information in treatment planning may lead to 
more optimal treatment plans, avoiding geographical miss and minimizing mar-
gins. We showed that by using RC-CT the ITVs were significantly smaller than 
ITVs delineated in the CTfb, suggesting that considerable dose escalation might 
be possible. However, analysis of the CTV coverage (see further) suggested that 
underdosage may occur when the ITVhv is not used, such that the CThv seems to 
be the optimal dataset for delineation. 
Tumor delineation 
We used the RC-CT information to determine the ITV with three different 
methods, the CTslow, the CThv and the CT10ph. The smallest volume was obtained 
using the CTslow scan. This can be explained by the “smear out effect”, which 
Figure 6: Craniocaudal trajectory of the center of mass of the tumor in one patient with a geo-
graphical miss. The locations of the isocenter of all treatment plans are indicated. 
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plays an important role using the CTslow. Regions where the tumor stays for very 
short time may therefore show a lower density and less contrast, and may there-
fore not be recognized as tumor. Therefore, the GTV delineation is very de-
pendent on Window/Level settings. Especially the most cranial and caudal parts 
of the motion path can be missed. Furthermore, particularly in slow CT images, 
it is sometimes difficult to distinguish tumor from infiltrate. 
The delineation of the ITV10ph for all the different phases of the respiratory cy-
cle was labour-intensive. Although other authors also suggested using only a 
few phases to determine the ITV, this remains time-consuming and is more sub-
ject to variations in delineations 12. 
 
First results, reported by Hugo et al., showed that the mean position (half venti-
lation) during the treatment course and the breathing pattern remains stable, 
supporting the use of the half ventilation scan for tumor delineation 10. In addi-
tion, in an earlier study we showed that the tumor motion does not change sig-
nificantly during a course of radiotherapy 3. 
Internal margins and systematic errors 
The internal margin due to respiration applied to the half ventilation CT, A/4 
(with A the peak-to-peak amplitude), is quite tight, in comparison with other 
authors 7, 25. However, the projection of these plans on all the respiratory phases 
did not show any underdosage, thus this margin recipe for internal motions 
seems to be valid. The average motion observed in our study was comparable 
with other studies using CT scans to evaluate tumor motion 2, 16. In addition, we 
could not found a significant difference in tumor motion depending on the tu-
mor location, which is in agreement with several other authors 26, 27. 
There was a difference in average tumor position between the different treat-
ment techniques based on the RC-CT and the CTfb scan for some patients. This 
resulted in a geographical miss when using the CTfb. For patients with a smaller 
motion (< 7 mm) of the lesion this effect would of course be less pronounced 
and will probably not be clinically relevant because this systematic error will be 
covered by additional setup errors. 
Tumor coverage 
The next step was to study the influence of tumor motion on the CTV coverage 
for the four different treatment plans. For this purpose, we estimated the actu-
ally delivered dose distribution by projecting the treatment plans on all 10 
phases of the RC-CT, and by averaging the dose distributions over the 10 
phases. This part of the study was difficult, since due to limitations of the plan-
ning system it was not possible to summarize the dose volume histograms 
(DVH) of the different breathing phases. The mean doses in the different CTVs 
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were not significantly different between the treatment plans, although for one 
patient the 95% mean CTV dose was not reached (Fig. 4) for the treatment plan 
based on the CTfb and the CTslow. The minimum doses were more difficult to 
interpret, because the planning system only gave information about the absolute 
minimum dose, but it does not provide information about the location of this 
minimum. Therefore, it is possible that a cold spot (Dose < 95%) observed in 
one phase of the respiratory cycle is compensated by a higher dose (Dose > 
100%) in the same voxel in another phase. 
The minimal dose data were analyzed in more detail with the use of a 3-point 
moving average. Using these strict criteria, in several patients a real underdos-
age was find when using the CTslow. This would give evidence for the benefical 
effect of gated treatment for patients with a large tumor motion, like stated in 
other articles 23. However, it has to be realized that the analysis of CTV cover-
age was carried out for treatment plans based on the ITVs. The advantage of 
this choice was that we could separately analyze the effect of tumor motion on 
CTV coverage. However, it cannot be excluded that when repeating this analy-
sis of CTV coverage for PTV plans, this would probably show less underdos-
age. 
 
In conclusion, smaller internal target volumes could be reached using informa-
tion about breathing and tumor motion. Although the CTslow reduced the ITV 
the most, the delineation is inaccurate due to the blurring of the lesion at the 
edges. In addition, the CTV coverage analysis suggested that use of the CTslow 
for delineation might result in underdosage. Therefore we propose that the 
treatment plan based on the half ventilation CT, combined with the individual 
anisotropic margins, is the most suitable method for delineation of lung tumors. 
This method is easy (only one phase), the tumor is clearly visible (no blurring 
due to motion) and the reduced margin is adequate. 
APPENDIX: CALCULATION OF INTERNAL MARGINS 
Internal margins can be calculated using the margin recipe proposed by van 
Herk 25. The total margin (MPTV) can individually be calculated by the following 
formula: 
 
2222 7052 ernalintsetupernalintsetupPTV ..M σσ ++Σ+Σ=   (A1) 
 
With ∑setup and ∑internal being the standard deviation of the systematic error for 
setup and organ motion respectively, σsetup and σinternal the standard deviation of 
the random error for setup and organ motion respectively. 
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Assuming a sinusoidal tumor motion with peak-to-peak amplitude of A, the in-
ternal margin can be calculated as follows: 
 
22
A
ernalinternalint ==Σ σ      (A2) 
 
Using this in Equation A1 gives: 
 
82222 Asetupernalintsetuptotal +Σ=Σ+Σ=Σ  
 
82222 Asetupernalintsetuptotal +=+= σσσσ  
 
When using a total PTV margin of 10 mm, and using our known set-up error 
from our institute, i.e. a standard deviation of 2 mm both for systematic and 
random errors based on EPID measurements, we assumed a tumor motion of 7 
mm. The setup errors have been calculated in a previous group of lung cancer 
patients with the same immobilization method. Since this is the major source of 
setup uncertainties we could extrapolate these results to our patient group 
For a tumor moving 7 mm with respiration, the margin recipe thus prescribes an 
internal margin of 8 mm for a free breathing CT based plan (setup errors ex-
cluded). 
 
In half ventilation CT the systematic error is zero, while the random error σinternal 
of a tumor with motion A is again A/2√2. Applying the margin recipe yields an 
internal margin of 0.7A/√8 or approximately A/4. 
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ABSTRACT 
Purpose: Motion of lung tumors with respiration causes difficulties in the imag-
ing with CT and PET. Since accurate knowledge of the position of the tumor 
and the surrounding tissues is needed for radiation treatment planning it is im-
portant to improve CT-PET image acquisition. The purpose of this study was to 
evaluate the potential to improve image acquisition using phased attenuation 
correction in respiration correlated CT-PET, where data of both modalities was 
binned retrospectively. 
Methods and materials: Respiration correlated scans were made on a Siemens 
Biograph Sensation 16 CT-PET scanner which was modified to make a low 
pitch CT scan and list-mode PET scan possible. A lollipop phantom was used in 
the experiments. The sphere with a diameter of 3.1 cm was filled with approxi-
mately 20 MBq 18F-FDG. Three longitudinal movement amplitudes were tested: 
2.5, 3.9 and 4.8 cm. After collection of the raw CT data, list-mode PET data, 
and the respiratory signal CT-PET images were binned to ten phases with help 
of in-house built software. Each PET phase was corrected for attenuation with 
CT data of the corresponding phase. For comparison, the attenuation correction 
was also performed with non-respiration correlated (non-RC) CT data. The vol-
ume and the amplitude of the movement were calculated for every phase of both 
the CT and PET data (with phased attenuation correction). Maximum and aver-
age activity concentrations were compared between the phased and non-phased 
attenuation corrected PET. 
Results: With a standard, non-RC CT-PET scan, the volume was underesti-
mated by as much as 46% in CT and the PET volume was overestimated to 
370%. The volumes found with RC-CT-PET scanning had average deviations 
of 1.9% (± 4.8%) and 1.5% (± 3.4%) from the actual volume, for the CT and 
PET volumes respectively. 
Evaluation of the maximum activity concentration showed a clear displacement 
in the images with non-RC attenuation correction, and activity values were on 
average 14% (± 12%) lower than with phased attenuation correction. The stan-
dard deviation of the maximum activity values found in the different phases was 
a factor 10 smaller when phased attenuation correction was applied. 
Conclusion: In this phantom study we have shown that a combination of respi-
ration correlated CT-PET scanning with application of phased attenuation cor-
rection can improve the imaging of moving objects and can lead to improved 
volume estimation and a more precise localization and quantification of the ac-
tivity. 
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INTRODUCTION 
The combination of CT and PET scanning is the best way to image lung tumors 
for radiotherapy 1, 2. However, with the integration of the two modalities in one 
machine problems may occur because CT-PET combines a fast multi-slice 
computed tomography (CT) technique with the much slower positron emitted 
tomography (PET), which should be considered when imaging lung tumors that 
may move up to 2 cm (peak-to-peak amplitude) with respiration 3. A multi-slice 
CT scan of the thorax is completed in a few seconds and a tumor might be re-
corded in less than a second. Given the respiration cycle length (3-6 seconds) a 
moving tumor will most likely not be imaged at its average position in a multi-
slice CT scan. The measurement of a single bed position with PET on the other 
hand takes about 5 minutes, and will represent several full respiratory cycles. 
On a PET image a moving tumor will thus be smeared out around its average 
position. 
When the tumor movement is considerable these shortcomings of the two sepa-
rate imaging modalities can lead to a distortion of the combined CT-PET image 
4-7 resulting in an underestimation of the measured standardized uptake value 8 
(SUV, which is a prognostic factor in lung cancer 9) or a mislocalization of the 
tumor. Therefore, in radiotherapy, an isotropic margin of usually 15 mm is 
added to the tumor volume that is visible on CT-PET images to account for mi-
croscopic disease and for the possible mislocalization of the tumor on the CT-
PET image and for tumor movement during radiation. Depending on the actual 
movement of the tumor this margin may be too small or too large leading to an 
under-dosage of the tumor or an over-dosage of the normal tissue, respectively. 
 
To reduce the influence of movement on tumor location several new techniques 
have been developed. One of these involves correlation of the respiration signal 
to the scan data. This technique has previously been studied and shows good 
results for both CT 10, 11 and PET 12, 13. In a respiration correlated CT scan (RC-
CT) the respiration signal is recorded simultaneously with the acquisition of the 
CT data. This data is then binned retrospectively according to the respiration 
phase during which it was acquired. This provides information on the tumor 
position for each phase of the respiration. 
Previous studies with 4D-CT-PET in patients 14, 15 show good results in reduc-
ing motion artifacts and increasing maximum SUV. In these studies however, 
the PET data is acquired in a gated mode and binned prospectively into 10 frac-
tions of, for example, 500 ms. Because the bins have predefined time lengths 
problems may arise in the case of irregular breathing patterns. 
The respiration correlated PET (RC-PET) scanning in the protocol proposed in 
this study uses continuous acquisition of the data in list-mode and phase binning 
is carried out retrospectively. In retrospective binning the time length of the bins 
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is determined individually for each period of the respiration. This way the 
binning can take into account a varying breathing frequency. 
 
In a CT-PET scanner attenuation correction of PET can be performed automati-
cally with information obtained from the fast CT scan. This CT image repre-
sents the position of the lung tumor and surrounding tissues during only part of 
the respiratory cycle, however, while the PET image contains the information of 
several full-breathing cycles. The CT image used to correct for attenuation then 
not fully corresponds to the PET image, thereby introducing motion artifacts 16. 
After binning the CT and uncorrected PET data into corresponding phases, the 
tumor and tissue positions on PET and CT match more closely. Therefore an 
additional advantage of phase binning is the possible reduction of motion arti-
facts introduced to the PET scan during CT-based attenuation correction. Ap-
plying phase correlated attenuation correction will thus, most likely, lead to a 
more accurate correction and fewer introductions of motion artifacts. A great 
advantage of an improved attenuation correction would be the possibility of 
auto-segmentation for delineation of tumors based on the SUV. 
 
For radiotherapy of lung cancer patients the ultimate goal is to adapt the mar-
gins needed in delineation of the tumor to the actual movement of the tumor in 
each patient. The aim of the current study is to show the potential of respiration 
correlation of PET with retrospective binning and of phased attenuation correc-
tion in RC-CT-PET scanning. 
METHODS AND MATERIALS 
Scans were made on a Siemens Biograph Sensation 16 CT-PET scanner (Sie-
mens Medical Solutions, Hoffmann Estates, IL, USA). For the 16-slice spiral 
CT scan the following settings were used; 0.125 pitch, 3.0 mm/s table feed, 0.5 
s rotation time, 16 × 1.5 mm scanning slice thickness, 3 mm reconstructed slice 
thickness, 500 mm transaxial field-of-view. The PET data was obtained in list-
mode using a modified list-mode research package originally provided by Sie-
mens. List-mode data were acquired for 10 minutes, retrospectively binned ac-
cording to the respiration cycle and reconstructed with 3 mm reconstructed slice 
thickness. 
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Phantom 
For analysis of the accuracy of respiration correlated PET scanning in general 
and phased attenuation correction in particular, a so-called lollipop phantom 
was used (Fig. 1). 
The sphere at the end of the rod was filled with approximately 20 MBq 18F-
fluoro-deoxyglucose (FDG). A sphere with a diameter of approximately 3.2 cm 
and a volume of 16.0 cc is used (Model ECT/HS/ST, Data Spectrum Corpora-
tion (DSC), Hillsborough, NC, USA). The positions 1 to 5 (see Fig. 1a) can be 
varied in order to get different movement amplitudes. The sphere moved paral-
lel to the cranial-caudal axis. Three longitudinal peak-to-peak amplitude settings 
were tested of 2.5, 3.9 and 4.8 cm, respectively. The rod was mounted on a disc, 
which is powered by a motor. The frequency of the motion was set to approxi-
mately 18 rotations per minute, corresponding to 0.3 Hz. This is comparable to 
the average respiration frequency of humans. 
The respiration signal was measured with two systems; the first system was 
synchronized with the CT on time, the second with the PET on time. For CT 
synchronization the Anzai system (AZ-733V, Anzai Medical Corporation, To-
kyo, Japan) was used. This consists of a pressure load cell that is fitted into a 
chest belt. The signal for the PET data was acquired with a soft, foam-filled 
sensor (Graseby, UK) connected via a tube to an air pressure detector (BioVET 
monitoring system, Spin Systems, Brisbane, Australia). This system is based on 
the flow in the tube caused by pressure on the foam, and not like the Anzai sys-
tem on the pressure itself. 
The belt, in which both cells are fitted, was wrapped around the bottom plate of 
the phantom and connected to the rod through a rubber band as shown in Fig. 
1b. 
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Figure 1: The lollipop phantom; a) schematically and b) actual. 
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The maximum movement amplitude found for lung tumors is about 2 cm with 
an average of 12 mm in cranial-caudal direction 3. The sensitivity of the Anzai, 
however, was not suitable for measurement of amplitudes smaller than the 2.5 
cm tested in this study. 
For comparison purposes regular non-RC-CT and PET scans were also made. 
To show the advantage of phased attenuation correction, correction of the 
phased PET data was also performed with the non-RC-CT scan. 
Due to a scanner problem no non-respiratory correlated CT-PET scan was made 
for the sphere moving with an amplitude of 4.8 cm. 
Phase binning 
CT 
After acquisition, the CT data was binned to ten phases according to the respira-
tion phase during which it was recorded. The respiration signal was synchro-
nized with the CT data by recording the CT on time. Phase binning was per-
formed with a modified version of a software package that was provided by 
Siemens. Each period was divided into ten bins of 10% each, where phase one 
was chosen to start at the maximum amplitude. 
PET 
Phase binning was also performed retrospectively. A trigger could be set at an 
arbitrary amplitude of the respiratory signal. The trigger signal was used for 
retrospective sorting of the raw list-mode data into 10 phase bins. The binning 
was, like the binning of CT data, based on phase only and not on the amplitude. 
The trigger, and thus phase one, was again chosen to start at the maximum am-
plitude of the signal. 
Attenuation correction 
The protocol proposed here required attenuation correction to be applied outside 
the scanner. Software was therefore developed in-house (Matlab, Mathworks 
Inc, Natick, MA, USA). The attenuation correction process as described by Ki-
nahan et al. 17, 18 was followed. This correction is based on the following for-
mula: 
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where the term on the left represents the actual distribution of FDG in the pa-
tient, the exponential term stands for the attenuation along the line of response 
(LOR) at detector position x’(x, y) and projection angle φ(x, y), and p(x’,φ) is the 
measured signal. 
An overview of the steps in the attenuation correction process is given in Fig. 2.  
 
After the field of view (FOV) and number of pixels have been equalized the 
map of attenuation correction factors (ACF) can be obtained through forward 
projection. With forward projection a sinogram is constructed. This consists of 
the integrals along the LORs. The attenuation correction factors in the sinogram 
then need to be multiplied by the pixel size to account for the path length. Tak-
ing the exponent completed the correction factors. 
The raw PET data of the corresponding slice and phase is also converted to a 
sinogram. If the PET and CT images have matching FOV and the same number 
of pixels, each element of the PET sinogram has a corresponding element in the 
ACF sinogram. Multiplying each element of the PET sinogram with the value 
of the corresponding ACF element will perform the attenuation correction. The 
corrected PET sinogram can then be converted back to an image through back 
projection or iterative image reconstruction (OSEM). 
The procedure discussed here was applied to the data of every slice and every 
phase. 
Figure 2: Overview of the steps in the attenuation correction process. 
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Analysis 
Maximum activity concentration values in each of the phases obtained with the 
phased and non-RC attenuation correction were determined and the percentage 
deviation per phase was calculated. 
The accuracy of the respiration correlation was determined by comparing the 
movement amplitude of the spheres on the PET data to the motion found with 
RC-CT and to the real amplitude. For the measurements on the CT and PET 
images, the absolute vertical position of the spheres (centre) was calculated on 
sagittal images for each of the ten phases. The maximum displacement was cal-
culated as the distance of the minimum and maximum sphere position. 
The volumes of the spheres on the PET and CT images were compared to the 
volume of the actual sphere. This analysis was used to determine both the accu-
racy of the respiration correlation as well as that of the phased attenuation cor-
rection. The PET volume was determined using a 34% threshold in the region of 
interest, as was determined with in-house experiments following the methods 
described by Erdi et al. 19 and Daisne et al. 20. The maximum activity concentra-
tion (100%) was determined by averaging the nine highest values found within 
all the phases. This average was taken to account for the influence of extreme 
values. 
The sphere volumes in CT images were determined after manual delineation of 
the sphere with window width and window level settings of 1000 and 0, respec-
tively. 
RESULTS 
Fig. 3 gives an example of the phased PET (bottom) and CT (top) images of the 
experiment with a 2.5 cm amplitude. 
 
In Fig. 4 two images of the same slice and phase of a PET scan from the ex-
periment with a 3.9 cm amplitude are given. On the left the image is shown 
where attenuation correction of the phased PET scan was applied with phased 
and RC-CT data. The image in the middle shows the same slice and phase of the 
same PET scan, but now attenuation correction was applied with the use of a 
non-RC CT scan. For both images of the phased PET (mid and left, Fig. 4) the 
same window width and window level settings were used, scaled between 0 to 
the maximum activity concentration found in the dataset with phased attenua-
tion correction. The image on the right in Fig. 4 is the non-RC PET image of the 
same experiment. All three images show the same area. Because the amplitude 
(3.9 cm) is larger than the sphere diameter (3.2 cm) the non-RC PET image 
(right) shows a region with low activity in the middle. 
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Measurements of the maximum activities were performed for the ten phases of 
both the phased attenuation correction and the non-respiratory correlated at-
tenuation correction. 
The dataset obtained with non-correlated attenuation correction showed much 
larger standard deviations than the dataset with phased attenuation correction. 
Average maximum activity concentrations of 44864 ± 6054 Bq/ml (13.5%) and 
40066 ± 5142 Bq/ml (12.8%) were found for the two experiments with non-
correlated attenuation correction, while in the data with phased attenuation cor-
rection average maximum activity concentrations were 49431 ± 622 Bq/ml 
(1.3%) and 49852 ± 771 Bq/ml (1.5%). 
In the experiment with a 2.5 cm amplitude the average and maximum difference 
between the two correction methods were 9.2% and 28.2% respectively. In the 
second experiment average and maximum deviations of respectively, 19.6% and 
30.0% were found between the two correction methods (Table 1). 
 
Fig. 3: 10 phases of the respiration correlated PET (bottom) and CT (top) data for a motion ampli-
tude of 2.5 cm. 
Figure 4: PET image with phased and respiration correlated attenuation correction (left), with 
non-RC attenuation correction (mid) and of the non-respiration correlated PET (right). The two 
phased images were made with the same window width and window level settings; other settings 
were used for the non-respiration correlated image. All three images show the same area. 
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Table 1: Percentage difference, for the 10 phases, between the maximum activity concentra-
tions measured in data reconstructed with non-respiration correlated attenuation correction and 
those measured in data that was reconstructed with phased attenuation correction. 
Phase Experiment 1 
(2.5 cm amplitude) 
Experiment 2 
(3.9 cm amplitude) 
1 2.4 -30.0 
2 -0.3 -28.7 
3 -14.8 -29.7 
4 -28.2 -4.6 
5 -26.3 -2.5 
6 -20.5 -21.0 
7 -11.1 -20.2 
8 -0.2 -14.5 
9 3.1 -16.7 
10 4.2 -28.4 
average -9.2 -19.6 
 
The maximum value found in the non-RC PET data of experiment 1 with a 2.5 
cm amplitude was 52839 Bq/ml, which is 7% higher than the average maximum 
activity concentration (49431 Bq/ml) found for the RC-PET data with the same 
amplitude. In the experiment with a 3.9 cm amplitude a maximum activity con-
centration of 12316 Bq/ml was found for the non-RC PET data, that is 75% 
lower than the average maximum activity concentration (49852 Bq/ml) of the 
RC-PET data of the same experiment. 
Motion amplitude 
The center positions of the spheres for the different phases of CT and PET, re-
constructed with respiration correlated attenuation correction, are plotted in Fig. 
5. In Table 2 an overview of the movement amplitudes is given. 
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Table 2: Movement amplitudes (cm) measurement accuracy determined for the three experi-
ments in both CT and PET, attenuation correction was performed with respiration correlated 
CT data, compared to the true amplitude. 
 Experiment True CT PET 
1 2.5 ± 0.1 2.4 ± 0.3 2.1 ± 0.3 
2 3.9 ± 0.1 3.9 ± 0.3 3.9 ± 0.3 
3 4.9 ± 0.1 4.8 ± 0.3 4.8 ± 0.3 
Volume 
In Table 3 an overview of the CT and PET volumes, for the clinical and phased 
data, is given. The actual sphere volume is 16.0 cc. 
Figure 5: Centre position of the sphere at the ten phases on CT and PET, reconstructed with res-
piration correlated attenuation correction, images for three movement amplitudes of 2.5, 3.9 and 
4.8 cm, respectively. 
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In the non-RC CT scans the volume was underestimated by 22% and 46% in the 
two experiments. The PET volume in the non-RC scans on the other hand was 
overestimated by 156% in the first experiment and by as much as 370% in the 
second experiment. 
The phased scans of CT show that the protocol used here results in measured 
volumes of 16.1 ± 0.7, 16.2 ± 0.6 and 16.7 ± 0.9 cc for the three experiments, 
respectively. The volumes found in the PET images are 16.2 ± 0.6, 16.5 ± 0.3 
and 16.1 ± 0.7 cc, respectively. 
The average and maximum deviation from the true volume was 1.4% and 8.1% 
(experiment 3, phase 4) respectively for PET. The volumes determined with CT 
have an average deviation of 1.9%. A maximum deviation of 10.6% (experi-
ment 1, phase 8 and experiment 3, phase 1) was found for CT based volumes. 
 
Table 3: Volumes (cc) as determined for the non-respiration correlated CT and PET images 
and for those recorded with respiration correlation. The true volume of the sphere is 16.0 cc. 
Due to a scanner problem no non-respiratory correlated CT-PET scan was made for the ampli-
tude of 4.8 cm. 
Experiment 1 
(2.5 cm amplitude) 
Experiment 2 
(3.9 cm amplitude) 
Experiment 3 
(4.8 cm amplitude) 
 
CT PET CT PET CT PET 
Non-RC CT-PET 12.5 40.9 8.6 75.3 × × 
Phase 1 15.9 16.4 17.2 16.7 17.7 15.6 
Phase 2 16.2 15.6 16.5 16.7 16.3 15.8 
Phase 3 15.3 15.6 15.5 15.9 17.3 15.5 
Phase 4 16.0 16.8 16.3 16.6 16.0 17.3 
Phase 5 15.7 16.9 14.8 16.8 17.6 16.5 
Phase 6 16.6 15.6 16.1 16.5 17.6 16.7 
Phase 7 15.7 15.6 16.4 15.9 16.4 16.1 
Phase 8 17.7 16.3 16.6 16.7 16.2 15.0 
Phase 9 16.0 16.7 16.0 16.6 14.9 15.9 
R
C
-C
T
-P
E
T
 
Phase 10 15.7 15.9 16.2 16.5 16.7 16.2 
 Average ± SD 16.1±0.7 16.2±0.6 16.2±0.6 16.5±0.3 16.7±0.9 16.1±0.7 
DISCUSSION 
This phantom study showed that phased attenuation correction of respiration 
correlated PET images compared to non-respiration correlated attenuation cor-
rection leads to a more accurate localization of the tumor, an improved tumor 
volume definition, and a more precise determination of the activity concentra-
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tion, and more particularly the maximum activity concentration. Respiration 
correlated scanning and phased attenuation correction will therefore offer new 
and more precise information of the tumor, thus providing a better basis for ra-
diation treatment planning. With information of tumor motion, internal margins 
can be determined for each patient individually and adapted to the actual 
movement in each direction. Moreover, with respiration correlation and phased 
attenuation correction an SUV determination is more reliable and thus better 
suited for use in tumor characterization and automatic delineation. To achieve 
good image quality in respiration correlated PET imaging in patients an optimal 
acquisition time and number of bins should be further investigated in a patient 
trial. 
 
In Fig. 4 the image with non-respiration correlated attenuation correction shows 
that the maximum activity is clearly misplaced. In clinical practice such a mo-
tion artifact could result in a mislocalization of the tumor. Moreover the average 
maximum activity concentration found in the sphere is lower than in the data 
that was corrected with phased CTs. In a recent study with a gated, prospec-
tively binned, PET protocol Nehmeh et al. 15 compared attenuation correction 
with a non-RC CT to RC-CT. They found that phased attenuation correction led 
to an improved match of CT and PET data of up to 41%, while maximum SUV 
was increased by a maximum of 16%. Pevsner et al. 8 found an underestimation 
of the activity concentration in the sphere between 19 and 75%. 
In the current study the difference in average maximum activity concentrations 
between the two attenuation correction methods reached up to 31%, with an 
average of about 17% for the two experiments combined. It must be kept in 
mind however that in our experiments the spheres were simply placed in air, 
and little actual attenuation will have occurred. One could argue that the differ-
ence between phased and non-RC attenuation correction might therefore even 
be bigger in the presence of more attenuation. However, in the imaging of mov-
ing lung tumors, not all the attenuating tissues will move to the same degree as 
the tumor. The correction of attenuation that was caused by less mobile tissues 
will therefore not improve distinctly with the use of phased attenuation correc-
tion. The benefits of phased attenuation correction will largely depend on the 
relative contribution to the attenuation by moving tissues as compared to the 
more stationary tissues and might thus not be as striking as suggested by the 
results presented in this paper. 
 
The volume of the sphere is greatly underestimated in non-RC CT images in 
this study, up to 46% deviation from the true volume. Others have found vol-
ume deviations between minus 35% and plus 79% in non-RC CT in comparison 
with RC-CT 15, 21. This large range, both underestimating and overestimating the 
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volume, emphasizes again the importance of using corresponding RC-CT im-
ages for attenuation correction. 
Volumes determined from the respiration correlated CT and PET images both 
show only minor deviations from the true volume, 1.9% and 1.4% on average 
for the respective modalities. This good result demonstrates the accuracy of 
both the phase binning process and the phased attenuation correction. 
 
Various publications 15, 22-24 have reported a decrease in tumor volume when 
using gated PET as compared to non-RC scanning, regardless of their attenua-
tion correction methods. The volumes determined in the current study from the 
non-RC data confirm that in PET smearing appears with a non-RC scanning 
protocol (Table 3). When the motion amplitude is smaller than the sphere’s di-
ameter, as was the case in experiment 1 with a 2.5 cm amplitude, non-
respiration correlated PET data showed a average maximum activity concentra-
tion that was 7% higher than the average maximum activity concentration found 
with the RC-PET data. This high average maximum activity concentration was 
found in the centre region of the motion, where some part of the sphere was pre-
sent in every phase. In the 3.9 cm amplitude experiment the average maximum 
activity concentration found in the non-RC data was 75% lower than found with 
RC-PET. Since the volume is determined with a threshold of 34% of the maxi-
mum activity concentration, the threshold value is set too low and will thus 
cause an even bigger overestimation of the PET volume than smearing alone. 
The difference in the ratio between the sphere diameter and the motion ampli-
tude thus can explain the relatively bigger overestimation of the PET volume 
with the non-RC PET scan in experiment 2, which had a deviation of 370% 
from the actual volume as compared to a deviation of 156% in experiment 1. 
 
The motion amplitudes found with RC-PET and RC-CT (Table 2) corresponds 
well with the actual displacement. Taking the measurement error of 3 mm, 
equal to the slice thickness, and the partial volume averaging effect into consid-
eration the calculated differences will not be significant. This suggests an accu-
rate phase binning for both modalities. 
The CT and PET phases in experiments 2 and 3 (motion amplitudes of 3.9 and 
4.8 cm, respectively) show good correlation. The determinations of the sphere 
centre in experiment 1, however, indicate that a slight phase shift was still pre-
sent. Because the respiratory signals were recorded with different devices the 
starting point of the first phase bin in CT and PET was determined with differ-
ent software. For both systems the maximum amplitude of the respiratory signal 
was set as the starting point. Differences in the respiration measurement tech-
niques of the two systems may have caused the resultant phase shift. Synchroni-
zation of both modalities with a single device for respiration correlation will 
most likely dispose of this resulting phase difference. 
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CONCLUSION 
Valuable information is lost when scans, either CT or PET, are not correlated 
with respiration. Appropriate attenuation correction is at least as important. 
Phased attenuation correction not only gives a more accurate overall correction, 
but perhaps even more important, it provides a better match of PET and CT and 
results in a more reliable SUV and tumor volume. Combining RC-CT-PET 
scanning with phased attenuation correction will result in images with less 
smearing, less motion artifacts and thus in improved volume estimation and lo-
calization and quantification of the activity concentration. 
 
In future studies the feasibility of phased attenuation correction in respiration 
correlated CT-PET for lung cancer patients will be examined. 
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ABSTRACT 
Respiratory motion in PET and PET/CT studies blurs the images of tumors and 
causes attenuation-related errors. In rare instances, this problem even causes 
localization errors and the disappearance of tumors that should be detectable. 
Attenuation errors are severe near the diaphragm and can be enhanced when the 
attenuation correction is based on a CT series acquired during a breath-hold. To 
quantify the errors and identify the parameters associated with them, we per-
formed a simulation based on respiratory-gated CT studies of five lung cancer 
patients. Diaphragmatic motion ranged from 8 to 25 mm in the five patients. 
The CT series were converted to 511-keV attenuation maps which were for-
ward-projected and exponentiated to form sinograms of PET attenuation factors 
at each phase of respiration. The CT images were also segmented to form a PET 
object, moving with the same motion as the CT series. In the moving PET ob-
ject, spherical 20-mm mobile tumors were created in the vicinity of the dome of 
the liver, and immobile 20-mm tumors in the mid chest region. The moving 
PET objects were forward-projected and attenuated, then reconstructed in sev-
eral ways: phase-matched PET and CT; gated PET with ungated CT; ungated 
PET with gated CT; and conventional PET. Spatial resolution and statistical 
noise were not modeled. In each case, tumor uptake recovery factor was defined 
by comparing the maximum reconstructed pixel value with the known correct 
value. Phase-matched gated PET and CT gave essentially perfect PET recon-
structions in the simulation. Gated PET with ungated CT gave tumors of the 
correct shape, but recovery was too large by an amount that depended on the 
extent of the motion, as much as 90% for mobile tumors and 60% for immobile 
tumors. Gated CT with ungated PET resulted in blurred tumors and caused the 
recovery errors between −50% and +75%. Recovery in clinical scans would be 
0% to 20% lower than stated, because spatial resolution was not included in the 
simulation. Mobile tumors near the dome of the liver were subject to the largest 
errors in either case. Conventional PET for 20 mm tumors was quantitative in 
cases of motion less than 15 mm, because of canceling errors in blurring and 
attenuation, but the recovery factors were too low by as much as 30% in cases 
of motion greater than 15 mm. Quantitative PET imaging near the diaphragm 
requires proper matching of attenuation information to the emission informa-
tion. The problem of missed tumors near the diaphragm can be reduced by ac-
quiring attenuation correction information near end expiration. A simple 
PET/CT protocol requiring no gating equipment also addresses this problem. 
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INTRODUCTION 
Accurate measurement of tumor standard uptake values (SUV) is an important 
requirement in many PET applications. In whole-body PET studies SUV is be-
lieved to be an indicator of tumor avidity and a predictor of patient survival 
rates1-4, and accurate quantitation is important when autodelineation is used in 
therapy planning5-8. Indeed, an important requirement for PET in oncology is to 
detect every tumor that is large enough and has enough tracer uptake to be de-
tectable, even when measurement errors have the potential to cause image-
reconstruction errors that result in a missed or mislocated tumor. Respiratory 
motion is one factor with the potential to reduce quantitative accuracy and to 
cause missed or misplaced tumors near the diaphragm. For example, the report 
by Keall et al. shows that significant motion is observed in many regions of sig-
nificance to oncology 9 and the report by Osman et al. indicates the possibility 
of localization and detection errors near the diaphragm 10. In the state-of-the-art, 
however, PET and PET/CT reconstruction algorithms are based on the assump-
tion that the patient does not move during the measurement of the emission si-
nogram and the attenuation factors (AF). 
 
Motion causes two phenomena which lead to image artifacts. First, the tracer 
distribution moves, blurring the image. Second, the AFs change with time, lead-
ing to too much or too little correction for attenuation on some lines of re-
sponse. The latter problem is severe near the diaphragm and is sometimes en-
hanced when the AFs are based on a CT series acquired during a breath-hold, 
with the associated problem that lesions in fusion images of CT and PET, could 
be mislocated, e.g. from the liver into the lung10,11. One goal of this paper is to 
indicate clearly, in the case of PET tumor imaging, what kinds of error arise 
from respiratory motion in conventional PET (CP), considering the complicated 
interplay between these two sources of error. 
 
Another goal of this paper is to demonstrate the advantages of respiratory gating 
(RG) in acquisition of the PET or AF information 12-14. We are interested in res-
piratory-gated PET (GP), in respiratory-gated CT (GCT), in PET/CT performed 
with attenuation measurements from non-gated CT, in non-gated PET/CT with 
gated CT, and in PET/CT in which both modalities are gated. Practical prob-
lems are associated with clinical and phantom-based investigations of the bene-
fits of gating. One problem is the low statistics in each phase of GP. Another 
problem is that laboratory studies are likely to use an unrealistic model of the 
breathing seen in patients. In this paper, we avoid those problems by using GCT 
as the basis for a simulated PET emission data set, created with a digital com-
puter. To our knowledge such a simulation has not yet been reported in the lit-
erature. A preliminary version of this work was presented earlier 15. 
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This approach can address the following issues. How well does conventional 
PET do in the presence of such motion? Does the answer depend strongly on the 
location of the tumor that is affected by motion? Is phase matching of GP and 
GCT quantitative? Does GP or GCT by itself solve the motion problem, deliver-
ing a quantitative result? What PET/CT imaging protocols, based on technology 
available today, address respiration-related errors? 
METHODS 
Our investigation is derived from a set of five GCT studies of lung cancer pa-
tients, selected at random from the population of patients receiving GCT at 
Maastro Clinic. Patients’ breathing was monitored by a strain gauge worn 
around the abdomen 16. Low-pitch helical CT scans of the chest were performed 
with a sixteen-slice CT scanner (Sensation 16, Siemens AG, Forchheim, Ger-
many). The data for the five patients were retrospectively reconstructed into 
images representing a 500 mm field of view sampled by a 512 × 512 matrix, 
with 3 mm between slices, and 10 phases of the respiration cycle starting at end 
inspiration. GCT images were converted to a map ( )rb ,rµ  of PET attenuation 
coefficients 17 at each phase of respiration r and image location b
r
. These were 
transformed to a sinogram of AF values at those phases by applying a high-
resolution forward projector 18 then rebinned to 168 radial and 168 angular bins. 
Our equation for this is 
 
( ) ( ){ }( )rbRrdAF ,exp, rr µ−= ,    (1) 
 
where R is the Radon transform and d
r
 represents a sinogram bin. Related to 
this quantity is the average attenuation, which, if the patient’s breathing pattern 
were perfectly regular, would be the same as the AF in a high-quality scan in a 
PET attenuation scan with transmission sources. For us the defining equation in 
the case of ten gates is 
 
( ) ( )∑=
r
rdAFdAF ,
10
1 rr
.    (2) 
 
Other related quantities are the sinogram of attenuation correction factors (ACF) 
in each gate, 
 
( ) ( )rdAFrdACF ,
1
, r
r
= ,    (3) 
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and the ACF corresponding to the average attenuation, 
 
( ) ( )dAFdACF r
r 1
= ,     (4) 
 
The CT series were also segmented to form a simulated PET volume in which a 
solitary tumor could be imbedded. The PET volumes were defined through a 
segmentation procedure whose parameters were determined by studying typical 
whole-body PET/CT studies. First, to enable a smooth segmentation, the vol-
ume was smoothed in three dimensions with a gaussian kernel whose full width 
at half maximum was 3 mm. Next, the segmentation procedure was run. Pixels 
with CT numbers between -25 and 200 HU, representing soft tissue and mar-
row, were assigned a SUV of 1.0. Pixels between -300 and -25 HU (fat) were 
assigned SUV = 0.3. Pixels between -950 and -300 (lung) were assigned SUV = 
0.17. Pixels above 200 HU (bone) were assigned SUV = 0.1. This procedure 
had several unrealistic characteristics. For example, the blood in the ventricles 
of the heart was treated like soft tissue and clothing and blankets were some-
times treated like fat. 
By inspecting coronal and sagittal sections through the sequence of image vol-
umes of each of the five patients, we located the dome of the liver (DOL) in 
each phase of respiration. We used a model in which the motion of the DOL is 
entirely in the superior / inferior (SI) direction, the most common direction of 
tumor motion in the survey of Keall et al. 9 and in the study by Liu et al. 19 We 
simulated a solitary tumor in one of six places: three mobile tumors were simu-
lated on the right side, and three immobile ones in the mid chest. The mobile 
ones were assigned a position relative to the DOL position in each gate. Each 
simulated tumor, mobile or immobile, was assigned SUV = 5.0 and a diameter 
of 10, 20, or 30 mm. A mobile tumor denoted DOL was centered 5 mm below 
the DOL position. A mobile tumor denoted LRL was defined 25 mm higher 
than the DOL tumor, in the lower right lung, that is, 20 mm above the dome of 
the liver. A mobile tumor denoted ULL was defined 15 mm below the DOL 
tumor, in the upper lobe of the liver. The three immobile tumors were placed in 
the mid chest and were denoted MC1, MC2, and MC3. Their SI coordinates 
were set equal to the mean positions of the mobile LRL, DOL, and ULL tumors, 
respectively. The six tumor locations are indicated by Fig. 1. 
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Because there were in principle three tumor diameters, six locations, five pa-
tients, and ten phases of respiration, this procedure should lead to the creation of 
900 simulated PET volumes to be processed in our study. However, we proc-
essed data for the 10 and 30 mm tumors in only a few cases when it became 
clear that most of the results could be understood by considering just the 20 mm 
tumors. The voxelized PET volume in each gate r and voxel b
r
 is denoted 
( )rbO ,r . We transformed these into unattenuated 2D sinograms, ( )rdp attno ,_
r
, 
using the forward projector referred to above, again with 168 radial and 168 
angular samples. The equation for this is 
 
( ) ( ){ }rbORrdp attno ,,_
rr
= .    (5) 
 
Attenuated 2D PET sinograms were made by multiplying the PET sinograms by 
the AF sinograms: 
 
( ) ( ) ( )rdprdAFrdp attno ,,, _
rrr
×= .   (6) 
 
These would be the sinograms measured by a PET scanner with respiratory gat-
ing, apart from effects such as limited spatial resolution, scattered radiation, and 
spatial sensitivity variations. Those effects were not included in the simulation, 
so that the study could focus exclusively on effects due to motion. We also were 
interested in the time-averaged sinogram, defined as 
 
( ) ( )∑=
r
rdpdp ,
10
1 rr
.     (7) 
 
Six types of PET volume were extracted for analysis and comparison. The first 
of these was ( )rbO ,r , described above. Second was the time average of these, 
denoted 
 
Figure 1. Coronal section through a segmented PET object, showing the locations of simulated 
tumors. The patient is shown at end inspiration. Abbreviations refer to gated lower right lung, 
dome of the liver, upper lobe of the liver, and mid-chest positions 1, 2, 3. 
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( ) ( )∑=
r
rbObO ,
10
1 rr
.     (8) 
 
Third was the series derived by reconstructing the gated sinograms with at-
tenuation correction derived from the matched CT gate. These were made with 
filtered backprojection according to the equation 
 
( ) ( ) ( ){ }rdACFrdpRrbI GCTGP ,,, 1
rrr
×= −− ,  (9) 
 
where R
−1
 is the inverse Radon transformation. Although iterative reconstruc-
tion is now the usual reconstruction method in whole-body PET 20,21, filtered 
backprojection is appropriate in the absence of statistical noise, because it is a 
gold standard and because there is no question of when to stop the iterations. 
With the exceptions defined by equations 13 and 14 below, we do not blur the 
reconstructed images to give a clinical level of spatial resolution. 
 
The fourth PET series to be compared was derived by reconstructing gated si-
nograms with the average attenuation. This series was associated with the respi-
ratory gate index used for PET reconstruction. It represents, under the assump-
tion of regular breathing, what is achievable when gated PET is used on a PET 
scanner with a conventional measurement of the attenuation, i.e. a 511-keV 
transmission scan with rotating rods of 68Ge. The defining equation is 
 
( ) ( ) ( ){ }dACFrdpRrbIGP
rrr
×= − ,, 1 .   (10) 
 
Similarly, the fifth PET series to be compared was obtained when the emission 
sinograms were time-averaged, i.e. not gated, but the CT was gated. The PET 
series is associated with the respiratory gate index of the CT that is used for AC. 
Considering this dataset, one can ask whether a particular state of respiration 
can be used for attenuation correction. Also, we can investigate what happens 
when the free-breathing patient is imaged with a very fast CT scan at an arbi-
trary state of respiration. The defining equation for this case is 
 
( ) ( ) ( ){ }rdACFdpRrbIGCT ,, 1
rrr
×= − .   (11) 
 
Conventional PET was the sixth PET series to be compared. In this case, both 
the emission and attenuation were time-averaged. Again operating under the 
assumption that one breathing cycle is the same as a long time average, we have 
the following defining equation. 
 
( ) ( ) ( ){ } ( )∑=×= −
r
GPCP rbIdACFdpRbI ,
10
11 rrrr . (12) 
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The seventh, final type of PET image to be compared was the GCT image based 
on CT acquired at EE or EI. In these cases, and these cases only, we attempted 
to model the spatial resolution of state-of-the-art PET scanners. Our equations 
for these images are 
 
( ) ( ) ( )bgrbIbI
EEr
GCTEEGCT
rrr
⊗=
=
− , ,   (13) 
 
and 
 
( ) ( ) ( )bgrbIbI
EIr
GCTEIGCT
rrr
⊗=
=
− , ,   (14) 
 
where the symbol ⊗ represents convolution and g is a three-dimensional gaus-
sian kernel, whose full width at half maximum was set to 6.4 mm to represent 4 
mm instrument resolution and 5 mm smoothing to reduce image noise. 
 
We analyzed each of these PET volumes in three ways, based on a maximum-
intensity coronal projection over a 10-mm coronal slice that contained the tu-
mor. First, the SUV of the tumor was defined as the maximum pixel value in the 
coronal slice containing the tumor. We converted this to a percent recovery fig-
ure by dividing by the expected SUV value (the value is 5.0) and multiplying by 
100. This maximum-pixel method, and related methods based on regions around 
the maximum, are used commonly in clinical PET and PET/CT 1-4. Second, the 
image of the tumor itself was inspected to see if the correct shape is obtained in 
the reconstruction. A round shape of the same diameter as the lesion (10, 20, or 
30 mm) was expected. Third, the image of the surrounding tissues was in-
spected visually for artifacts. 
RESULTS 
The diaphragmatic motion model 
The motion of the DOL in our model is characterized in each patient and at each 
phase of respiration by a single value, the z coordinate used to simulate the po-
sitions of the mobile tumors. The total excursions in z (and the root mean 
square) for the five patients, ranked from least motion to most motion, were: 
patient 1, 8.4 mm (2.8 mm); patient 2, 11.1 mm (3.4 mm); patient 3, 13.8 mm 
(4.3 mm); patient 4, 19.8 mm (5.4 mm); and patient 5, 25.2 mm (8.5) mm. 
Patients 3 and 5 had actual large tumors in the lower right lung. In both cases, 
the diaphragm could be visualized in sagittal and coronal sections, allowing us 
to define the DOL unambiguously. In both cases, our methodology placed the 
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simulated LRL tumor inside these actual masses. The other three patient studies 
had no such large masses in the lower right lung. 
Typical images 
Fig. 2 presents coronal sections through ( )rbO ,r , ( )bO r , ( )rbI GCTGP ,
r
− , 
( )rbIGP ,
r
, ( )rbIGCT ,
r
, and ( )bICP
r
 for patient 4. The figure also indicates which 
phases represent end expiration (EE) and end inspiration (EI) as determined 
from the DOL position. The percent recovery of the lesion SUV in each position 
is printed in each frame of the picture. 
 
 
 
Figure 2. Coronal sections through PET series associated with the 20-mm dome of the liver tumor 
in patient 4. The figure presents the PET object at each gate, the average object, three gated re-
constructed image sequences, and a non-gated reconstruction, as explained in the text. SUV re-
covery is indicated with a percent value in each frame of the picture. Arrows indicate prominent 
artifacts. Abbreviations refer to gated PET, gated CT, conventional PET, end expiration, and end 
inspiration. 
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In this simulation, the phase-matched reconstructions (GP-GCT) produced cor-
rect SUV recovery and created no striking artifacts. Actually, recovered values 
were in most cases 1% to 2% too high because of reconstruction noise. 
 
Fig. 2 also indicates that the recovery varied from phase to phase when one used 
the GP and GCT methods. This is discussed in the following sections. Recon-
struction artifacts were evident when one used either of those methods. They 
were particularly noticeable near the diaphragm. These are indicated with ar-
rows in Fig. 2. 
 
Using this approach, we simulated mobile lung lesions 20 mm in diameter in all 
six of the locations introduced above, and saved the results. We simulated 10 
and 30 mm lesions in our earlier analysis 15 of patient 5 and repeated the analy-
sis of the 10 and 30 mm sizes for patient 4. Our study of those two lesion di-
ameters showed that the pattern of artifacts was the same as it was for the larger 
tumors, except that the 10 mm tumor’s SUV recovery was worse than in the 
case of a 20 mm tumor, presumably because the motion is larger relative to its 
size, and that, conversely, the 30 mm tumor’s SUV recovery was better. Believ-
ing that this was a trend, we focused our analysis on tumors with a simulated 
diameter of 20 mm. 
Motion blurring and SUV recovery 
The motion-blurring phenomenon is best studied by examining the time-
averaged simulated tumor, ( )bO r . One would expect that respiration should blur 
edges in the object, and this was borne out by our study of the diaphragm image 
in ( )bO r , for example the bottom left corner of Fig. 2. The tumor’s image was 
distended and blurred in the SI direction. Also, the diaphragm’s sharp edges 
were replaced with diffuse ones. In ( )bO r , the tumor uptake determined as the 
maximum pixel was 100% in the mobile tumors in patients 1, 2, 3, 4 where the 
motion was less than the tumor diameter, but uptake was between 69% and 73% 
in patient 5, where the motion exceeded the tumor diameter. 
 
Fig. 3 illustrates the blurring of the moving tumors. The figure shows the 20-
mm tumors at the dome of the liver in patient 2, who had 11.3 mm of respira-
tory motion, and patient 5, who had 25.2 mm of motion. The figure compares 
EE and EI, and includes a comparison with the time-averaged object and the 
conventional PET reconstruction (CP). One will notice a slight flattening at the 
edges of the sphere, due to our use of a model in which the separation between 
slices was 3 mm. 
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The figure shows that phase-matched PET/CT, represented by the GP-GCT im-
ages, was in principle capable of generating an essentially perfect replica of the 
object itself at each phase of respiration. The tumor had the correct shape and 
was uniformly filled with the correct values. The surrounding tissues were also 
reproduced well. When the PET was gated but the CT was not, the shape of the 
tumor was correct but the distribution of activity inside the tumor was non-
uniform, and SUV values in the surrounding tissues were wrong. When the CT 
was gated and the PET was not, the tumor was distorted and the background 
values were in error. Conventional PET, in these examples, gave nearly the 
same image as motion blurring alone. 
 
Considering all six tumor locations in patients 1, 2, 3, who had less than 15 mm 
of breathing motion, and all ten phases of respiration, we found the range of 
values shown in Table 1. GP-GCT always gave essentially 100% recovery. In 
Figure 3. Coronal section through a simulated 20-mm tumor in patients 2 and 5 at the dome of the 
liver, at respiratory phases EE and EI. Averages are also shown. Abbreviations refer to gated 
PET, gated CT, conventional PET, end expiration, and end inspiration. 
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the case of GP, the largest error (overestimation of the recovery) occurred at or 
near EI and the most negative error (underestimation) occurred at or near EE. 
 
Table 1. Range of SUV recovery for 20 mm lesions in patients 1, 2, and 3 who had less than 15 
mm of breathing motion. The average value is presented if the range is less than 5%. The val-
ues reported in the table are the smallest and largest recovery values in these three patients, 
considering all phases of respiration. Abbreviations refer to gated PET, gated CT, conventional 
PET, the lower right lung, the dome of the liver, the upper lobe of the liver, and three positions 
in the mid chest. 
  GP-GCT GP GCT CP 
LRL 102% 100-110% 97-109% 101% 
DOL 101% 93-145% 90-122% 100% 
m
ob
il
e 
ULL 102% 94-114% 94-112% 100% 
MC1 102% 99-108% 97-119% 102% 
MC2 102% 97-111% 99-112% 101% 
im
m
ob
il
e 
MC3 102% 92-115% 93-120% 101% 
 
We also present the recovery values for patients 4 and 5, who had more than 15 
mm of motion. These are summarized in Table 2. 
 
Table 2. Range of SUV recovery for 20 mm lesions in patients 4 and 5 who had more than 15 
mm of breathing motion. The average value is presented if the range is less than 5%.The val-
ues reported in the table are the smallest and largest recovery values in these two patients, con-
sidering all phases of respiration. Abbreviations refer to gated PET, gated CT, conventional 
PET, the lower right lung, the dome of the liver, the upper lobe of the liver, and three positions 
in the mid chest. 
  GP-GCT GP GCT CP 
LRL 102% 100-158% 68-106% 70-89% 
DOL 101% 92-191% 45-120% 76-100% 
m
ob
il
e 
ULL 101% 73-134% 55-108% 72-101% 
MC1 102% 100-108% 100-108% 101% 
MC2 102% 85-164% 91-130% 102% 
im
m
ob
il
e 
MC3 102% 85-189% 78-175% 102% 
 
 
We calculated the SUV recovery for all six tumors reconstructed by the GCT 
method at EE and EI, with gaussian filtering included, according to Equations 
13 and 14. The recovery values are plotted in Fig. 4 as a function of the amount 
of diaphragmatic motion. 
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DISCUSSION 
A quantitative PET or PET/CT reconstruction procedure requires compensation 
for the physical effects that distinguish the actual measurement from an ideal 
measurement based on unattenuated line integrals of the radioactivity density. 
Those effects include photon attenuation, statistical fluctuations, a background 
Figure 4. SUV recovery for 20 mm tumors measured with non-gated PET, reconstructed with 
(a,b) CT at end expiration and (c,d) CT at end inspiration. Six tumor locations are reported: (a,c) 
lower right lung, dome of the liver, and upper lobe of the liver; and (b,d) positions 1, 2, 3 in the 
mid chest. 
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of scattered radiation, random coincidences, positron range effects, non-
colinearity in the two annihilation photons, detector sensitivity variations, and 
patient motion. In oncological PET, attenuation is normally the largest of these 
effects, with attenuation factors sometimes in excess of 100 in abdominal and 
shoulder sections but about an order of magnitude less than that in lung sec-
tions. At the level of the diaphragm, this largest effect changes from moment to 
moment with the patient’s breathing. Motion of the radioactive tracer in internal 
organs is also an important effect in this region in the breathing patient. At the 
outset of this investigation, it seemed to us that an understanding of the effect of 
breathing upon PET’s accuracy in this anatomical region should include a real-
istic model of the diaphragm’s actual motion in cancer patients. Respiratory-
gated CT made this possible, providing measurement of the anatomy of the en-
tire chest. 
Our study of respiratory motion effects in PET/CT was driven by GCT series 
from five patient studies. The range of diaphragmatic motion in this set of five 
studies was from 8 to 25 mm, with three of the five cases showing motion less 
than 15 mm. This range of motion is typical of the range seen in a number of 
clinics around the world 9,19. We performed some calculations with 10 and 30 
mm tumors but only presented results associated with 20 mm tumors. Large 
tumors, for example, 30 mm, are less blurred by motion. Although breathing 
artifacts in the imaging of smaller tumors, for example 10 mm, are of great con-
cern clinically, in actual measurements the limitations of detector resolution, 
statistical noise, and partial volume effects preclude an accurate measurement of 
the uptake of such small tumors. Since good SUV recovery is possible for 20 
mm lesions, we felt it was appropriate to simplify our presentation by consider-
ing mainly this tumor size. The actual resolution in a clinical scan depends on 
reconstruction parameters, for example the reconstruction method, the number 
of iterations in the case of iterative reconstruction, and the filtering parameter 
which is chosen to control statistical noise. 
In our simulation, the combination of gated PET with gated CT provided accu-
rate results for each patient and each tumor location at every phase of respira-
tion. This indicates that the Radon transform of the PET object, generated by 
our forward projector, was correctly inverted by our filtered backprojection al-
gorithm. This is a reassuring check on the correctness of the computational tools 
that we used. 
Gating of the PET alone gave the correct tumor shape but was not quantitative. 
Gating of the CT alone gave a shape like the shape caused by motion blur alone, 
and was not quantitative. This was also true of conventional PET. A PET/CT 
study performed using a CT scan of a free-breathing patient should be similar to 
gated CT with a random choice of the respiratory phase, provided that the CT 
scan is performed rapidly enough, i.e. it unavoidably has the same kinds of er-
rors as ungated PET with GCT. A PET/CT study with a CT scan at deep inspi-
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ration cannot be modeled by our simulation, since the position of the diaphragm 
is likely to be outside the range seen in the PET scan of a freely breathing pa-
tient. 
Mobile tumors were more susceptible to quantitation errors because they were 
blurred and also subject to attenuation errors. Immobile tumors were subject 
only to attenuation errors, yet even these tumors cannot be assigned the correct 
values by GP or GCT alone. In our simulation, CP was more accurate than ei-
ther GP or GCT in the imaging of 20 mm tumors. This appears to be due to can-
celing errors in emission blurring (underestimation) and attenuation correction 
(overestimation). Our limited study of 10 and 30 mm tumors indicated that mo-
tion blurring of 10 mm tumors was so great that the attenuation errors no longer 
compensated for it, whereas recovery for 30 mm tumors in CP was comparable 
to recovery for 20 mm tumors. In some cases CP had significant quantitation 
errors in imaging the 20 mm tumors, especially when the tumor was mobile and 
the motion was large. 
When respiration moves a tumor by more than the diameter of the tumor, no 
PET or PET/CT reconstruction method can be expected to recover the tumor’s 
actual SUV values, unless the method accounts for the motion. In our simula-
tion of this case, no part of the tumor at EE overlapped the tumor at EI. On the 
other hand, if in our simulation the total motion was less than the diameter, the 
bottom of the tumor at EE overlapped the top of the tumor at EI. Since we as-
sumed that the uptake was uniform throughout the tumor, this situation creates 
the illusion that a piece of the tumor did not move. Because we focused our at-
tention on 20 mm tumors, and because SUV values were assigned based on 
maximum pixel values, motion less than 15 mm had relatively little effect. 
The poorest SUV recovery was for tumors close to the dome of the liver. We 
believe that this was due to large changes, over the course of the respiratory cy-
cle, in attenuation values. The upper lobe of the liver was also strongly influ-
enced by attenuation changes, though the effect was less than at the DOL. 
Quantitative errors in the lower right lung were of a smaller magnitude and we 
believe are mostly due to motion-blurring alone, with much smaller attenuation 
errors. 
In many clinics where oncological PET/CT is performed today, the PET data 
are not gated and a CT scan is performed without special equipment or breath-
ing instructions that would assure data acquisition at a particular, measured 
phase of breathing. In the case of a freely breathing patient, the phase most 
likely to be measured by the spiraling X-ray source is EE, because people nor-
mally pause between breaths, though the data could be acquired at any phase 
between EE and EI. We gave special consideration to those two extremes and in 
Fig. 4 plotted SUV recovery for 20-mm tumors as a function of the extent of the 
five patients’ diaphragmatic motion. In these cases we included a post-
reconstruction filter to give a more realistic estimate of the recovery achievable 
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in an actual PET/CT scanner, considering spatial resolution. The partial volume 
effects educed uptake between 0% and 10%. 
Fig. 4 illustrates the complexity of respiration’s effect upon PET/CT. Part (a) of 
the figure gives the impression that CT performed at EE gave correct PET/CT 
results, i.e. errors no larger than 20% in imaging of a mobile tumor in the lower 
lung, at the diaphragm, and in the upper lobe of the liver. However, part (b) 
shows that, again with CT performed at EE, immobile tumors at the level of the 
lower right lung are correctly reconstructed while tumors lower than that are 
overcorrected by amounts varying from 0% to 60%. In fact, the pattern indi-
cated by part (a) shows that motion blurring, which should lower reconstructed 
values, is canceled by an overcorrection for the attenuation. The attenuation er-
rors are even larger near the DOL than they are in the mid chest. Part (d) of the 
figure gives the impression that, with CT performed at EI, the immobile tumors 
in the mid-chest are reconstructed rather with underestimation in the range from 
0% to 30%, apart from effects attributable to a 10% loss in resolution, while 
part (c) clearly shows that the mobile tumors, again with CT performed at EI, 
suffer a large undercorrection for attenuation. The pattern in part (d) is ex-
plained by the fact that much of the detected radiation from tumors in the mid 
chest is emitted during the part of the breathing cycle near EI when the lungs 
are full of air and the attenuation is least; so the EI attenuation correction works 
fairly well for the immobile tumors. The mobile tumors represented by part (c) 
move with the diaphragm, and therefore the attenuation vary less through the 
breathing cycle. In this case, the reconstructed tumor intensity is lowered by 
three phenomena: inadequate correction for attenuation; motion blurring; and a 
small loss of resolution. There is no canceling error in this case. When the CT 
scan is performed during free breathing, tumors near the diaphragm will be 
overcorrected or undercorrected by an amount that will not be known to the 
phsysician reading the images. If the CT data were acquired in an unnatural 
phase of breathing, for example at full inspiration to afford a good view of chest 
anatomy, the undercorrection for attenuation should be even larger, and lesions 
could be completely missed. A practical way of dealing with these problems is 
discussed below. 
Gated CT is relatively new technology, made practical by the introduction of 
ever faster CT scanners with large numbers of detector rows. In our methodol-
ogy for simulating a PET/CT acquisition and reconstruction system with breath-
ing motion, gated CT volumes were converted into PET volumes and attenua-
tion sinograms to represent the essential features of respiratory motion. This 
approach to studying respiration artifacts in PET/CT has benefits not easily 
achieved in other approaches, for example clinical studies and phantom studies. 
First, this approach has a gold standard, since one always compares the tumors 
to the known tumor introduced in the simulation. Clinical studies hardly ever 
have such a gold standard to compare to. Second, the motions are realistic since 
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they come from actual patients. In our view, it would be very difficult to create 
phantom studies in which the motions are modeled with this level of realism. 
Since actual human tissue is used in our model of the attenuation correction, this 
approach even includes complex attenuation-related phenomena such as the 
compression of lung tissue during breathing. Third, we are able to explore the 
effect of respiratory motion without the confusion of other effects that are pre-
sent in actual PET studies: limited counts per acquired frame; limits to the de-
tector resolution; three instead of two-dimensional geometry; scattered radia-
tion; and other data corrections. When we want to study motion in isolation 
from other effects, it is advantageous to be able to turn them off. 
Our segmentation procedure had some unrealistic features. Blood in the ventri-
cles of the heart was treated like soft tissue and clothing and blankets were 
sometimes treated like fat. These problems do not concern us greatly, for two 
reasons. First, the unrealistic effects did not occur close to the lung lesions, 
where the motion-related effects were large. Second, we believe that the funda-
mental lessons of the simulation do not depend on objects in the background. 
The respiratory gates were defined at ten equally spaced intervals in the respira-
tory cycle. A correct physical description of the PET and AF acquisitions would 
involve integration over all breaths. If we assume a regular and smooth pattern 
of breathing, the addition of ten phases is nearly the same as time integration, in 
the sense that a Riemann integral can be approximated with the trapezoid rule. 
Our model completely ignores motion within each gate. We are not concerned 
by this because time integration of the motion in such a short frame, which is 
the appropriate physical model, is well approximated by the average value 
which we used, given the smooth nature of normal breathing. 
The GP/GCT combination gives quantitative PET images in conditions of no 
statistical noise, and under the assumption that the two modalities can be 
matched perfectly. Clinically, none of the conditions of this simulation can be 
met realistically, and in addition cardiac motions in the same territory pose a 
separate problem that this simulation did not address. Challenges for the future 
include finding ways of matching the two modalities well enough to achieve 
quantitative accuracy in essentially every scan, especially in the presence of 
variable breathing patterns 22,23, and finding ways to improve the statistical ac-
curacy of images based on very low statistics per frame. 
This simulation can be used to guide practitioners of oncological PET/CT to 
make the best possible use of existing technology in the face of respiration-
related artifacts. The mismatch between the CT and PET images leads to a 
number of potential problems, including localization and attenuation correction 
errors. Particularly when a tumor is near the diaphragm in the base of the lungs 
or in the superior portion of the liver, respiration may result in incorrect local-
ization or even in the tumor being missed because of the undercorrection for 
attenuation. Fortunately, in a study by Osman et al., the incidence of misposi-
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tioning errors was small (less than 2% of cases) 10. Nevertheless, careful atten-
tion should be given when reviewing the region near the diaphragm. The review 
should include PET images made without attenuation correction. Although 
those images are not quantitative, they are unaffected by attenuation correction 
errors. In the case of cooperative patients, undercorrection of attenuation due to 
breathing can be avoided by acquiring the CT scan of the thorax near EE. For 
patients who are unable to follow breathing instructions, the technologist can 
acquire two or three fast, low-dose CT scans during free breathing 24. The ap-
propriate CT scan for attenuation correction, i.e. the one that most closely corre-
sponds to EE, is identified as the one in which the diaphragm is positioned 
highest. Such a procedure should reduce the likelihood that tumors near the dia-
phragm are missed because of respiration artifacts, and would be particularly 
appropriate for mobile tumors. For stationary tumors, our work indicates that 
quantitative imaging is more accurate when the attenuation information is de-
rived near EI. A multi-CT protocol like the one mentioned above can also be 
used to select the scan in which the diaphragm is lowest. This is the breathing 
phase proposed by Nehmeh et al. for tumor imaging 11. Therefore, existing tech-
nology provides several strategies for tumor imaging in the region near the dia-
phragm. 
SUMMARY 
We used gated CT series to provide a realistic basis for simulating errors in PET 
and PET/CT that are due to respiratory motion. To our knowledge this has not 
been done previously. 
We showed that, in the conditions of the simulation, the combination of gated 
PET and gated CT was quantitative but other methods were not. In the majority 
of patients whose breathing motions are less than 15 mm, motion-related errors 
are in the range of 20% or less in the case of 20 mm tumors. Conventional PET 
was not quantitative, but there were a remarkable number of cases in our simu-
lation of 20 mm tumors, indeed, nearly all of them, in which canceling errors 
due to emission blurring and attenuation overestimation led to a nearly correct 
result in conventional PET, for example in Fig. 2. 
We showed that a large amount of motion caused relatively large errors. Al-
though we did not discuss it at length in this report, our simulations showed that 
10 mm tumors were blurred to a greater extent by motion. Quantitative imaging 
of such tumors is in any case challenged by spatial-resolution effects, which 
could be larger than the motion blurring, depending on processing parameters. 
Conversely, 30 mm tumors were blurred less by motion. We demonstrated that 
gated PET by itself gave the correct shape for tumors, but without proper at-
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tenuation information gated PET could not be relied upon to give a quantitative 
image of the tumor. 
The largest uptake errors occurred in tumors at the diaphragm. The upper lobe 
of the liver was another region where large errors occurred. The lower lung was 
a territory where uptake errors were smaller in most cases, presumably because 
the attenuation-correction errors are less while the motion blurring was the 
same. 
Although proper alignment of the emission and transmission measurements is 
necessary for accurate tumor imaging near the diaphragm, the serious problem 
of a missed tumor can be addressed without respiratory gating, using simple CT 
protocols to acquire images near end expiration. By using such a protocol, tu-
mor SUV values are overestimated by an amount in the range from 0% to 60%. 
In cases of suspected tumors near the diaphragm, the physician should review 
the PET images made without attenuation. 
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ABSTRACT 
Purpose: To investigate the change in tumor volume, motion and breathing fre-
quency during a course of radiotherapy, for locally advanced non-small cell 
lung cancer. 
Patients and Methods: Twenty-three patients underwent CT-PET and Respira-
tion Correlated CT scans prior to treatment, which was repeated in the first and 
second week following the start of radiotherapy. Patients were treated with an 
accelerated fractionation schedule, 1.8 Gy BID, with a total tumor dose depend-
ing on pre-set dose constraints for the lungs and the spinal cord. 
Results: A striking heterogeneity of tumor volume changes was observed at all 
time points. In some patients the volume decreased > 30% (3/23) in others the 
volume increased > 30% (4/24) but for the majority of patients (16/23) the tu-
mor volume only changed slightly (< 30%). No significant changes in average 
tumor motion or breathing frequencies were seen during treatment. Although 
quite some changes in individual tumor motion were seen, only in one patient 
would this have led to an increase of the internal margin > 1 mm in one direc-
tion, one week after the start of treatment, and in three patients for one direc-
tion, 2 weeks after the start of the treatment. 
Conclusion: A large variability of changes in tumor volume between the pa-
tients was observed. This underscores the need for repeated imaging during the 
course of radiotherapy. However, the changes in tumor motion are small, which 
indicates that repeated respiration correlated CT does not appear to be neces-
sary. 
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INTRODUCTION 
Radiation therapy, alone or in combination with chemotherapy or surgery, is 
important in the treatment of lung cancer 1. Nowadays, target volume delinea-
tion is often based on sophisticated imaging techniques such as CT and FDG-
PET scans, as this improves the diagnostic accuracy and may allow radiation 
dose escalation 2-5. Breathing induced tumor motion and hence appropriate mar-
gins can be taken into account using 4D-CT information from respiration corre-
lated CT (RC-CT) scans. Incorporating this temporal information in radiother-
apy planning could also lead to a more accurate delineation of the gross tumor 
volume. In general, smaller margins can be applied which would make dose 
escalation or a decrease of normal tissue exposure possible 6. 
However, radiation treatment planning is based on imaging taken at a single 
time-point before the start of radiotherapy, and therefore any changes of tumor 
motion, tumor volume or breathing frequency during the course of fractionated 
radiotherapy are not incorporated in the treatment planning process. 
Few data on volume changes during radiotherapy for lung cancer patients have 
been reported 7-10, showing conflicting results. Moreover, the evolution of the 
tumor motion during radiotherapy was only reported in stereotactic radiotherapy 
for stage I NSCLC patients 10, although this information is important for Adap-
tive RadioTherapy (ART). 
We therefore investigated the changes of tumor volume, tumor motion and 
breathing frequency during the first 2 weeks of an accelerated course of radio-
therapy in patients with locally advanced non-small cell lung cancer (NSCLC). 
PATIENTS AND METHODS 
Patients 
Twenty-three patients with histological or cytological proven non-small cell 
lung cancer (NSCLC) (UICC stage II-III) were included in this study, from De-
cember 2004 until September 2005. Twenty patients received three cycles of 
carboplatin and gemcitabine chemotherapy before radiotherapy, had a WHO 
performance status 0-1 and a good lung function (FEV1 ≥ 50 % and DLCO ≥ 
50 %). Three patients did not receive chemotherapy due to medical reasons. The 
response to induction chemotherapy was evaluated using the RECIST-criteria 
11. No concurrent chemotherapy was given. Patients were treated using our cur-
rent standard CT-PET simulation, radiation treatment planning, and fractiona-
tion schedule, as described below. 
The Medical Ethics Committee according to the Dutch law approved the trial. 
All patients gave written informed consent before entering this study. 
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Radiotherapy simulation 
Patients were simulated in radiotherapy position on a dedicated CT-PET-
simulator with both arms above the head and on an immobilization and patient 
laser marker system. Radiotherapy technologists trained specifically for this 
purpose always carried out the simulation. The CT-PET scanner used was a 
Siemens Biograph (SOMATOM Sensation-16 with an ECAT ACCEL PET 
scanner). 
An intravenous injection of 18F-Fluoro-Deoxy-Glucose (FDG) (Tyco Health 
Care, Amsterdam, The Netherlands) of (weight × 4 + 20) MBq was followed by 
10 ml physiologic saline. After a 45 minutes uptake period, during which the 
patient was encouraged to rest, PET and CT images were acquired. A spiral CT 
with intravenous contrast was performed covering the complete thoracic region. 
Radiotherapy planning 
Radiotherapy planning was performed on a XiO (Computerized Medical Sys-
tems,St Louis, Missouri) treatment planning system, using inhomogeneity cor-
rections, based on a convolution algorithm. For all patients, the Gross Tumor 
Volume (GTV) and the Planning Target Volume (PTV) were defined, based on 
CT-PET data, obtained prior to radiotherapy (i.e. post chemotherapy in case of 
inducton chemotherapy). The Clinical Target Volume (CTV) was defined as the 
GTV with a 5 mm margin incorporating microscopic disease. This CTV was 
subsequently expanded with 1 cm to draw the PTV to incorporate the internal 
respiratory motion and setup errors. 
For the volume comparison in this study, the CT-GTV was defined as the pri-
mary tumor on lung window (W = 1600, L = -800). 
Contouring of the lungs was carried out automatically by the treatment planning 
system. For the calculation of the mean lung dose (MLD), the volume of both 
lungs excluding the GTV was used 12. The spinal cord was drawn throughout 
the whole CT scan and was considered to be at the inner margin of the bony 
spinal canal. 
A 3D conformal treatment plan was calculated on the PTV for all patients ac-
cording to ICRU 50 guidelines 13. Dosimetric values were calculated on the ba-
sis of dose-volume histograms and dose distributions on each axial CT plan. 
Radiotherapy dose and normal tissue constraints 
For each patient, the radiation dose was escalated to a mean lung dose (MLD) 
of 19 Gy while respecting a maximum spinal cord dose of 54 Gy. There were no 
esophageal dose constraints. As the tumor dose was delivered in 1.8 Gy frac-
tions, a maximum deviation of the constraints of ± 4 % was allowed. Radiother-
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apy was always delivered twice a day (BID), with a minimum of 8 hours be-
tween the two fractions, and given 5 days per week. 
Respiration Correlated CT scans (RC-CT) 
For the patients who gave informed consent for this study, the CT-PET was 
immediately followed by a respiration correlated CT, using offline correlation 
of the 16-slice spiral CT scan of the CT-PET system. This had been modified to 
enable a low pitch (minimum 0.1), in combination with a respiratory signal ob-
tained by a pressure sensor in a chest belt (AZ-733V, Anzai Medical Corpora-
tion, Tokyo, Japan). The raw CT data were reconstructed in 10 phases, from 0% 
to 100% in steps of 10% of the respiration period starting at end inspiration. In-
house developed software with Matlab (Mathworks Inc, Natick, MA) was used 
to measure the motion of the lesion in all three orthogonal directions. 
Study design 
During the course of radiotherapy, the patients underwent a repeat CT-PET scan 
and a respiration correlated CT in treatment position, one and two weeks after 
the start of treatment. At all time points, the primary tumor was delineated using 
the free-breathing CT rather than on a single phase of a respiration correlated 
CT, as respiration correlated CT data was not available in all patients (see Table 
3). This approach assumes that no blurring of the moving tumor occurs in the 
free-breathing CT. This assumption was checked and found to be valid as the 
high-speed 16-slice CT scan protocol, effectively “freezes” the tumor in a single 
phase during a free-breathing CT. The tumor was delineated for each patient by 
the same physician to avoid interobserver variability. To study the intra-
observer variability, all pre-treatment CT-scans were delineated twice by the 
same physician, as was the case for ten patients for all time points, with at least 
a 3 month time interval. 
Due to technical and logistical problems, a complete image dataset at all three 
time points, was not available for all patients. We missed a CT-PET dataset for 
one patient one week after the start of treatment and for three patients, two 
weeks after the start of treatment. 
Endpoints and statistical analysis 
We determined the tumor volumes prior to 1 and 2 weeks, after start of the 
treatment, based on the GTVs drawn on the free-breathing CT. In addition, we 
used the respiration correlated CT to quantify the tumor motion at all 3 time 
points. Tumor motion was expressed as a 3D vector 14, which is the quadratic 
sum of the motions in the three orthogonal directions. Finally, breathing fre-
quency was recorded at all three time-points during the respiration correlated 
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CT. All results are expressed as the mean ± standard deviation (SD). Statistical 
differences between paired parameters from the three time points were evalu-
ated using the Wilcoxon signed rank test. Differences were considered to be 
significant when the p-value was less than 0.05. 
RESULTS 
Patient characteristics 
The patient characteristics are shown in Table 1. The mean values of the total 
tumor dose (TTD) and the corresponding mean lung dose (MLD) were 61.7 Gy 
± 9.8 Gy [range: 46.8 Gy – 79.2 Gy] and 16.4 Gy ± 3.4 Gy [range: 6.8 Gy – 
20.8 Gy], respectively. The GTV of the primary tumor before radiotherapy was 
87.5 cm³ ± 137.7 cm³ [range: 0.4 cm³ – 660.2 cm³]. 
The first repeat scan was made after the patient received on average a dose of 
20.4 Gy ± 4.1 Gy (about 11 fractions) and the second scan after 38.3 Gy ± 5.1 
Gy (about 21 fractions) (Table 2). 
Volume changes of the primary tumor 
A striking heterogeneity of the changes in volume of the primary tumor during 
radiotherapy was observed. Using an arbitrarily chosen cut-off level of 30%, 
four patients (17%) showed an increase of the tumor volume of > 30%, for six-
teen patients (70%) the volume change varied < 30% while for three patients 
(13%) the volume decreased > 30%. In Fig. 1 these patients are indicated with a 
dotted line for the patients with a large increase in tumor volume, a dashed line 
for those patients with a large decrease and a solid line for the rest of the pa-
tients. 
Although the average volumes do not reflect the individual changes, we ob-
served a significant increase in average tumor volume in the patients (n = 22) 
for which data at the first and second time point was available, from 90.9 cm³ ± 
139.9 cm³ to 99.2 cm³ ± 130.4 cm³ from the start of radiation to week 1 (p = 
0.049). For time point at week 2, we missed the CT information for three pa-
tients. In the remaining 20 patients the tumor decreased on average from 94.7 
cm³ ± 146.3 cm³ to 86.4 cm³ ± 109.8 cm³ from the start of radiation to week 2 (p 
= 0.940) (Table 2 and Fig. 2). 
No significant difference in tumor volume changes was observed between pa-
tients with stable disease and partial response to induction chemotherapy. 
For the 43 delineations, which were performed twice, we found an average in-
tra-observer variability of 1.2 % ± 4.4 %, with a maximum deviation of 9.5 %. 
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Table 1: Patient characteristics. 
Patient 
no. 
Age 
(years) 
Gender Stage Location 
of the pri-
mary tu-
mor 
Re-
sponse 
chemo-
therapy 
TTD 
(Gy) 
MLD 
(Gy) 
OTT 
(days) 
1 52 F T1N3M0 RLL PR 54.0 17.6 17 
2 54 M T3N2M0 RML SD 54.0 19.3 20 
3 75 M T3N2M0 RUL PR 54.0 15.2 20 
4 71 F T3N1M0 RUL no 
chemo 
64.8 20.7 23 
5 71 M T2N3M0 RUL PR 54.0 14.7 23 
6 61 M T1N3M0 RML PR 68.4 14.9 22 
7 71 M T2N3M0 LLL PR 54.0 16.0 19 
8 77 M T4N2M0 RUL PR 61.2 17.6 22 
9 74 F T2N0M0 RLL no 
chemo 
54.0 16.3 20 
10 79 F T4N0M0 RLL PR 57.6 18.3 23 
11 57 M T1N3M0 LUL PR 64.8 8.5 27 
12 68 M T4N0M0 RUL PR 54.0 6.8 20 
13 63 M T4N0M0 RLL SD 64.8 17.3 24 
14 59 F T2N2M0 RML PR 46.8 20.0 16 
15 55 M T4N2M0 LUL SD 79.2 16.4 29 
16 52 F T2N3M0 LLL PR 54.0 15.6 20 
17 50 F T4N2M0 LLL PR 61.2 20.8 21 
18 71 M T4N2M0 RUL PR 79.2 13.6 29 
19 61 F T2N2M0 RML PR 57.6 19.0 21 
20 62 M T2N2M0 RUL PR 68.4 18.8 27 
21 80 M T2N0M0 LLL no 
chemo 
61.2 15.2 21 
22 56 M T4N2M0 LUL SD 79.2 17.8 30 
23 54 M T2N3M0 LUL SD 79.2 16.1 30 
Mean 64.0     61.7 16.4 22.8 
SD 9.6     9.8 3.4 4.1 
TTD = Total Tumor Dose; MLD = Mean Lung Dose; OTT = Overall Treatment Time 
F = Female; M = Male; PR = Partial Remission as response to induction chemotherapy; SD = 
Stable Disease as response to induction chemotherapy (RECIST criteria) 
RLL: Right Lower Lobe; LLL: Left Lower Lobe; RUL: Right Upper Lobe:LUL: Left Upper 
Lobe; RML: Right Middle Lobe 
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Table 2: Evolution of the Gross Tumor Volume of the primary tumor during radiotherapy. 
Patient 
no. 
Volume 
before RT 
(cm3) 
Corresponding 
dose after one 
week of RT (Gy) 
Volume 
after one 
week of RT 
(cm3) 
Corresponding 
dose after two 
weeks of RT (Gy) 
Volume 
after two 
weeks of 
RT (cm3) 
1 7.9 19.8 4.7 37.8 5.2 
2 660.2 18.0 580.3 34.2 455.9 
3 53.1 18.0 65.9 NA NA 
4 26.6 19.8 14.7 37.8 2.8 
5 97.3 18.0 155.0 36.0 134.6 
6 7.5 19.8 4.3 34.2 5.0 
7 28.1 16.2 43.8 37.8 36.4 
8 3.5 19.8 5.9 41.4 6.0 
9 64.9 27.0 35.8 NA NA 
10 12.2 NA NA 36.0 10.8 
11 0.4 19.8 0.5 NA NA 
12 63.2 23.4 64.6 37.8 72.3 
13 67.2 19.8 88.6 48.6 42.2 
14 272.2 23.4 323.8 41.4 288.9 
15 92.9 19.8 104.3 37.8 84.0 
16 79.0 21.6 99.7 39.6 83.8 
17 92.9 19.8 153.5 37.8 121.1 
18 7.3 21.6 6.2 32.4 6.4 
19 101.9 16.2 131.2 41.4 80.1 
20 24.2 19.8 28.0 37.8 26.7 
21 107.7 14.4 114.7 27 105.3 
22 73.0 18 75.9 39.6 65.0 
23 69.0 34.2 79.9 50.4 95.8 
Mean 87.5 20.4 99.2 38.3 84.4 
SD 137.7 4.1 130.4 5.1 109.8 
p = 0.049 one week vs prior; p = 0.007 two weeks vs one week; p = 0.940 two weeks vs prior 
RT: Radiotherapy 
NA: Not Assessed because of technical problems 
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Changes of the motion of the primary tumor 
Tumor motion, expressed as a 3D vector, which is the quadratic sum of the mo-
tion in the three orthogonal directions and the breathing frequency are shown in 
Table 3 and Fig. 3. On average, the total vector motion changed from 7.8 mm ± 
4.8 mm initially to 7.8 mm ± 5.9 mm and 8.0 mm ± 5.6 mm one and two weeks 
after the start of the radiotherapy respectively. All differences compared to the 
initial tumor motion were not statistically different from each other (p = 0.969 
and p = 0.582 respectively). 
When we looked at the individual differences for the motion for all directions 
compared to the initial motion, we observed a maximal absolute difference of 
4.5 mm and 6.4 mm one and two weeks after the start of radiotherapy. The 
maximal difference between week 2 and week 1 after the start of radiotherapy 
was 5.4 mm. In Fig 3, a histogram of these differences is shown. 
If we use the peak to peak amplitude divided by four, as used for the internal 
margin in van Herk’s margin recipe 15, only for one patient, for one direction the 
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Figure 1: The CT volumes, relative to the volume prior to treatment, were plotted versus the 
dose. The thick black line is the average relative CT volume together with the standard deviation. 
The dotted lines represents the patients where the tumor increased more than 30%, the dashed 
lines those patients with a decrease of more than 30%. 
Chapter 5 86 
internal margin increased more than 1 mm one week after the start of radiother-
apy. Two weeks after radiotherapy the internal margin should have been 
changed for three patients with more than 1 mm (Fig. 3). 
Change of the breathing frequency 
The breathing frequency was not statistically different at the three time points. 
On average, the frequency changed from 18.5 ± 3.6 breathing cycles per minute 
(BPM) to 19.2 ± 4.1 BPM and 18.3 ± 4.5 BPM (p = 0.800 and p = 0.880 respec-
tively). 
DISCUSSION 
For high precision radiation therapy, it is important to have, during a course of 
radiation therapy, knowledge of the changes of several parameters, such as the 
tumor volume and tumor motion. 
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Figure 2: 3D Vector motion, which is the quadratic sum of the motion in three orthogonal direc-
tions, plotted versus the dose. The thick black line represents the average tumor motion, together 
with the standard deviation. 
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We observed a large heterogeneity of the changes in tumor volume in our pa-
tient population. Only a few patients (3/23) showed a large systematic decrease 
(> 30%) in tumor volume, whereas in the majority of patients (16/23), the tumor 
volume only slightly changed (< 30%). We even found a large increase in tumor 
volume for four out of 23 patients. The clinical impact of these volume changes 
and how to adapt treatment is however still unclear. Further clinical and plan-
ning studies need to be done to clarify this problem. 
So, in contrast to other investigators 7,8, no significant decrease in the tumor 
volume during the first two weeks of radiotherapy was found. Several differ-
ences between the reported studies and our study may explain the differences. 
In contrast to the present study, in the studies of Kupelian et al. 7 and Erridge et 
al. 8, patients were treated with a conventional fractionation scheme (2 Gy/day) 
delivered over an overall treatment time of more than 40 days. In our study, all 
patients received an accelerated schedule in which 1.8 Gy per fraction was de-
livered BID, 5 days per week. It may be that the decrease of the tumor volume 
by radiation-induced cancer cell death was offset by treatment-induced inflam-
mation, which once again increased the volume. The net result may be a stable 
volume. Comparable results in tumor volume changes on CT scans in the first 
two weeks due to radiotherapy have been described when high doses per frac-
Figure 3: Histogram of the differences (mm) in motion amplitude between all time points. The 
differences for all three orthogonal directions are shown. 
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tions (7.5 Gy – 20 Gy) are used in stereotactic radiotherapy for stage I NSCLC 
9, 10. We may get more insight in the internal tumor processes by analyzing the 
FDG distribution in the tumor during the course of radiation. Unfortunately it is 
still too early to correlate these changes in tumor volume with outcome. These 
analyses will however be the subject of another paper. 
 
Table 3: 3D Vector motion and breathing frequency before and during the radiation treatment. 
 Before RT After one week of RT After two weeks of RT 
Patient no. 3D Vector BPM 3D Vector BPM 3D Vector BPM 
5 7.7 22.2 9.2 22.2 8.2 25.5 
6 8.1 15.5 11.0 12.0 16.0 17.6 
7 4.5 24.0 2.9 23.1 3.9 21.6 
12 0.5 14.0 0.7 15.0 1.6 12.6 
14 16.3 17.5 21.0 17.6 17.8 19.0 
15 4.2 12.9 7.3 23.5 4.7 17.1 
16 9.5 19.2 6.2 25.5 8.2 21.1 
17 4.2 21.6 3.1 21.6 4.0 24.5 
19 11.4 22.2 7.4 20.3 9.8 16.1 
20 4.5 16.9 1.6 16.3 2.5 16.7 
21 15.6 19.7 15.8 17.9 15.1 17.9 
22 7.0 16.0 6.9 15.4 4.6 9.9 
MEAN 7.8 18.5 7.8 19.2 8.0 18.3 
SD 4.8 3.6 5.9 4.1 5.6 4.5 
3D Vector: p = 0.969 one week vs prior; p = 0.582 two weeks vs prior 
BPM: p = 0.799 one week vs prior; p = 0.875 two weeks vs prior 
BPM: Breathing cycles Per Minute 
 
To the best of our knowledge, this is the first study dealing with the changes of 
the motion and the breathing frequency of patients with locally advanced (Stage 
II-III) NSCLC during a course of radiotherapy. Underberg et al. 10 described 
similar findings for Stage I NSCLC treated with hypofractionated stereotactic 
radiotherapy. Although we found no significant changes, on average, in tumor 
motion and breathing frequency, during the first two weeks of radiotherapy, in 
some patients quite a wide variation was seen. However, even for the largest 
difference in tumor motion, the clinical implication on the size of the PTV and 
hence on the treatment fields is limited, since only a fraction of this motion is 
used for PTV expansion to account for the tumor motion. Only for one patient, 
for one direction the internal margin increased more than 1 mm one week after 
the start of radiotherapy. Two weeks after radiotherapy the internal margin 
should have been changed for three patients with more than 1 mm (Fig. 3). In 
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this patient group, the respiration correlated CT information will not influence 
the internal margin that needs to be taken. 
In conclusion, our results clearly show that, at least when an accelerated radio-
therapy schedule is given, changes in the volume of the primary tumor do occur 
during the first two weeks of radiotherapy. A large variability among the pa-
tients was observed, indicating that repeated imaging during the course of radio-
therapy is necessary to know the changes in GTV and to be able to individualize 
radiation treatment. In contrast, repeated respiration correlated CT imaging dur-
ing radiotherapy does not appear to be necessary as the changes in tumor mo-
tion are small, and will not lead to a change in treatment. 
REFERENCES 
1. De Ruysscher D, Wanders R, Boersma L, et al. Radiotherapy in the management of lung 
cancer. International Journal of Respiratory Care 2005;Winter:1-5. 
2. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET 
CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a 
modeling study. Int J Radiat Oncol Biol Phys 2005;61:649-655. 
3. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedi-
cated combined PET-CT-simulator of patients with non-small cell lung cancer on dose lim-
iting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 
2005;77:5-10. 
4. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation 
based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective 
clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-994. 
5. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a 
phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients 
with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-
328. 
6. Bosmans G, Buijssen J, Dekker A, et al. An “in silico” clinical trial comparing free breath-
ing, slow and respiratory correlated computed tomography in lung cancer patients. Radio-
ther Oncol 2005;76:S92. 
7. Kupelian PA, Ramsey C, Meeks SL, et al. Serial megavoltage CT imaging during external 
beam radiotherapy for non-small-cell lung cancer: Observations on tumor regression during 
treatment. Int J Radiat Oncol Biol Phys 2005;63:1024-1028. 
8. Erridge SC, Seppenwoolde Y, Muller SH, et al. Portal imaging to assess set-up errors, tu-
mor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung can-
cer. Radiother Oncol 2003;66:75-85. 
9. Senan S, Underberg R, Slotman B, et al. Time trends in target volumes during stereotactic 
radiotherapy for Stage I non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 
2004;60:S281-S282. 
10. Underberg R, Lagerwaard F, van Tinteren H, et al. Time trends in target volumes for stage I 
non-small-cell lung cancer after stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 
2006; 64(4):1221-8. 
Chapter 5 90 
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to 
treatment in solid tumors. European Organization for Research and Treatment of Cancer, 
National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl 
Cancer Inst 2000;92:205-216. 
12. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung 
dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998;42:1-9. 
13. ICRU report 62: Prescribing, recording, and reporting photon beam therapy (Supplement to 
ICRU report 50). Bethesda, MD: International Commission on Radiation Units and Meas-
urements. 1999. 
14. van Sornsen de Koste JR, Lagerwaard FJ, Nijssen-Visser MR, et al. Tumor location cannot 
predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans. 
Int J Radiat Oncol Biol Phys 2003;56:348-354. 
15. van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol 2004;14:52-64. 
Repeat PET 91 
CHAP T E R   
6
 
Time trends in the maximal uptake of FDG 
on PET scan during thoracic radiotherapy. A 
prospective study in locally advanced non-
small cell lung cancer (NSCLC) patients 
Radiother Oncol. 2007;82(2):145-52 
Chapter 6 
Repeat PET 
Angela van Baardwijk* 
Geert Bosmans* 
André Dekker 
Marinus van Kroonenburgh 
Liesbeth Boersma 
Stofferinus Wanders 
Michel Öllers 
Ruud Houben 
André Minken 
Philippe Lambin 
Dirk De Ruysscher 
 
* these authors equally contributed to this study 
Chapter 6 92 
ABSTRACT 
Background and purpose: 18F-fluoro-2-deoxy-glucose (FDG) uptake on PET 
scan is a prognostic factor for outcome in NSCLC. We investigated changes in 
FDG uptake during fractionated radiotherapy in relation to metabolic response 
with the ultimate aim to adapt treatment according to early response. 
Methods and materials: Twenty-three patients, medically inoperable or with 
advanced NSCLC, underwent four repeated PET-CT scans before, during and 
after radiotherapy. Changes in maximal standardized uptake value (SUVmax) 
were described. Patients were treated with accelerated radiotherapy with a total 
tumor-dose depending on normal tissue dose constraints. 
Results: The most striking result was the large intra-individual heterogeneity in 
the evolution of SUVmax. For the total group a non-significant increase in the 
first week (p = 0.05), and a decrease in the second week (p = 0.02) and after 
radiotherapy (p < 0.01) was observed. Different time trends were shown for re-
sponders (no change during radiotherapy) and non-responders (48% increase 
during first week, p = 0.02 and 15% decrease in the second week, p = 0.04). 
Non-responders had a higher SUVmax on all time points investigated. 
Conclusions: Time trends in SUVmax showed a large intra-individual heteroge-
neity and different patterns for metabolic responders and non-responders. These 
new findings may reflect intrinsic tumor characteristics and might finally be 
useful to adapt treatment. 
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INTRODUCTION 
Thoracic irradiation plays an important role in the management of advanced 
non-small cell lung cancer (NSCLC). Although the prognosis of these patients 
has improved, local tumor control is still not achieved in the majority of the pa-
tients 37,44,45. Local tumor control can be improved by increasing the total radia-
tion dose and the addition of chemotherapy to radiotherapy, but normal tissue 
toxicity, like esophagitis and radiation pneumonitis, is dose limiting 3,11,20,30,34,38. 
A more individualized prediction of response to a specific therapy is needed in 
order to avoid needless treatment or to be able to propose an alternative therapy 
if possible 29,42,46. Methods to describe tumor characteristics include imaging 
techniques, like positron emission tomography (PET). In different tumor sites 
pre- and post-treatment PET scans have been correlated to outcome 19,24,57. In-
deed, the maximal uptake of 18F-fluoro-2-deoxy-glucose (FDG) in the primary 
lung tumor as measured on a PET-scan before treatment was consistently shown 
to be a significant, independent, prognostic factor for survival in NSCLC, both 
in case of surgical resection and radical radiotherapy 1,5,15,18,25,53. On the other 
hand, a post-treatment PET scan can predict residual disease and hence outcome 
in NSCLC 9,26,32,33,56. Although there is a paucity on data dealing with the evolu-
tion of FDG uptake during fractionated radiotherapy, it is logical to study these 
time trends as an early predictive parameter, as has been shown for chemother-
apy 12,14,16,22,26. We hypothesized that changes in uptake might reflect early tu-
mor response during radiotherapy, which might finally allow further individu-
alization and adaptation of treatment before therapy is completed 7. 
 
The aim of the current study was to describe changes in the uptake of FDG on 
PET scans during a course of radiotherapy in patients with NSCLC and to in-
vestigate whether there are differences in time trends in FDG uptake between 
metabolic responders and non-responders. 
METHODS AND MATERIALS 
Study population 
From December 2004 to September 2005, 23 patients with medically inoperable 
or locally advanced NSCLC were enrolled in a phase I study. Patients with lo-
calized, histologically confirmed NSCLC, a WHO-performance score of 0 or 1, 
a weight loss of < 10% in 6 months and a reasonable lung function (a FEV1 > 
50% of predicted value and a DLCO ≥ 50%) were eligible. In case of previous 
chemotherapy, radiotherapy was started after a minimum of 14 days after the 
last chemotherapy course. The response to induction chemotherapy was evalu-
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ated using the RECIST-criteria 48. No previous radiotherapy to the chest was 
allowed. Patients were not eligible if they had any other concomitant malignant 
disease, a recent severe cardiac disease or active peptic esophagitis. 
PET-CT-scan 
As part of this phase I study repeated PET-CT scans (before start of radiother-
apy, on day 7 and day 14 during radiotherapy and 70 days after radiotherapy) 
were performed in radiotherapy position on a dedicated PET-CT-simulator with 
both arms above the head and using a laser marker system. The PET-CT scan-
ner used was a BiographTM (SOMATOM Sensation 16 with its ECAT ACCEL 
PET scanner, Siemens). Patients were fasting for at least 6 h before the exami-
nation. FDG (MDS Nordion, Liege, Belgium) was injected intravenously and 
followed by physiologic saline (10 ml). The injected total activity of FDG de-
pended on the weight of the patient: (weight × 4 + 20) MBq. After a rest period 
of 45 min (time needed for uptake of FDG) PET and CT images were acquired. 
The CT-scan performed was a spiral CT-scan of the whole thorax, with intrave-
nous contrast. The PET images were acquired in 5-min bed positions, while 2 or 
3 positions were needed to scan the thoracic region. The standardized uptake 
value (SUV) was used to measure the amount of uptake of FDG in the primary 
tumor. A region of interest (ROI) was drawn on the 3D-images in E-soft (ver-
sion 5.0.24.5, Siemens, Erlangen, Germany) around the region of the primary 
tumor. SUV was calculated as activity concentration of FDG uptake divided by 
injected dose/body weight 49. To avoid partial volume effects as much as possi-
ble, the maximal SUV (SUVmax) within this ROI was calculated and used for 
correlations. 
Treatment description 
All patients enrolled in this phase I study were irradiated using an individual-
ized prescribed maximal tolerated dose (MTD). This total tumor dose (TTD) 
was based on normal tissue constraints instead of a classic fixed prescribed 
dose. For the lungs a mean lung dose (MLD) of 19.0 Gray (Gy) and for the spi-
nal cord a maximal dose of 54.0 Gy were used as dose constraints. The maximal 
allowed TTD was 79.2 Gy or lower if any of the normal dose constraints were 
reached. The margin from GTV (gross tumor volume) to CTV (clinical target 
volume) was 5 mm and for the PTV (planning target volume) another 10 mm 
for the primary tumor and 5 mm for lymph nodes were added. No elective nodal 
irradiation was carried out. A 3D conformal treatment plan, using three to six 
coplanar 10 MV photon fields, was calculated according to the ICRU guidelines 
27. Calculations were performed using an XiO treatment planning system (Com-
puter Medical System Inc.) with a FFT convolution algorithm for inhomogene-
ity corrections 35. Patients were irradiated on a linear accelerator (Elekta SL 15, 
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Crawley, United Kingdom). Radiotherapy was delivered twice daily, with at 
least an 8-h interval (BID scheme) and with a fraction size of 1.8 Gy. Results 
concerning toxicity and outcome of this phase I study will be reported sepa-
rately. 
Assessment of metabolic response 
Metabolic response was measured 70 days after radiotherapy by means of a 
PET-CT scan. This scan was compared to the pre-treatment scan, following the 
recommendations of the EORTC (Table 1) 58. The total group was divided in 
responders, showing complete metabolic response (CMR) or partial metabolic 
response (PMR), and non-responders with stable metabolic disease (SMD) or 
progressive metabolic disease (PMD). 
 
Table 1. EORTC Criteria. Definition of metabolic response on PET-CT scans 70 days after 
radiotherapy. 
CMR Complete resolution of FDG uptake in tumor, not distinguish-
able from surrounding tissue 
PMR Reduction of more than 25% in SUV 
SMD Changes in SUV of less than 25% 
PMD Increase of SUV of more than 25% or new (metastatic) lesions 
EORTC: European Organization for Research and Treatment of Cancer; CMR: complete meta-
bolic response; PMR: partial metabolic response; SMD: stable metabolic disease; PMD: pro-
gressive metabolic disease; SUV: standardized uptake value. 
Statistics 
The SPSS software (SPSS for Windows, version 14.0, SPSS Inc., Chicago, IL) 
was used for statistical analysis. Results are expressed as mean ± SD (standard 
deviation) for individual results and as mean ± SE (standard error of the mean) 
for groups. The paired Student’s t-test was used to compare the SUVmax on dif-
ferent time points, whereas the Mann–Whitney U-test and the Fisher’s exact test 
was used to compare the different groups. Follow-up was updated and frozen at 
July 1st of 2006. Survival estimates were calculated using the Kaplan–Meier 
method and comparison of the survival curves were made using the log-rank 
test. Patients lost to follow-up were censored from survival data. Two-tailed p-
values are provided and p-values less than 0.05 were considered statistically 
significant. 
Chapter 6 96 
Ethics 
This study has been reviewed and approved by the local Medical Ethical Com-
mittee, according to the Dutch law and regulations. All patients gave written 
informed consent before entering this study. 
RESULTS 
Patient characteristics 
The patient characteristics are depicted in Table 2. Three patients did not re-
ceive chemotherapy, while 20 patients received platinum-based chemotherapy 
(Cisplatin or Carboplatin, combined with Gemcitabin). As a result of induction 
chemotherapy 15 patients showed a partial remission and 5 patients showed sta-
ble disease. The median interval between the last course of chemotherapy and 
the start of radiotherapy was 35 ± 16 days (range: 14–56 days). The average 
total tumor dose (TTD) given was 62.5 ± 9.7 Gy (range: 46.8–79.2 Gy) in an 
overall treatment time (OTT) of 22 days (range: 17–30 days). The first PET-CT 
scan was performed before start of radiotherapy (median 9 days before start of 
radiotherapy, range 4–13 days), the second on day 7 of radiotherapy (at a me-
dian dose of 19.8 ± 4.1 Gy) and the third on day 14 of radiotherapy (at a median 
dose of 37.8 ± 5.1 Gy). The fourth PET-CT scan was performed 70 days after 
the last day of radiotherapy (median: 71 ± 12 days). Because of logistic reasons 
or technical problems with the PET-scan, no PET information was available for 
1 patient on day 7 and for 4 patients on day 14 of radiotherapy. For 3 patients no 
PET scan was available after radiotherapy, in one because of technical reasons 
and in 2 patients because of early death after radiotherapy due to a myocardial 
infarction and a pulmonary infection. The median follow-up (FU) from start of 
RT was 9.2 ± 3.8 months. 
Time trends in maximal SUV 
There was a large heterogeneity in the changes in SUVmax of the primary tumor 
during the radiation treatment between patients (Fig. 1). Out of the 22 patients 
who had a PET-CT at day 7 of radiotherapy, 4 patients (18%) showed a de-
crease of more than 25% of the SUVmax, whereas 41% (9/22) showed an in-
crease of more than 25%. The remainder (9/22) showed a stable SUVmax (< 25% 
change) compared to pre-treatment values. 
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Table 2: Patient characteristics 
patient 
no. 
age 
(yr) 
sex cTNM pathology response to 
induction 
chemo-
therapy 
OTT 
(days) 
TTD 
(Gy) 
Metabolic 
response 
70 days 
after RT 
1 52 f T1N3M0 adenoca PR 21 54.0 CMR 
2 54 m T3N2M0 Large cell ca SD 21 54.0 PMD 
3 75 m T3N2M0 large cell ca PR 21 54.0 no scan 
4 71 f T3N1M0 scc no chemo 28 64.8 CMR 
5 71 m T2N3M0 adenoca PR 21 54.0 † 
6 61 m T1N3M0 scc PR 27 64.8 CMR 
7 71 m T2N3M0 adenoca PR 20 60.0 PMD 
8 77 m T4N2M0 large cell ca PR 22 61.2 CMR 
9 74 f T2N0M0 large cell ca no chemo 20 54.0 PMR 
10 79 f T4N0M0 large cell ca PR 24 57.6 PMR 
11 57 m T1N3M0 large cell ca PR 30 64.8 CMR 
12 68 m T4N0M0 adenoca PR 21 54.0 CMR 
13 63 m T4N0M0 scc SD 24 64.8 SMD 
14 59 f T2N2M0 large cell ca PR 17 46.8 PMD 
15 55 m T4N2M0 adenoca SD 30 79,2 PMD 
16 52 f T2N3M0 scc PR 21 54.0 PMD 
17 50 f T4N2M0 large cell ca PR 22 61.2 PMD 
18 71 m T4N2M0 large cell ca PR 30 79.2 PMR 
19 61 f T2N2M0 large cell ca PR 21 57.6 SMD 
20 62 m T2N2M0 large cell ca PR 27 68.4 CMR 
21 80 m T2N0M0 scc no chemo 22 61.2 † 
22 56 m T4N2M0 large cell ca SD 30 79.2 PMR 
23 54 m T2N3M0 large cell ca SD 30 79.2 PMD 
scc = squamous cell carcinoma, PR = partial remission as response to induction chemotherapy, 
SD = stable disease as response to induction chemotherapy, OTT = overall treatment time of 
radiotherapy, TTD = total tumour dose, CMR = complete metabolic response, PMR = partial 
metabolic response, SMD = stable metabolic disease, PMD = progressive metabolic disease. 
†= patient died within first 70 days after radiotherapy. 
 
 
For the whole patient group, the SUVmax was on average 7.3 ± 0.8 (range: 0.6–
16.1) before start of radiotherapy, which increased to 8.9 ± 1.2 (range: 1.3–23.1) 
on day 7 of treatment (p = 0.05). In the second week, a significant decrease was 
observed to a SUVmax of 8.1 ± 1.0 (range: 2.1–17.8) (p = 0.02). Seventy days 
after treatment the SUVmax further decreased to a mean level of 4.8 ± 3.3 (range: 
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1.2–13.4), a significant decrease compared to day 14 of treatment (p = 0.001) 
and compared to pre-treatment levels (p = 0.005) (Fig. 2a). Analysing the subset 
of patients (n = 16), who received a PET-CT scan at all time points during ra-
diotherapy, similar results were obtained: SUVmax before radiotherapy 7.0 ± 0.9 
and at day 7 9.7 ± 1.5 (p = 0.02), day 14 8.0 ± 1.1 (p = 0.02) and 70 days after 
radiotherapy 4.7 ± 0.8 (p = 0.002). 
Metabolic responders versus non-responders 
In 20 patients a PET-CT scan was performed 70 days after treatment. In 1 pa-
tient (with visually a CMR) no SUVmax could be calculated, due to a software 
problem. Eleven patients (55%) showed a metabolic response 70 days after ra-
Figure 1. The absolute (maximal SUV (standardized uptake value) plotted versus time (before 
start RT, day 7 and day 14 during RT and 70 days after RT) for all individual patients with a CT-
PET scan at day 70. 
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diotherapy [7 patients CMR and 4 patients PMR], while 9 patients (45%) 
showed no response [2 patients SMD, 7 patients PMD]. Concerning the PMD 
group, 4 patients had metastatic disease and 3 patients showed loco-regional 
progression. 
 
 
 
Patients with a metabolic response 70 days after thoracic irradiation had a sig-
nificantly longer overall survival (estimated survival of 100% after 9 months of 
follow-up) compared to the patients with stable or progressive disease (esti-
mated survival of 63% after 9 months of follow-up) (p = 0.005) (Fig. 3). No 
difference was observed between total radiation dose prescribed (p = 0.4) and 
the overall treatment time of radiotherapy (p = 0.2) between metabolic respond-
ers and non-responders. 
In the group of metabolic responders no change in SUVmax was observed during 
the course of radiotherapy. Only after radiotherapy a mean decrease of 46% of 
the SUVmax was observed from 5.0 ± 0.8 on day 14 during radiotherapy to 2.7 ± 
0.4 70 days after radiotherapy (p = 0.02; Fig. 2b, Table 3). In contrast to this 
finding, the group of non-responders showed a significant increase of the SU-
Vmax in the first week of radiotherapy. In this group the SUVmax before treatment 
was on average 8.9 ± 1.1 and increased to 13.2 ± 1.7 in the first week (p = 0.02). 
In the second week a decrease was observed to an average level of 11.5 ± 1.3 (p 
= 0.04), with a further decrease after radiotherapy to a mean of 6.9 ± 1.2 (p = 
0.02). Similar results were obtained for the subset of patients with a PET-CT 
scan on day 0, 7 and 14: for the responders SUVmax did not change during radio-
Figure 2. Average change in maximal SUV for the total group of patients (a) and for metabolic 
responders (complete and partial metabolic response) versus non-responders (stable metabolic 
disease and progressive metabolic disease) (b), * indicates a significant difference. 
(a) (b) 
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therapy (before radiotherapy, 5.1 ± 1.1; day 7, 5.3 ± 4.6 ± 0.8; day 14, 4.6 ± 
0.8), while for the non-responders the SUVmax increased during the first week 
and decreased again during the second week of radiotherapy (before radiother-
apy,8.9 ± 1.2; day 7, 14.0 ± 1.7 (p = 0.01) and day 14, 11.5 ± 1.3(p = 0.04). 
 
Not only a difference in time trends in SUVmax was observed between respond-
ers and non-responders, but the non-responders also showed a significant higher 
SUVmax than the responders at all time points investigated (Fig. 2, Table 3). 
The number of patients in this study was however too small to test the predic-
tive value of the time trends in SUVmax in relation to metabolic response. 
  
Figure 3. Actuarial analysis of overall survival (Kaplan-Meier) in months for metabolic respond-
ers (n=11) and non-responders (n=9), classified according to EORTC-criteria. p-value of log-rank 
test. 
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Influence of induction chemotherapy 
In total 20 patients received induction chemotherapy, of which 18 patients were 
evaluable 70 days after irradiation. The group of patients achieving a partial 
remission after induction chemotherapy (13/18) showed in higher percentage 
metabolic response after radiotherapy (metabolic response rate, 62%) as patients 
showing stable disease as a result of the induction chemotherapy (metabolic 
response rate, 20%), although this difference was not significant (p = 0.3). The 
time patterns of the SUVmax in relation to metabolic response as described above 
for the total group were similar in patients having received induction chemo-
therapy. 
This excludes the possibility that the 3 individuals, who did not receive system-
atic treatment, would have influenced the overall results. 
 
Table 3. Maximal SUV (mean ± SE) before start of radiotherapy, on day 7 and 14 during ra-
diotherapy and 70 days after radiotherapy for the total group, for patients showing a metabolic 
response (CMR or PMR) or no metabolic response (SMD or PMD) on radiotherapy 70 days 
after irradiation. P-value of Mann-Whitney U-test to compare the group of metabolic respond-
ers and non-responders. 
 Total group Metabolic  
responders 
Metabolic  
non-responders 
 
Maximal 
SUV 
mean SE (N) mean SE (N) mean SE (N) p 
Before start 
of radiother-
apy 
7.3 0.8 (23) 5.1 0.9 (11) 8.9 1.1 (9) 0.020 
Day 7 of  
radiotherapy 
8.9 1.2 (22) 4.8 1.1 (10) 13.2 1.7 (9) 0.001 
Day 14 of 
radiotherapy 
8.1 1.0 (19) 5.0 0.8 (9) 11.5 1.3 (8) <0.001 
70 days after 
radiotherpy 
4.5 0.7 (19) 2.7 0.4 (10) 6.5 1.2 (9) 0.002 
DISCUSSION 
Until now the PET-scan is mainly used before start of radiotherapy for staging 
purposes, to delineate the primary tumor and/or mediastinal lymph nodes and 
after therapy to assess the remission status 2,6,13,17,21,32,33,39,50,52,54. Similar to early 
response measurements during chemotherapy, FDG-PET scans performed in the 
beginning of radiotherapy might give information on the later tumor response 
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14,22,26,41. However, only limited data on this subject are available in the literature 
12,16. We therefore assessed in the present study the time trends of FDG uptake 
during radiation treatment in NSCLC. 
A striking result was the large heterogeneity in the SUVmax in serial PET-scans 
between the individual patients. While some patients showed an increase, others 
show a stable or decreased FDG uptake after 1 week of radiation. This confirms 
the findings of Erdi et al., who described serial PET-scans during radiation ther-
apy in 2 NSCLC patients 16. De Geus-Oei et al. investigated repeated FDG-PET 
scans in patients treated with accelerated radiotherapy with carbogen and 
nicotinamide (ARCON) for head-and-neck cancer and also showed very hetero-
geneous changes in SUVmax after hyperoxygenation with a median interval of 2 
days between the two scans 12. Investigating the time trends we observed for the 
total group a trend in increase of the SUVmax (p = 0.05) during the first week of 
radiotherapy, followed by a significant decrease in the second week of treatment 
and in the first 70 days after treatment. Only few other authors described re-
peated (CT)-PET scans during radiation therapy. Geets et al. described re-
imaging with FDG-PET scan during radiation treatment in head-and-neck pa-
tients 23. After an average dose of 46 Gy, 18 patients received a repeat PET-
scan, which was hard to interpret due to inflammation. 
In our patients with NSCLC we did not encounter this problem. de Geus-Oei et 
al. showed in 22 patients with head and-neck tumors a median decrease of rela-
tive change of SUVmax of 4%, comparing the PET scan after hyperoxygenation 
to the baseline scan 12. Lin et al. described repeated PET-scans during treatment 
in cervical patients, but no results concerning the (maximal) SUV were investi-
gated 31. In both the study of Lin and Geets, most patients received concurrent 
chemo-radiation, while in the study of de Geus-Oei et al. patients were treated 
with ARCON. 
By using the EORTC criteria to evaluate the metabolic response after 70 days 
we could confirm the findings of Mac Manus et al. that metabolic responders 
had a better overall survival than the non-responders (p = 0.005) 33. Moreover, a 
significant difference in the time trends of SUVmax during radiotherapy between 
metabolic responders and non-responders was found. Metabolic non-responders 
had a higher SUVmax at all time points investigated and showed a significant 
increase in SUVmax during the first week of irradiation followed by a decrease. 
In contrast, the responders showed a stable SUVmax during irradiation. The 
number of included patients was however too small to calculate the predictive 
value of the changes in SUVmax during a course of radiation. The question thus 
remains what causes the observed time trends and their relation with subsequent 
response. A first hypothesis is that the increase of SUVmax during the first week 
is due to inflammation, since a rather high median dose of 19.8 Gy (1.8 Gy 
BID) was already delivered at the time point of the first repeat PET-CT scan. 
Radiation is known to be a potent inducer of inflammation in several tissues 
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28,43,51. However, this cannot explain the differences in metabolic responders and 
non-responders, since one would also expect inflammatory changes in the group 
of responders. Another possibility is that the SUVmax provides information re-
lated to intrinsic biological characteristics of the tumor, such as tumor hypoxia. 
As hypoxia is strongly related to therapy resistance and the occurrence of me-
tastases, this hypothesis is particularly attractive. Hypoxia might play a role in 
the uptake of FDG, since it leads via the hypoxia inducible factor-1α (HIF-1α) 
pathway to up regulation of glucose transporters. However, contradictory find-
ings concerning the relation between FDG uptake and hypoxia have been pub-
lished 8,10,36,40,47,55,59,60. 
Although the radiation dose (range: 46.8–79.2 Gy) could have influenced the 
response rate, a dose–response relation could not be established in this series, 
presumably due to the limited number of patients 11,34. Another possibility is 
that the response on induction chemotherapy may also affect the subsequent 
response to radiation. However, this could not be shown in our study. To fully 
exclude the influence of induction chemotherapy it would have been best to per-
form the first PET-CT scan before start of any treatment. Although most of our 
patients underwent a PET-(CT) scan before start of chemotherapy, most of these 
scans were performed at different PET-(CT) scanners in affiliated hospitals. 
Since maximal SUV of different scanners cannot be compared directly, we were 
not able to encompass maximal SUV before start of chemotherapy into our re-
sults. 
Lastly, the overall treatment time of radiotherapy might influence response after 
radiotherapy 4. We did not find such a correlation between OTT of radiotherapy 
and the metabolic response rate, but this may be due to a short OTT (less than 5 
weeks) in all patients. Our present working hypothesis is that the difference in 
time trends of SUVmax as observed between responders and non-responders 
might reflect a complex relationship between several factors, like changes in 
blood flow as well as changes in the extracellular compartment, together with 
intrinsic tumor properties, which all contribute to the uptake of the FDG tracer. 
Further in-depth studies, including analysis of several plasma markers at differ-
ent time points, to address this question are ongoing. 
In conclusion, a large heterogeneity in changes in SUVmax was observed during 
thoracic radiation. Differences in time trends of SUVmax during radiotherapy 
were found between metabolic responders and non-responders. Further research 
addressing the question whether these time trends can predict response, the bio-
logical meaning of the different time trends and whether it finally might enable 
individualized adjustments of treatment is ongoing. The final goal, being predic-
tion of response early during the course of radiotherapy to enable early adjust-
ments, like prescribing a higher total dose, adjusting the fractionation scheme or 
adding another form of treatment. 
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ABSTRACT 
Purpose: Knowledge of changes in GTV and motion of GTV during a course of 
radiotherapy is necessary for accurate treatment delivery. This study describes 
the time trends in nodal CT volume and nodal motion for patients with locally 
advanced NSCLC. 
Patients and Methods: In a prospective clinical trial 12 patients, with a total of 
22 positive nodes, underwent a CT-PET scan prior to treatment, as well as in the 
first and second week following start of radiotherapy. Volume changes could be 
measured for all nodes. For 21 nodes, the motion was measured based on a res-
piration correlated CT (RC-CT) scan. Repeated RC-CT scans were available for 
11 nodes to evaluate the change in motion. 
Results: In 6/22 (27%) patients the nodal volume increased > 30% while in 3/22 
(14%) the volume decreased > 30%. On average, the nodal volume did not 
change significantly (from 4.9 to 5.1 to 4.6 cm3). The average motion of the 
nodal areas was initially 5.6 mm ± 2.8 mm. This motion decreased slightly dur-
ing therapy but not statistically significant. However, large inter-patient and 
inter-nodal motion differences were observed. 
Conclusion: A large variability of changes in nodal volume between patients 
was observed. However, this had limited clinical impact, since volumes and 
hence volume changes were small. The nodal motion did not change signifi-
cantly during therapy. However, because of the large inter patient variability of 
nodal motion prior to treatment, internal margins for nodal areas should be cal-
culated before radiotherapy using RC-CT, such that the margins can be applied 
for individual patients. Repeated imaging of the nodes seems however to be of 
limited use, as the observed individual changes in nodal volume and motion 
tend to fall within the commonly applied margins. 
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INTRODUCTION 
Radiotherapy plays an important role in the management of patients suffering 
from non-small cell lung cancer (NSCLC). Obviously, accurate definition of 
target volumes is crucial. Several authors showed that the use of FDG-PET in-
formation improves target delineation, as indicated by a reduced interobserver 
variation This has been ascribed to the ability of FDG-PET to better discrimi-
nate involved from non-involved nodes, tumor from atelectasis and the applica-
tion of automated contouring systems 1-8. 
Respiration correlated CT (RC-CT) scans have been shown to be able to take 
into account motion of the tumor 9, 10. With this relatively new technique tumor 
motion can be measured in 3 dimensions, and these data can subsequently be 
used to apply the internal margins, as defined by the ICRU 11, 12. 
Besides optimal delineation before the start of radiation, adequate radiotherapy 
also needs to take into account the changes in volume and motion of target vol-
umes during therapy. Indeed, many research groups have demonstrated striking 
volume changes during a course of radiotherapy 13-17. In a previous paper we 
found that the motion of the primary tumor during a course of radiotherapy on 
average did not show significant changes, but for individual patients sometimes 
larger changes in motion were seen 13. However, all studies presented data on 
the primary tumor, whereas none described changes of the volume of mediasti-
nal lymph nodes. Even less data are available on the mobility of mediastinal 
lymph nodes prior to and during a course of radiation therapy. Moreover, only 
one study used four-dimensional CT scanning to assess nodal motion 18 and 
other authors used surrogate methods to estimate nodal motion in three dimen-
sions, like repeated CT imaging 19 or orthogonal fluoroscopy of calcified lymph 
nodes 20. 
In summary, no data are available on changes of real time nodal motion and 
nodal volume during a course of radiotherapy. More detailed information on 
nodal motion and changes in nodal volume and motion would allow to indi-
vidually adapt the internal margin and thereby allow further optimization of the 
treatment plans, i.e. to reduce geograhical misses whilst mimizing the dose to 
the normal tissues. Therefore, the aim of the present study was to analyze 
changes in nodal volumes and nodal motion during the first 2 weeks of an ac-
celerated course of radiotherapy in patients with locally advanced non-small cell 
lung cancer (NSCLC), using RC-CT scans.  
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PATIENTS AND METHODS 
Patients 
Twenty-three patients with histological or cytological proven non-small cell 
lung cancer (NSCLC) were enrolled in this prospective study, which was part of 
a phase I trial. Patients were included from December 2004 until September 
2005. Five patients had initially no positive lymph nodes (N0), while four pa-
tients became node negative on the FDG-PET scan after chemotherapy. Two 
patients had a primary tumor with direct extensive invasion in the mediastinum, 
making distinguishing the primary tumor and the involved lymph nodes impos-
sible. This resulted in a total of 12 patients with 22 positive nodal areas. The 
Naruke/ATS-LCSG standardized mapping system was used to define the ana-
tomical location of the lymph node involvement 21. No concurrent chemother-
apy was given. 
The Medical Ethics Committee according to the Dutch law approved this study. 
All patients gave written informed consent before entering this study. 
Radiotherapy simulation 
Patients were simulated in radiotherapy position on a dedicated CT-PET-
simulator with both arms above the head using an immobilization device and 
patient laser marker system. Radiotherapy technologists trained specifically for 
this purpose carried out the simulation. The CT-PET scanner used was a Sie-
mens Biograph (SOMATOM Sensation-16 with an ECAT ACCEL PET scan-
ner). A spiral CT with intravenous contrast was performed covering the com-
plete thoracic region 13. 
Respiration Correlated CT scans (RC-CT) 
The CT-PET was immediately followed by a respiration correlated CT, using 
offline correlation of the 16-slice spiral CT scan of the CT-PET system. This 
had been modified to enable a low pitch (minimum 0.1), in combination with a 
respiratory signal obtained by a pressure sensor in a chest belt (AZ-733V, Anzai 
Medical Corporation, Tokyo, Japan). The raw CT data were reconstructed in 10 
phases, from 0% to 100% in steps of 10% of the respiration period starting at 
end inspiration. In-house developed software with Matlab (Mathworks Inc, Na-
tick, MA) was used to measure the motion of the lymph node in all three or-
thogonal directions 9. This was performed manually by measuring the largest 
distance between the respiration phases on a movie in an axial, sagittal and cor-
onal view. 
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Radiotherapy planning 
Radiotherapy planning was performed on an XiO (Computerized Medical Sys-
tems, St Louis, Missouri) treatment planning system, using inhomogeneity cor-
rections, based on a convolution algorithm. For all patients, the Gross Tumor 
Volume (GTV) was defined based on CT-PET data, obtained prior to radiother-
apy (i.e. post chemotherapy in case of induction chemotherapy for the primary 
tumor and pre chemotherapy for the lymph nodes). For the volume comparison 
in this study, the CT-Nodal Volume was defined as the FDG-PET positive 
lymph nodes, as described by the report of nuclear medicine post-
chemotherapy, delineated on the CT with a mediastinal window-level setting 
(W = 600, L = 40). 
Radiotherapy dose and normal tissue dose constraints 
For each patient, the radiation dose was escalated to a mean lung dose (MLD) 
of 19 Gy ± 1 Gy while respecting a maximum spinal cord dose of 54 Gy. There 
were no esophageal dose constraints. The maximal allowed total tumor dose 
(TTD) was 79.2 Gy or lower if any of the normal tissue dose constraints were 
reached. Radiotherapy was always delivered twice a day (BID), with a mini-
mum of 8 hours interval between the two fractions, and given 5 days per week 
with a fraction dose of 1.8 Gy. 
Study design 
Patients underwent repeated CT-PET scans and respiration correlated CT scans 
in treatment position, before and one and two weeks during radiotherapy. At all 
time points, the nodal volume was delineated using the free-breathing CT. Al-
though in principle this may have led to blurring artifacts, our high-speed 16 
slice CT-scan protocol effectively “freezes” the lesion in a single phase during a 
free breathing CT-scan.  This assumption was found to be valid for the primary 
tumor and was subsequently extrapolated to the nodal areas. The nodal volume 
was delineated for each patient by the same physician to avoid interobserver 
variability. To study the intra-observer variability, seven (32%) nodal volumes 
were delineated twice by the same physician for all time points, with at least a 3 
months time interval. The ratio between the two delineations was calculated and 
reported as a percentage. 
Due to technical and logistical problems, a complete image dataset at all three 
time points, was not available for two patients. A CT-PET dataset (with in total 
four nodal areas) two weeks after the start of treatment was not obtained for 
these two patients. 
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Endpoints and statistical analysis 
We determined the nodal volumes (NV) prior to radiation, 1 and 2 weeks after 
start of the treatment, based on the NVs drawn on the free-breathing CT. In ad-
dition, the respiration correlated CT was used to quantify the nodal motion at all 
3 time points. Nodal motion was expressed as a 3D vector 22, which is the quad-
ratic sum of the motions in the three orthogonal directions. All results are ex-
pressed as the mean ± standard deviation (SD). Statistical differences between 
paired parameters from the three time points were evaluated using the Wilcoxon 
signed rank test. Differences were considered to be significant when the p-value 
was less than 0.05. 
 
Table 1: Patient characteristics. 
Patient 
no. 
Age 
(years) 
Gender Clinical 
stage 
Involved nodal 
stations 
TTD 
(Gy) 
MLD 
(Gy) 
OTT 
(days) 
1 54 M T3N2M0 7 54.0 19.3 20 
2 75 M T3N2M0 7, 4R 54.0 15.2 20 
3 71 M T2N3M0 7, 3, 5, 2R 54.0 14.7 23 
4 61 M T1N2M0 7, 4R 68.4 14.9 22 
5 77 M T4N2M0 7, 4R, 10R 61.2 17.6 22 
6 57 M T1N2M0 2R, 4R 64.8 8.5 27 
7 59 F T2N2M0 7, 2R 46.8 20.0 16 
8 55 M T4N2M0 5 79.2 16.4 29 
9 52 F T2N2M0 7, 10L 54.0 15.6 20 
10 50 F T4N2M0 7 61.2 20.8 21 
11 71 M T4N2M0 2, 4R 79.2 13.6 29 
12 54 M T2N3M0 2L 79.2 16.1 30 
Mean 61.3    63.0 16.1 23.3 
SD 9.6    11.3 3.3 4.5 
TTD = Total Tumor Dose; MLD = Mean Lung Dose; OTT = Overall Treatment Time 
F = Female; M = Male; 
RESULTS 
Patient characteristics 
Patient characteristics are shown in Table 1. The mean values of the total tumor 
dose (TTD) and the corresponding mean lung dose (MLD) were 63.0 Gy ± 11.3 
Gy [range: 46.8 Gy – 79.2 Gy] and 16.1 Gy ± 3.3 Gy [range: 8.5 Gy – 20.8 Gy], 
respectively. The average volume per pathological lymph node before radio-
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therapy was 4.9 cm³ ± 4.4 cm³ [range: 0.2 cm³ – 19.6 cm³]. The first repeat scan 
was made after the patient received on average a dose of 21.2 Gy ± 4.4 Gy 
(about 12 fractions) and the second scan after 38.5 Gy ± 5.2 Gy (about 21 frac-
tions). 
Volume changes of the mediastinal lymph nodes 
A large heterogeneity of nodal volume changes between patients was observed 
at all time points (Table 2). In 6/22 (27%) patients the nodal volume increased > 
30%, while in 3/22 (14%) the volume decreased > 30%. For the majority of 
nodal areas (13/22) the volume changed only slightly (< 30%) (Fig. 1). 
On average the nodal volume changed from 4.9 cm3 ± 4.4 cm3 prior to treat-
ment, to 5.1 cm3 ± 4.1 cm3 and 4.6 cm3 ± 4.2 cm3 1 and 2 weeks after the start of 
treatment, respectively. These changes were not significant (p = 0.897 prior ver-
sus week 1, p = 0.177 prior versus week 2 and p = 0.084 week 2 versus week 1). 
Figure 1: Nodal volumes (NV), relative to the volume prior to treatment as a function of the dose. 
The thick black line represents the mean relative CT volume together with the standard deviation. 
The dotted lines represent the individual patients where the NV increased more than 30%; the 
dashed lines those patients with a decrease of more than 30%. A solid grey line is used for the 
remaining patients. 
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Intra-observer variability in delineation of the mediastinal lymph nodes 
For the 21 delineations on three different time points which were performed 
twice an average intra-observer variability of 11.6 % ± 9.4 %, with a maximum 
deviation of 37.4% was found. Since similar volume changes were observed for 
the second delineation (data not shown) this variability did not influence the 
results on the volume changes of the mediastinal areas during radiotherapy. 
 
Table 2: Evolution of the Nodal Volume during radiotherapy. 
Patient 
no. 
Nodal 
area 
Volume be-
fore RT 
(cm3) 
Volume one week after 
start RT (cm3) and relative 
change (%) 
Volume two weeks after 
start RT (cm3) and relative 
change (%) 
1 7 11.8 11.2 (-5%) 10.1 (-14%) 
2 7 3.5 2.6 (-26%) NA 
 4R 3.1 4.5 (+45%) NA 
3 7 2.2 1.5 (-32%) 1.3 (-41%) 
 2R 19.6 16.8 (-14%) 14.9 (-24%) 
 3 0.2 0.3 (+50%) 0.3 (+50%) 
 5 1.8 0.7 (-61%) 0.7 (-61%) 
4 7 6.2 5.9 (-5%) 3.2 (-48%) 
 4R 6.1 5.6 (-8%) 3.6 (-41%) 
5 10R 3.6 9.5 (+163%) 10.9 (+202%) 
 4R 2.9 3.0 (+3%) 2.0 (-31%) 
 7 1.8 4.9 (+172%) 8.2 (+355%) 
6 2R 9.3 8.2 (-12%) NA 
 4R 6.6 4.7 (-29%) NA 
7 2R 0.6 0.5 (-17%) 0.5 (-17%) 
 7 5.7 6.0 (+5) 6.0 (+5%) 
8 5 0.8 0.5 (-38%) 1.0 (+25%) 
9 10L 1.5 3.2 (+113%) 1.9 ( +27%) 
 7 6.1 6.6 (+8%) 5.6 (-8%) 
10 7 3.4 4.4 (+29%) 3.8 (+12%) 
11 2, 4R 7.6 9.9 (+30%) 6.9 (-9%) 
12 2L 2.5 2.7 (+8%) 1.9 (-24%) 
Mean  4.9 5.1 (+4%) 4.6 (-6%) 
SD  4.4 4.1 4.2 
p = 0.897 one week vs prior; p = 0.084 two weeks vs one week; p = 0.177 two weeks vs prior 
RT: Radiotherapy; NA: Not Assessed because of thecnical problems 
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Motion changes of nodal areas 
Nodal motion is shown in Table 3 and Fig 2. For one nodal area it was not pos-
sible to measure the motion because of its limited size (0.2 cm3). The mean ini-
tial motion before start of radiotherapy of all nodes was 5.6 mm ± 2.8 mm. The 
motion was larger in cranial-caudal direction (4.3 mm ± 3.2 mm) compared 
with the other directions (ventro-dorsal 1.8 mm ± 1.5 mm and left-right 2.0 mm 
± 1.3 mm). The 3D motion changed to 5.8 mm ± 2.6 mm and 5.3 mm ± 2.7 mm 
one and two weeks after the start of the radiotherapy respectively. All differ-
ences compared to the initial nodal motion were not statistically significant dif-
ferent from each other (p = 0.838 and p = 0.221 respectively). 
 
Table 3: 3D Vector motion before and during radiation treatment. 
Patient 
no. 
Nodal 
area 
Motion prior to 
treatment (mm) 
Motion after one 
week of RT (mm) 
Motion after two 
weeks of RT (mm) 
1 7 4.9   
2 7 3.6   
 4R 6.4   
3 7 4.2 4.0 1.4 
 2R 2.1 2.2 2.2 
 3 NA   
 5 1.4 3.7 1.4 
4 7 6.7 9.3 6.1 
 4R 6.7 7.8 7.2 
5 10R 3.3   
 4R 3.7   
 7 4.3   
6 2R 6.4   
 4R 7.0   
7 2R 12.3 9.2 7.9 
 7 6.7 6.3 9.0 
8 5 4.3 4.6 3.3 
9 10L 9.1 9.1 6.7 
 7 3.9 3.6 6.7 
10 7 11.0 4.4 6.3 
11 2, 4R 7.7   
12 2L 2.1   
Mean  5.6 5.8 5.3 
SD  2.8 2.6 2.7 
p = 0.838 one week vs prior; p = 0.507 two weeks vs one week; p = 0.221 two weeks vs prior 
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In order to investigate the influence of the anatomical location of the nodes on 
its motion, the involved lymph nodes were classified based on their location: 
infra-carinal (N = 10) versus supra-carinal (N = 12). The motion was 5.8 mm ± 
2.6 mm versus 5.5 mm ± 3.2 mm respectively (p = 0.812). However, in individ-
ual patients, large inter-nodal motion differences could occur (e.g. patient nrs: 2, 
7 and 9) (Table 3). 
 
DISCUSSION 
To the best of our knowledge, this is the first report about time trends of nodal 
volume and motion of involved mediastinal lymph nodes in patients with 
NSCLC during radiotherapy. This information is clinically relevant since 
changes in size and mobility of all tumor localizations (e.g. the primary tumor 
and the lymph nodes) during a course of radiotherapy are needed as an input for 
adaptive radiotherapy approaches.  
Figure 2: 3D Vector motion (quadratic sum of the motion in three orthogonal directions) as a 
function of the dose. The gray lines represent the individual patient data, while the thick black line 
represents the mean tumor motion, together with the standard deviation. 
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Our results show that, similar to the volume changes of the primary tumor vol-
umes 13, the individual volumes of the mediastinal lymph nodes may change 
considerably during radiotherapy and that a large heterogeneity of nodal volume 
changes between patients was observed. The nodal volume increased > 30% in 
27% of the patients and decreased > 30% in 14% of the patients. In a previous 
study of our group, for the primary tumor, 17% of the patients showed a large 
increase of tumor volume and 13% of the patients had a large decrease of the 
tumor 13. We did not find a correlation between the tumor increase and decrease 
versus the change in volume of the involved mediastinal lymph nodes in the 
same patient. Intra-patient differences were also observed that may be explained 
by the different location and the size of the nodal areas within the patient.  
Intra-observer variability could not explain the time trends of the nodal volume 
changes. Remarkably, the relative intra-observer variability for delineation of 
the nodes was substantially larger than the intra-observer variability of the pri-
mary tumor (1.2 % ±  4.4%) 13. This can probably be ascribed to the fact that a 
small intra-observer variation in the small absolute nodal volumes has larger 
relative effect than small intra-observer variation in the large primary tumor 
volumes. 
However, since the nodal volume was relatively small (average 4.9 cm3, range: 
0.2 cm3 - 19.6 cm3), the clinical impact of the volume changes is probably lim-
ited. Assuming that nodes are spherical, the average observed volume change 
would result in a difference of the radius of 1 mm or less for 85% of the investi-
gated nodes [range: -2 mm − +5 mm]. Only in one patient two lymph nodes 
showed an increase of respectively 4 mm and 5 mm of the radius. In this case, 
adaptation of the gross tumor volume might have been appropriate depending 
on the used treatment technique (e.g. motion adapted) and margins. The motion 
of those lymph nodes was relatively small (3D vector: 3.3 mm and 4.3 mm re-
spectively). Our clinically applied GTV-PTV margin of 1 cm, consisting of a 3 
mm margin for CTV 23 and 7 mm for PTV, would probably have covered most 
of the change in volume during therapy. This, in contrast with the changes of 
the volume of the primary tumor during therapy, where in some patients signifi-
cant changes were observed and adaptive radiotherapy could be beneficial 13. 
The motion of the nodal areas, which are more constrained by surrounding tis-
sue, was smaller than the motion of the primary tumor. Prior to therapy, the 3D 
vector was on average 5.6 mm ± 2.8 mm versus 7.8 mm ± 4.8 mm 13 for the 
nodes and primary tumor respectively. These results are in agreement with Piet 
et al. 18, who also used 4D-CT scans to evaluate the nodal motion. They re-
ported a 3D vector motion of 6.2 mm ± 2.9 mm.  Jenkins et al. 20 used orthogo-
nal fluoroscopic imaging to asses the motion of calcified lymph nodes.  These 
investigators observed the motion during several breathing cycles and therefore 
have probably taken the maximum respiration excursion. They found a larger 
nodal motion of 7.0 mm ± 4.7 mm especially in the cranial caudal direction. 
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The difference with our results may be due to the motion measurement method 
and to a different patient population.  
Taking into account the peak-to-peak amplitude divided by four in our study to 
calculate the internal margin 9, an average isotropic internal margin of 1.4 mm 
would suffice, so the 5 mm margin proposed by van Sörnsen de Koste et al. 19, 
seems rather large.  However, since these authors used repeated 3D CT images, 
other factors like image correlation and intra-observer variations may have in-
fluenced their results. In the present study, we found a large inter-patient and 
inter-nodal difference in motion (range: 1.4 mm – 12.3 m), indicating that a 
general internal margin is not appropriate and the motion should individually be 
measured with an RC-CT. This might improve target definition and hence treat-
ment outcome. In agreement with the other investigators 18-20, we did not ob-
serve a difference in motion between the locations of the nodal areas.  
On average no change in nodal motion was observed during treatment although 
for some patients large differences could occur. When using a specific nodal 
internal margin these motion changes could influence treatment accuracy and 
adaptive strategies might be developed if the changes extend beyond the applied 
PTV margins. 
Until now respiratory management is mainly focused on the motion of the pri-
mary tumor 10. When extending this high precision treatment technique to the 
involved lymph nodes, the reported nodal volume and motion changes could 
play an important role in the accuracy of the treatment. 
In conclusion, our results show that a different internal margin should be ap-
plied to the nodal areas compared to the primary tumor. This internal margin 
should be defined individually with a four-dimensional imaging technique prior 
to therapy. On average the nodal volume as well as the nodal motion did not 
change significantly during the radiation although large inter patient differences 
were observed. In contrast to the primary tumor 13, repeated imaging of the 
nodes seems to be of limited use, as the observed individual changes in nodal 
volume and motion tend to fall within the applied margins.  
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For stage III non-small cell lung cancer (NSCLC) patients, radiation therapy 
plays a major role in their treatment with curative intent. Nevertheless, the 
prognosis remains grim, with most patients still experiencing local and distant 
tumor relapse. 
Local tumor control and hence survival could be improved by delivering higher 
doses to the tumor in a reasonably short overall treatment time, while at the 
same time keeping the radiation dose to surrounding healthy tissue tolerable. 
Problems to achieve this in clinical practice are respiration artifacts in imaging 
of the tumor and changes in the tumor during radiation therapy. 
Accurate imaging of lung tumors is difficult since respiration causes distorted 
images. Four-dimensional imaging, with the time being the fourth dimension, is 
therefore currently a ‘hot topic’ in radiotherapy. This technique is needed to 
achieve the accuracy of state-of-the art treatment delivery. 
Radiation treatment planning is mostly based on a single pre-treatment CT(-
PET) scan, but incorporating the tumor dynamics during a course of radiother-
apy into the treatment planning could probably improve treatment accuracy. 
Respiration Correlated (RC) or Four-Dimensional (4D) CT 
We first investigated how to use the 4D imaging data in the treatment planning. 
We compared the standard imaging protocol, a free breathing CT, with different 
methods of generating an internal target volume (ITV) based on the 4D or respi-
ration correlated CT scan. With a free breathing CT, no information about the 
respiration motion is known. Therefore general population based margins are 
used to create the planning target volume (PTV). These margins will be too big 
for some patients, where the tumor will not move that much, but in other pa-
tients, with a large tumor motion, the margin will be too small. For the first 
group, knowledge of the tumor motion in the individual patient could lead to a 
decrease in treatment fields and hence sparing more normal tissue, resulting in a 
lower normal tissue complication probability (NTCP). Another possibility 
would be to keep the same level of toxicity and to escalate the radiation dose to 
reach these normal tissue dose constraints. For the second group, the treatment 
fields should be enlarged, thereby reducing geographical misses and increasing 
the tumor control probability (TCP). 
Besides inappropriate margins, free breathing CT also might introduce system-
atic errors. The free breathing CT, with current fast multislice CT scanners, is 
actually a snapshot of the patient’s anatomy and could be taken at an extreme 
position near end expiration or end inspiration of the tumor. As such a CT does 
not represent patient geometry during irradiation, a large systematic error may 
be introduced, which will have a big impact on the treatment accuracy 1. 
One might overcome this problem by acquiring a slow CT instead of the snap-
shot, free breathing CT. We therefore simulated a slow CT by averaging all the 
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CTs taken at individual phases, and showed that it was sometimes difficult to 
delineate the tumor because of the blurred images, especially near the mediasti-
num or diaphragm. This resulted in too small volumes (Chapter 2) and therefore 
no optimal coverage of the Clinical Target Volume could be achieved. 
Treatment plans based on all the CT datasets (i.e. the full 4D-CT) will have bet-
ter CTV coverage but this method generated larger volumes than the treatment 
plan based on the half-ventilation CT scan. 
The half-ventilation method seems to be optimal since only one CT has to been 
delineated, individual anisotropic tumor motion can be incorporated and the 
proposed margin recipe of the peak-to-peak amplitude divided by four still 
achieved good CTV coverage (Chapter 2). 
The main advantage of using 4D-CT in treatment planning is reducing system-
atic errors, with the half-ventilation phase, and for some patients decreasing the 
internal safety margins which make dose escalation possible. 
Respiration Correlated CT-PET 
CT-PET imaging has proven to be beneficial for radiation treatment planning. It 
provides a more accurate estimate of the true extent of disease inside the thorax 
compared to CT and is a sensitive method for detection of distant metastasis 
outside the thorax 2. PET can also better identify involved lymph nodes than CT 
and it has been proven to be safe to only irradiate PET positive lymph nodes 3. 
However, it is difficult to define the GTV manually on a PET scan, since these 
images are for instance very susceptible to window level settings. Many sugges-
tions have been made for automatic delineations 4, but no good three-
dimensional validation with pathologic information has been performed. One of 
the prerequisites of auto-delineation is a quantitative PET, which is a challenge 
in a tumor moving with respiration. The main problem is the smearing out effect 
due to the respiration, which makes the intensity of a PET voxel not only a 
function of glucose metabolism, but also of the respiration. With respiration 
correlated PET, blurring does not occur, so it should improve target volume 
definition. Respiration correlated PET might also be very useful to image non-
homogeneous tumors. A malignant tumor is not a homogeneous mass, but is 
composed of regions that differ in radioresistance. This intra-tumor heterogene-
ity can be visualized with PET imaging and opens new therapeutic possibilities 
for individualized patient treatment. However, the visualization of this intra-
tumor heterogeneity could be distorted if no respiration correlation is per-
formed. 
Another consideration when trying to keep PET a quantitative technique, is the 
attenuation correction. In a CT-PET scanner, the CT information is used for the 
calculation of the attenuation correction. However, discrepancies between the 
fast CT and slow PET images could introduce artifacts. We therefore investi-
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gated how an RC-PET should be optimally corrected for attenuation in phantom 
measurements (Chapter 3) and in simulations based on real RC-CT patient data 
(Chapter 4). To allow reliable quantification of the PET-signal, attenuation re-
lated errors should be minimized. These errors depend on tumor location, tumor 
size and tumor motion. In all simulated cases, the phased attenuation correction 
yielded the best results.  
The binning of the images was based on the phase of the respiration instead of 
the amplitude of the respiration. The latter method is more accurate but can lead 
to gaps in the coronal images, depending on the patient’s breathing pattern. 
Phase binning exhibits no gaps but could generate artifacts due to misbinning 5. 
For RC-CT, with a relatively short acquisition time, we seldom see irregular 
breathing patterns. Therefore we believe that phase binning is an acceptable 
method of reconstruction. For RC-CT-PET, more research on a large patient 
scale is needed to quantify errors between the two methods. 
To allow the use of (RC-) CT-PET suitable for radiotherapy simulation and 
dose calculation, a flat carbon table should be used, a moveable laser system 
and the CT Hounsfield units should be calibrated to electron densities. Although 
this is an initial investment, in the end it will be more cost effective, since in 
that case no additional CT for radiotherapy planning has to be performed. 
In conclusion, the main reasons for making RC-CT-PET scans are: avoiding a 
systematic error, avoiding image blurring, and improving auto-delineation pro-
cedures since it allows quantification of the PET signal when using phased at-
tenuation correction. In addition, the RC-CT-PET also offers unique possibili-
ties for further research on intra-tumor heterogeneity and correlation of CT-PET 
with pathology data. This indicated that an RC-CT-PET should be the standard 
procedure for CT-PET imaging of lung cancer patients. 
Repeated imaging during radiotherapy 
The main purpose of repeat imaging during therapy is to see if the GTV and its 
motion changes during therapy. We used repeated CT-PET and repeated RC-CT 
scans to investigate these changes. This has the advantage, over in-room imag-
ing, that the diagnostic image quality is preserved. In addition, apart from ana-
tomical information it allows to investigate metabolic changes. The conse-
quence of anatomical changes could be a change in the size of the treatment 
fields. But maybe in some cases also the field geometry should be adjusted, 
when critical organs (e.g. the spinal cord) become dose limiting. 
We observed for some patients a large increase in tumor volume during therapy. 
For those patients tumor control might be improved by enlarging the treatment 
fields. For the patients with decreasing tumor volumes, more normal tissue can 
be spared with shrinking treatment fields. 
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Changes in tumor motion were relatively small, especially when looking at the 
impact on the internal safety margin, which is only a fraction of the motion 
(Chapter 5). 
The second purpose of repeated PET imaging was to see if we could find a pre-
dictive parameter for response early in the treatment and to enable early adjust-
ments, like prescribing a higher total dose, adjusting the fractionation scheme or 
adding another treatment modality (Chapter 6). With this information we can 
also investigate if the intra-tumor heterogeneity remains stable during therapy. 
This information is necessary to develop new treatment options, such as boost-
ing radio-resistant areas within the tumor. 
In locally advanced NSCLC, the mediastinal lymph nodes are often involved. 
Therefore similar knowledge as for the primary tumor is needed for adaptive 
treatment. When looking at the changes, for the volume as well as for the mo-
tion, the clinical impact is relatively small. However, like for tumor motion, 
there was a large inter-patient variability of nodal motion, even for involved 
lymph nodes close to the mediastinum (for example: nodal area seven 6). The 
nodal motion was somewhat smaller than tumor motion. Even within the same 
patient with multiple involved lymph nodes, differences were observed in nodal 
motion depending on its anatomical location (Chapter 7). This underscores the 
need of making an RC-CT not only for the tumor but also for the lymph nodes 
and to use a patient and nodal specific anisotropic internal margin. 
FUTURE PERSPECTIVES 
Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in 
both men and women. Therefore those patients are a big challenge as they have 
a very high incidence of both local tumor recurrence and distant failure. 
One of the first chains in the radiotherapy process is imaging the patient for tar-
get definition. A lot of effort has been made to incorporate PET information for 
treatment planning. A discussed before, this should be replaced by an RC-CT-
PET but currently no institution uses these scans routinely for all patients. 
Therefore RC-CT-PET scanning protocols should be optimized and standard-
ized to assure good image quality (i.e. a good signal/noise ratio). This includes 
investigating the benefits of phased attenuation, regarding quantitative parame-
ters like the SUVmax, on real RC-CT and RC-PET patient data. 
At present, no data are yet available on 3D correlation of PET information with 
the pathologic information. This could give information about the extent of the 
tumor and can be used as an input for developing auto-delineation protocols. 
This would reduce further the interobserver variation and would be less time 
consuming for the radiation oncologist. It will also facilitate multi-institutional 
studies when a uniform, preferably automated, delineation protocol is available. 
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Radiotherapy patients are mostly inoperable and therefore we are currently per-
forming a study to validate RC-CT-PET delineation with pathology in a differ-
ent, i.e. operable patient population 7. Another way to tackle this problem is to 
prospectively investigate the result of autodelineation algorithms by looking at 
local recurrence patterns. 
When resources do not allow to make RC-CT-PET images, another solution is 
described recently 8, 9. Deep inspiration breath hold (BH) CT-PET imaging 
looks promising and an increased detection and better characterization of lung 
lesions compared with a standard clinical CT-PET protocol is feasible. This 
technique is easy to implement in clinical practice and requires only a minor 
increase in the examination time. It also reduces breathing artifacts, misregistra-
tion, and inaccuracies in SUV measurements. Of course treatment should be 
performed in the same position which will increase treatment time on the linear 
accelerator and will be more critical to assure similar patient setup during treat-
ment. Another drawback of this approach is the ability of lung cancer patients to 
hold their breath during scanning and treatment. 
These innovative imaging techniques for FDG-PET scanning could also be ex-
trapolated to other tracers, which visualize different biological characteristics of 
the tumor. 
In the near future we will investigate if the information obtained by repeated 
CT-PET images, is worthwhile to adapt the treatment fields. Calculations will 
be done for the dose distribution of the tumor and the surrounding tissues. We 
also need to look more in depth at the biological variations during therapy and 
try to answer important questions why SUVmax changes occurs differently for 
metabolic responders versus metabolic non-responders. These comparisons will 
be performed using non-rigid registrations algorithms to minimize deformation 
artifacts. At all timepoints blood samples were acquired which could give more 
insight in these tumor dynamics. 
Gaining more knowledge of intra-tumor heterogeneity by imaging also implies 
improving treatment modalities. As the total radiation dose is restricted by vir-
tue of the normal tissue constraints, dose redistribution (higher dose to resistant 
and lower dose to sensitive areas) within the tumor has a theoretical advantage. 
This can be done by introducing IMRT (subvolume boosting or dose painting) 
and delivering a non-homogenous dose to more radioresistant areas within the 
tumor. Another possibility is to treat the radioresistant zones within the primary 
tumor with hypofractionation (fraction size of 10Gy − 20Gy) followed by radio-
therapy to the whole tumor, with more conventional fraction doses.  
Currently, most studies and predictive models, for instance to predict outcome 
or radiation induced normal tissue injury, are based on planned dose distribu-
tions. When the theoretical distribution could be replaced by the actual deliv-
ered dose, this will improve accuracy in developing these predictive algorithms. 
The delivered dose can be measured with repeated imaging using an electronic 
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portal imaging device (EPID), and research is ongoing of converting the two-
dimensional EPID information behind the patient to three-dimensional dose dis-
tributions within the patient 10. 
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Radiotherapy plays an important role in the management of treating lung cancer 
patients. In this thesis two approaches to improve radiotherapy for patients with 
lung cancer are investigated. The first approach is to better define the target us-
ing novel imaging techniques such as respiration correlated (RC-) CT and respi-
ration correlated CT-PET. These techniques take into account the intra-fraction 
variations and artifacts due to respiration. In the second approach the target is 
followed during treatment using repeated (RC-) CT and CT-PET imaging, with 
the final goal being adaptation of radiotherapy during treatment and tackle inter-
fraction changes. 
 
In Chapter 2 we determined which method of internal target volume (ITV) 
definition based on a respiration correlated CT (RC-CT) allows optimal tumor 
coverage. Therefore we acquired both a free breathing CT (CTfb) and an RC-CT 
scan. The RC-CT scan was used to measure tumor motion and to reconstruct a 
CT at 10 phases (CT10ph), amongst which the half ventilation CT (CThv). By av-
eraging the CT10ph, a slow CT (CTslow) was reconstructed. Based on those scans 
ITVs were delineated and treatments were planned, where for the ITVhv an in-
ternal margin (margin for tumor motion) of (motion amplitude)/4 was used. The 
treatment plans for the ITVs were projected on the 10 respiration phases and 
subsequently the absorbed dose was calculated and averaged over the ten phases 
to estimate the actual CTV coverage. This was an in silico (plannings) study 
based on real RC-CT patient data. The CThv seems to be the optimal dataset for 
delineation, using an adequate anisotropic internal margin. 
 
Since accurate knowledge of the position of the tumor and the surrounding tis-
sues is needed for radiation treatment planning it is important to improve CT-
PET image acquisition. In Chapter 3 we evaluated the potential to improve im-
age acquisition using phased attenuation correction in respiration correlated CT-
PET, where data of both modalities was binned retrospectively. After collection 
of the raw CT data, list-mode PET data, and the respiratory signal CT-PET im-
ages were binned to ten phases with help of in-house built software. Each PET 
phase was corrected for attenuation with CT data of the corresponding phase. 
For comparison, the attenuation correction was also performed with non-
respiration correlated (non-RC) CT data. With a standard, non-RC CT-PET 
scan, the volume was underestimated by as much as 46% in CT and the PET 
volume was overestimated to 370% whereas the volumes with RC-CT-PET 
scanning had small deviations from the actual volume. Evaluation of the maxi-
mum activity concentration showed a clear displacement in the images with 
non-RC attenuation correction. In this phantom study we have shown that a 
combination of respiration correlated CT-PET scanning with application of 
phased attenuation correction can improve the imaging of moving objects and 
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can lead to improved volume estimation and a more precise localization and 
quantification of the activity. 
 
To quantify the attenuation errors and identify the parameters associated with 
them, we performed a simulation based on respiratory-gated CT studies of five 
lung cancer patients in Chapter 4. The CT series were converted to 511-keV 
attenuation maps which were forward-projected and exponentiated to form si-
nograms of PET attenuation factors at each phase of respiration. The CT images 
were also segmented to form a PET object, moving with the same motion as the 
CT series. In the moving PET object, spherical 20-mm mobile tumors were cre-
ated in the vicinity of the dome of the liver, and immobile 20-mm tumors in the 
mid chest region. The moving PET objects were forward-projected and attenu-
ated, then reconstructed in several ways: phase-matched PET and CT; gated 
PET with ungated CT; ungated PET with gated CT; and conventional PET.  
Phase-matched gated PET and CT gave essentially perfect PET reconstructions 
in the simulation. Gated PET with ungated CT gave tumors of the correct shape, 
but recovery was too large by an amount that depended on the extent of the mo-
tion, as much as 90% for mobile tumors and 60% for immobile tumors. Gated 
CT with ungated PET resulted in blurred tumors and caused the recovery errors 
between −50% and +75%. Recovery in clinical scans would be 0% to 20% 
lower than stated. Quantitative PET imaging near the diaphragm requires proper 
matching of attenuation information to the emission information. 
 
Chapter 5 deals with the change in tumor volume, motion and breathing fre-
quency during a course of radiotherapy, for locally advanced non-small cell 
lung cancer. Twenty-three patients underwent CT-PET and Respiration Corre-
lated CT scans prior to treatment, which was repeated in the first and second 
week following the start of radiotherapy. Patients were treated with an acceler-
ated fractionation schedule with a total tumor dose depending on pre-set dose 
constraints for the lungs and the spinal cord. A striking heterogeneity of tumor 
volume changes was observed at all time points. In some patients the volume 
decreased > 30% in others the volume increased > 30% but for the majority of 
patients the tumor volume only changed slightly. No significant changes in av-
erage tumor motion or breathing frequencies were seen during treatment. These 
results underscore the need for repeated imaging during the course of radiother-
apy. However, the changes in tumor motion are small, which indicates that re-
peated respiration correlated CT does not appear to be necessary for the primary 
tumor. 
 
18F-fluoro-2-deoxy-glucose (FDG) uptake on PET scan is a prognostic factor for 
outcome in NSCLC. We investigated changes in FDG uptake during fraction-
ated radiotherapy in relation to metabolic response with the ultimate aim to 
Summary 135 
adapt treatment according to early response (chapter 6). The same patient 
population of the previous chapter was examined. Almost all patients had a 70 
days post treatment CT-PET scan. Changes in maximal standardized uptake 
value (SUVmax) were described. The most striking result was the large intra-
individual heterogeneity in the evolution of SUVmax. Different time trends were 
shown for responders (no change during radiotherapy) and non-responders 
(48% increase during first week). Non-responders had a higher SUVmax on all 
time points investigated. Time trends in SUVmax showed a large intra-individual 
heterogeneity and different patterns for metabolic responders and non-
responders. These new findings may reflect intrinsic tumor characteristics and 
might finally be useful to adapt treatment. 
 
Chapter 7 describes the time trends in nodal CT volume and nodal motion. 
Twelve patients, with a total of 22 positive nodes, underwent a CT-PET scan 
prior to treatment, as well as in the first and second week following start of ra-
diotherapy. Volume changes could be measured for all nodes. For 21 nodes, the 
motion was measured based on a respiration correlated CT (RC-CT) scan. Re-
peated RC-CT scans were available for 11 nodes to evaluate the change in mo-
tion. In 27% patients the nodal volume increased > 30% while in 14% the vol-
ume decreased > 30%. These changes had limited clinical impact, since vol-
umes and hence volume changes were small and on average, the nodal volume 
did not change significantly. The average motion of the nodal areas was initially 
5.6 mm ± 2.8 mm. This motion decreased slightly during therapy but not statis-
tically significant. Large inter-patient and inter-nodal motion differences were 
observed. However, because of the large inter patient variability of nodal mo-
tion prior to treatment, internal margins for nodal areas should be calculated 
before radiotherapy using RC-CT, such that the margins can be applied for in-
dividual patients. Repeated imaging of the nodes seems however to be of lim-
ited use, as the observed individual changes in nodal volume and motion tend to 
fall within the commonly applied margins. 
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Radiotherapie speelt een belangrijke rol in de behandeling van longkanker pati-
enten. In dit proefschrift worden twee benaderingen onderzocht om de radiothe-
rapie te verbeteren voor deze patiënten. De eerste benadering is het beter defini-
eren van het doelvolume, gebruik makend van vernieuwende beeldvormings-
technieken zoals ademhalingsgecorreleerde CT (RC-CT) en ademhalingsgecor-
releerde CT-PET (RC-CT-PET). Deze technieken houden rekening met de in-
tra-fractie veranderingen en artefacts te wijten aan de ademhaling. In de tweede 
benadering wordt het doelvolume gevolgd tijdens de behandeling gebruik ma-
kend van herhaalde (RC)-CT en CT-PET beeldvorming, met het uiteindelijke 
doel om de radiotherapiebehandeling aan te passen tijdens de behandeling en 
om de inter-fractie veranderingen aan te pakken. 
 
In Hoofdstuk 2 hebben we bepaald welke methode om het interne doelvolume 
(ITV) te bepalen, gebaseerd op een RC-CT, een optimale dekking van de tumor 
toelaat. Daarom hebben we zowel een gewone ‘vrije ademhalings’ CT (CTfb) en 
een RC-CT scan gemaakt. De RC-CT scan werd gebruikt om de tumorbeweging 
te meten en om een 10 fasen CT te reconstrueren (CT10ph), waaronder de half-
ventilatie CT (CThv). Door de CT10ph te middelen werd een ‘trage’ CT scan be-
komen (CTslow). Op basis van al deze scans werden ITVs ingetekend en behan-
delingen berekend, waarbij we voor het ITVhv een interne marge (marge voor de 
tumor beweging) van bewegingsamplitude gedeeld door vier werd gebruikt. Al 
de behandelplannen voor de verschillende ITVs werden geprojecteerd op de 10 
ademhalingsfasen en vervolgens werd de geabsorbeerde dosis berekend over 
alle 10 fasen om de reële dekking van de tumor in te schatten. Dit was een plan-
ningstudie gebaseerd op echte RC-CT patiënt gegevens. De CThv lijkt de opti-
male dataset te zijn voor intekening, gebruik makend van een voldoende grote 
anisotrope interne marge. 
 
Nauwkeurige kennis van de positie van de tumor en het omliggende weefsel is 
nodig voor de radiotherapiebehandelingsplanning en het is belangrijk om de 
CT-PET beeldvorming te verbeteren. In Hoofdstuk 3 hebben we de mogelijk-
heid geevalueerd om de acquisitie te verbeteren door gebruik te maken van ge-
faseerde verzwakkingscorrectie in RC-CT-PET, waar beide modaliteiten retro-
spectief opgedeeld zijn. Na het verzamelen van de ruwe CT gegevens, de list-
mode PET gegevens en het ademhalingssignaal, werden de CT-PET beelden 
opgedeeld in 10 fasen met behulp van zelf geschreven software. Elke PET fase 
was gecorrigeerd voor verzwakking met de CT gegevens van de overeenkom-
stige fase. Ter vergelijking was ook de verzwakkingscorrectie uitgevoerd met 
CT data die niet ademhalingsgecorreleerd was. Met een standaard, niet ademha-
lingsgecorreleerde CT-PET scan werd het volume onderschat tot 46% in de CT 
beelden en overschat tot 370% voor het PET volume, terwijl met de RC-CT-
PET de volumes konden bepaald worden met kleine afwijkingen ten opzichte 
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van het reële volume. Het evalueren van de maximale activiteitsconcentratie liet 
een duidelijke verschuiving zien in de niet ademhalingsgecorreleerde beelden 
van dit maximum. In deze fantoomstudie hebben we laten zien dat een combi-
natie van RC-CT-PET beeldvorming met toepassing van gefaseerde verzwak-
kingscorrectie, de beeldvorming kan verbeteren van bewegende voorwerpen en 
kan leiden tot een verbeterde volumebepaling en een meer precieze lokalisatie 
en kwantificatie van de activiteit. 
 
Om de verzwakkingsfouten te kwantificeren en de parameters te identificeren 
verbonden met deze fouten, hebben we een simulatie uitgevoerd gebaseerd op 
ademhalingsgecorreleerde CT studies van vijf longkanker patiënten in Hoofd-
stuk 4. De CT werd geconverteerd naar 511-keV verzwakkingsmappen welke 
voorwaarts geprojecteerd en geexponentieerd werden om sinogrammen te vor-
men van PET verzwakkingsfactoren voor elke fase van de ademhaling. De CT 
beelden werden ook gesegmenteerd om een PET object te vormen met dezelfde 
beweging als de CT data. In de bewegende PET objecten werden bolvormige 
20mm bewegende tumoren aangemaakt in de buurt van de top van de lever en 
niet bewegende tumoren in de buurt van het midden van de borstkas. De bewe-
gende PET objecten werden voorwaarts geprojecteerd en verzwakt en daarna op 
verschillende manieren gereconstrueerd: gefaseerde PET en CT, gated PET met 
ungated CT, ungated PET met gated CT en conventionele PET. De gefaseerde 
gated PET en CT gaf perfecte reconstructies in de simulatie. Gated PET met 
ungated CT gaf tumoren met de correcte vorm maar de recuperatie van de 
maximale activiteit was te groot, afhankelijk van de grootte van tumorbewe-
ging, tot 90% voor bewegende tumoren en 60% voor niet bewegende tumoren. 
Gated CT met ungated PET resulteerde in onscherpe tumoren en veroorzaakte 
fouten in recuperatie tussen −50% en +75%. In klinische scans zou de recupera-
tie 0% tot 20% lager uitvallen. Kwantitatieve PET beeldvorming dichtbij het 
diafragma vereist gepaste matching van verzwakkingsinformatie voor de emis-
sie informatie. 
 
Hoofdstuk 5 gaat over de verandering in tumorvolume, tumorbeweging en 
ademhalingsfrekwentie tijdens een radiotherapiebehandeling voor patiënten met 
uitgebreid niet-kleincellig longkanker. Drieëntwintig patiënten kregen een CT-
PET en RC-CT scan voor de behandeling die herhaald werd in de eerste en 
tweede week volgende op de start van de radiotherapie. De patiënten werden 
behandeld met een versneld fractionatieschema met een totale tumor dosis af-
hankelijk van voorgenomen dosisbeperkingen voor de longen en het ruggemerg. 
Een opvallende heterogeniteit van de tumorvolume veranderingen werd waar-
genomen op alle tijdstippen. Voor sommige patiënten werd het volume meer 
dan 30% kleiner, voor andere werd het meer dan 30% groter maar voor de 
meerderheid van de patiënten veranderde het volume slechts gering. Geen signi-
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ficante veranderingen in gemiddelde tumorbeweging of ademhalingsfrekwentie 
werd waargenomen tijdens de behandeling. Deze resultaten onderstrepen de 
noodzaak om herhaalde beeldvorming tijdens de radiotherapiebehandeling uit te 
voeren. De veranderingen in tumorbeweging waren klein, daarom lijken her-
haalde ademhalingsgecorreleerde CT scans niet noodzakelijk voor de primaire 
tumor. 
 
18F-fluoro-2-deoxy-glucose (FDG) opname op PET beelden is een voorspellen-
de factor voor de uitkomst voor patiënten met niet-kleincellig longkanker. We 
hebben de veranderingen onderzocht in deze FDG opname tijdens gefractio-
neerde radiotherapie in relatie tot de metabole respons met het uiteindelijke doel 
de behandeling aan te passen volgens de vroege respons (Hoofdstuk 6). De-
zelfde patiëntpopulatie als in het vorige hoofdstuk werd onderzocht. Bijna alle 
patiënten hadden ook een CT-PET 70 dagen na het einde van de behandeling. 
Veranderingen in de maximale gestandaardizeerde opname waarde (SUVmax) 
zijn beschreven. Het meest opvallende resultaat was de grote heterogeniteit in 
evolutie van de SUVmax tussen de patiënten. Verschillende tijd trends werden 
gezien voor responders (geen verandering tijdens radiotherapie) en voor niet-
responders (48% toename in de eerste week). Niet-responders hadden op ieder 
onderzocht tijdspunt een hogere SUVmax. Tijd trends in SUVmax lieten een grote 
intra-individuele heterogeniteit en verschillende patronen voor metabole res-
ponders en niet-responders zien. Deze nieuwe bevindingen weerspiegelen mo-
gelijks intrinsieke tumoreigenschappen en kunnen uiteindelijk bruikbaar zijn om 
de behandeling aan te passen. 
 
Hoofdstuk 7 beschrijft de tijd trends in kliervolume en klierbeweging op de CT 
scan. Twaalf patiënten, met in totaal 22 positieve klieren, ondergingen herhaal-
de CT-PET scans voor de behandeling en de eerste en tweede week na de start 
van de radiotherapie. Volumeveranderingen konden gemeten worden voor alle 
klieren. Voor 21 klieren was de beweging gemeten op basis van een RC-CT 
scan. Herhaalde RC-CT scans waren beschikbaar voor 11 klieren om de bewe-
gingsveranderingen te evalueren. In 27% van de patiënten nam het kliervolume 
toe met meer dan 30% terwijl in 14% het volume daalde meer dan 30%. Deze 
volumeveranderingen hebben echter weinig klinisch impact gezien de volumes 
en dus ook de volumeveranderingen klein zijn en gemiddeld veranderde het 
kliervolume niet significant. De gemiddelde beweging van de klierregio’s was 
initieel 5.6 mm ± 2.8 mm. Deze beweging verminderde lichtjes tijdens de radio-
therapiebehandeling maar niet statistich significant. Grote verschillen in bewe-
ging tussen de patiënten en tussen klierregio’s binnen dezelfde patiënt werden 
waargenomen. Vanwege de grote variabiliteit in klierbeweging tussen de patiën-
ten onderling, moeten de interne marges voor deze klierregio’s individueel be-
rekend worden voor de start van de behandeling gebruik makend van een RC-
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CT. Herhaalde beeldvorming voor de klieren lijkt echter van weinig nut, gezien 
de geobserveerde individuele veranderingen in kliervolume en klierbeweging 
lijkt omvat te zijn binnen de huidige toegepaste marges. 
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Het is altijd een risico om een dankwoord te schrijven omdat de kans bestaat dat 
je iemand, uiteraard niet moedwillig, kan vergeten. Vandaar dat ik wil beginnen 
met iedereen te bedanken die op welke manier dan ook heeft bijgedragen tot het 
welslagen van dit proefschrift. Hier horen natuurlijk ook de patiënten bij, die 
door hun deelname aan studies, het ons mogelijk maken om klinisch onderzoek 
te verrichten. 
 
Bijna vier jaar geleden overtuigde André Minken en Philippe Lambin mij om 
als klinisch fysicus te komen werken in Maastricht. Een bijkomende aantrek-
kingskracht was de mogelijkheid om te promoveren, een optie die ik op dat 
moment als interessant beschouwde maar niet echt als een meerwaarde. Nu, na 
het volmaken van dit proefschrift, zie ik het als een echte verrijking en niet al-
leen voor mijn ‘carrière’. 
 
Philippe Lambin, promotor. Beste Philippe, bedankt voor je aanmoedigingen en 
kritische bijdragen. Het is vaak onbegrijpelijk, met je drukke agenda, hoe snel je 
opmerkingen op manuscripten terug kwamen. 
 
Dirk De Ruysscher, co-promotor. Beste Dirk, zonder jouw onuitputtelijke idee-
en zou deze promotie nooit zo vlot verlopen zijn. Ik sta nog altijd versteld van 
de tijd die je kunt vrijmaken voor iedereen en ik apprecieer het enorm dat een 
(klinische) vraag nooit te veel is. Het enige probleem is dat een antwoord van 5 
minuutjes al vlug eindigde in discussies van een paar uur en resulteerde in extra 
werk voor de komende weken. 
 
André Dekker, co-promotor. André bedankt voor je inzichtelijke opmerkingen 
en aanbevelingen op de manuscripten, vaak van de lastigste om te beantwoor-
den, en het efficiënt sturen van mijn onderzoek. Je hebt ook voor een vlotte start 
van dit proefschrift gezorgd doordat ik een deel van je eigen onderzoek kon 
verder zetten. 
 
André Minken, mijn eerste begeleider. Beste André, je hebt me uiteindelijk 
overtuigd om te starten met de promotie. Hiervoor schiep je ook de ideale om-
standigheden door mij twee dagen per week onderzoekstijd te geven. De grote 
lijnen van dit proefschrift zijn ook nog onder jouw supervisie uitgezet.  
 
De promotiecommissie wil ik bedanken voor alle tijd gespendeerd aan het lezen 
en beoordelen van dit proefschrift.  
 
Beste Angela, het gezamenlijk uitvoeren en publiceren van ons onderzoek was 
zeer aangenaam. Ik kon ook steeds bij je terecht voor mijn (eenvoudige) klini-
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sche vragen, zoals ‘Waar zit de tumor?’. En samen probeerden we de waterval 
van Dirk’s ideeën te trotseren. Gelukkig stond ik hierbij niet alleen.  
 
Liesbeth Boersma, jou wil ik bedanken voor je vaak zeer terechte reviews van 
de manuscripten, zowel voor de grote lijnen maar zeker ook voor alle komma’s, 
punten en afkortingen. Het kritisch nalezen van dit proefschrift tussen je drukke 
bezigheden waardeer ik enorm. 
 
Verder wil ik ook alle andere co-auteurs bedanken voor het publiceerbaar ma-
ken van de manuscripten. Bedankt Rinus, Jeroen, Cathryn, Jim, Marije, Mari-
nus, Ruud, Norbert en Klaus. 
 
Mijn paranimfen, Hugo en Peter, bedankt voor de steun en plezier bij het beëin-
digen van het onderzoek. 
 
Uiteraard wil ik ook al mijn rechtstreekse (ex) collega klinisch fysici (i.o.) be-
danken voor het overnemen van de klinische taken tijdens een onderzoeksweek, 
congres of één of ander research bezoek. Bedankt Lars, Bas, Peter, Michel, Ro-
bert, Martina, Martijn, Erik en Ramon. 
 
Ook de rest van de hele KFG groep bedankt voor de aangename momenten tij-
dens lunchpauzes, commissioning metingen, avondjes uit,… 
 
Uiteindelijk zijn alle scans en behandelingen dagelijks uitgevoerd door de labo-
ranten en ingepland door de ondersteuning. Zonder deze, vaak onzichtbare inzet 
achter de schermen, kan er geen klinisch onderzoek verricht worden. Bedankt! 
 
Bianca, bedankt voor het ontwerpen van de cover in je avonduren, een kopzorg 
minder tijdens de voorbereiding. 
 
De secretariële ondersteuning is uiteraard onmisbaar in het kluwen van doku-
menten die ingediend moeten worden en voor het verzenden van alle proef-
schriften. Bedankt Rian, Simone, Sonia, Marlene en Nelly. 
 
Uiteindelijk wil ik ook familie en vrienden bedanken. Deze promotie was in de 
afgelopen drie jaren een continu gegeven en hopelijk kan ik nu eindelijk mijn 
hoofd ’s avonds en in het weekend leegmaken en meer tijd voor hen vrijmaken. 
 
Ann en Janne, bedankt voor jullie geduld en vanaf nu is je man en je papa er 
terug voor 100%.
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Geert Bosmans werd geboren op 1 juni 1973 in Hasselt (België) en groeide op 
in Zonhoven. Zowel lagere als middelbare school doorliep hij in Hasselt en be-
haalde in 1991 het ASO diploma (Wiskunde-Wetenschappen).  
Hierna ging hij natuurkunde (fysica) studeren, de eerste twee kandidaatsjaren 
aan het toenmalige Limburgs Universitair Centrum (nu Universiteit Hasselt) te 
Diepenbeek. In 1995 behaalde hij zijn licentiaatsdiploma natuurkunde aan de 
Katholieke Universiteit Leuven met een thesis in het vakgebied van halfgelei-
derfysica. 
Vermits de zuivere fysica hem niet kon bekoren volgde hij nog een bijkomende 
opleiding tot klinisch fysicus, waarvoor het diploma ‘aanvullende studies bio-
medische en klinische ingenieurstechnieken optie medische fysica’ gehaald 
moest worden. Hierin was een éénjarige stageperiode omvat die op de radiothe-
rapie afdeling van het UZ Leuven is gebeurd en waarbij ook een thesis over 
amorf silicium EPID’s werd gemaakt o.l.v. Prof. dr. Jan van Dam. 
Na een korte werkervaring in de ICT (Cap Gemini Belgium) is hij sinds begin 
1998 continu aan de slag als klinisch fysicus radiotherapie. Eerst in het Heilig 
Hart Ziekenhuis te Roeselare dan in het AZ-VUB te Brussel en tenslotte in het 
Limburgs Oncologisch Centrum te Hasselt. 
De nederlandse lokroep werd echter te groot en sinds oktober 2004 is hij werk-
zaam in Maastro Clinic te Maastricht. Na een verkorte opleiding niveau 3 stra-
lingsbescherming is hij vanaf januari 2005 geregistreerd als klinisch fysicus 
radiotherapie in Nederland.  
Zijn voornaamste aandachtsgebieden zijn CT-PET beeldvorming, stereotacti-
sche bestralingen en patiëntveiligheid. 
Hij is getrouwd met Ann Hendrickx en hebben samen één dochtertje, Janne. 
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